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Dendritic cells (DCs) are a myeloid cell type specialised in processing and presenting 
antigens to T cells and they represent essential mediators of innate and adaptive 
immunity. In humans, DCs represent a very rare population of cells (0.02-0.8 % of 
leukocytes in the blood) and this aspect limits the ability to study human DCs subsets 
and their potential application in cell therapy-based translational studies. In order to 
overcome these limitations and provide a reliable system to differentiate human DCs 
from an inexhaustible source of cells, this work aims to develop a new experimental 
system to generate DCs from induced pluripotent stem cells (iPSCs), both in in vitro 
and in vivo settings. In this regard, a culture system based on engineered mouse stromal 
cells was established to support human DC development through the induction of a 
definitive hematopoietic program in iPSC-derived hematopoietic progenitors.  
The differentiation of human DCs from cord blood-derived hematopoietic progenitors 
was achieved and the heterogeneity of in vitro generated CD1c+ cells was investigated. 
Moreover, the ability of Flt3L to influence the early stages of hemato-endothelial 
specification was unravelled. 
Ultimately, this approach will be applied to genetically modified iPSC using 
CRISPR/Cas9 system. Candidate genes were identified and targeted in iPSCs in order to 
assess their influence on i) manipulate subsets commitment through transcriptional 
networks perturbation (i.e. IRF8, IRF4, ID2) and ii) manipulate DCs immunogenicity 
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Chapter 1 Introduction 
1 Human dendritic cell development and in vitro modelling 
1.1 Mouse dendritic cells: brief history and subset characterisation 
Dendritic	 cells	 (DCs)	were	 first	described	by	Ralph	Steinman	and	Zanvil	Cohn	 in	
the	 early	 1970s	 by	 observing	 and	describing	 the	 heterogeneity	 of	 adherent	 cells	
isolated	 from	 mouse	 spleen1,2.	 In	 the	 seminal	 paper	 introducing	 the	 concept	 of	
dendritic	 cells	 for	 the	 first	 time,	 Steinman	 and	 Cohn	 observed	 “in	 addition	 to	
mononuclear	 phagocytes,	 granulocytes,	 and	 lymphocytes,	 [we	 noticed]	 a	 large	
stellate	cell	with	distinct	properties	from	the	former	cell	types”	and	they	first	named	
these	cells	dendritic	cells,	based	on	their	specific	morphology1.	A	 few	years	 later,	
the	 idea	that	dendritic	cells	represent	an	 independent	hematopoietic	 lineage	was	
further	supported	by	demonstrating	that	DCs	have	the	unique	ability	to	 initiate	a	
strong	 and	 specific	 T	 cell	 response	 in	 both	 syngeneic	 and	 allogeneic	 mixed	
leukocyte	 reactions3–5.	 This	 contributed	 to	 the	 identification	 of	 DCs	 as	 the	most	
potent	 antigen	 presenting	 cells	 (APCs)	 of	 the	 immune	 system,	 and	 firmly	
established	 the	 role	 of	 DCs	 as	 a	 bridge	 between	 innate	 and	 adaptive	 immunity.	
Indeed,	 DCs	 can	 sense	 peripheral	 tissues,	 capture	 environmental	 and	 cell-
associated	 antigens	 (Ag)	 and	 migrate	 to	 lymph	 nodes,	 where	 they	 process	 and	
present	 phagocytosed	 antigens	 to	 T	 cells,	 establishing	 an	 Ag-specific	 immune	
response.	Moreover,	the	identification	of	a	clonogenic	DC	progenitor,	the	common	
dendritic	 cells	 progenitor	 (CDP),	 in	 the	 mouse	 bone	 marrow,	 which	 has	 the	
potential	 to	 differentiate	 exclusively	 to	 dendritic	 cells,	 further	 consolidated	 the	
notion	that	DCs	represent	a	unique	cell	type	distinct	from	all	the	other	leukocytes6–









to	 produce	 massive	 amounts	 of	 type	 I	 interferon	 upon	 recognition	 of	 foreign	
nucleic	 acids	 by	 the	 Toll-like	 receptors	 7	 (TLR7)	 and	 9	 (TLR9),	 suggesting	 an	
important	 role	 for	 pDC	 during	 viral	 infection11.	 Like	 cDCs,	 pDCs	 arise	 from	 a	
common	dendritic	cells	progenitor	(CDP),	and	they	can	prime	T	cells	against	viral	
antigens	upon	stimulation11.	As	compared	to	conventional	DCs,	steady	state	pDCs	
express	 lower	 levels	 of	major	 histocompatibility	 complex	 II	 (MHCII)	 and	 CD11c,	
and	they	can	be	identified	by	the	co-expression	of	several	surface	markers,	such	as	
CD45RA,	B220	and	PDCA1.		
cDCs	 represent	 the	 subset	 originally	 described	 by	 Steinman	 and	 Cohn,	
characterized	 by	 the	 enhanced	 ability	 to	 sense	 peripheral	 tissues	 and	 trigger	 a	
specific	T	cell	response.	This	unique	ability	is	the	result	of	several	specific	features	
of	cDC,	consisting	of	i)	their	critical	localization	in	non-lymphoid	tissues	and	spleen	




and	 the	 lack	 of	 markers	 specific	 for	 T	 cells,	 B	 cells,	 NK	 cells,	 granulocytes	 and	
erythrocytes.	Moreover,	 even	 if	 they	 share	 a	 consistent	 number	 of	markers	with	
macrophages,	 cDCs	 can	 be	 successfully	 distinguished	 by	 the	 expression	 of	 the	
tyrosine	 kinase	 receptor	 fms-like	 tyrosine	 kinase	 3	 (Flt3/CD135/Flk2),	 their	





Conventional	 DCs	 can	 be	 further	 subdivided	 in	 two	 subsets,	 based	 on	 the	
expression	 of	 specific	 surface	 markers,	 which	 can	 vary	 depending	 on	 their	
lymphoid	 and	 non-lymphoid	 tissue	 localization.	 Lymphoid	 tissue-resident	 cDCs	
consist	 of	 two	 subsets,	 CD8α+	 cDCs	 and	 CD11b+	 cDCs,	 which	 correspond	 to	
CD103+	cDCs	and	CD11b+	cDC	in	non-lymphoid	organs.	
Mouse	 lymphoid	 CD8α+	 and	 non-lymphoid	 CD103+	 cDC	 subsets	 share	 their	
transcriptome	 profile,	 development	 requirements	 and	 the	 expression	 of	 subset-
specific	 markers	 such	 as	 XCR1,	 Clec9A	 (DNGR1),	 CADM1	 (Necl2)	 and	 higher	
expression	of	CD24,	as	compared	to	CD11b	DCs.	 	Mouse	CD8α+/CD103+	DCs	are	





this	 subset,	 such	 as	 CD172a	 (SIRPα).	 Differential	 expression	 of	 endothelial	 cell-
specific	adhesion	molecule	(ESAM)	suggests	heterogeneity	of	these	cells,	which	can	
be	further	separated	in	two	subpopulations	of	ESAMhi	CD11b+	and	ESAMlo	CD11b+	
cells21,22.	 Mouse	 CD11b+	 DCs	 are	 generally	 considered	 poor	 cross-presenters	 in	
vivo	 when	 compared	 to	 CD8α+/CD103+	 DCs,	 but	 they	 are	 characterized	 by	 a	
superior	ability	to	prime	CD4+	T	cells	via	MHC	class	II	presentation23,24.	
 
1.2 Human dendritic cells and the mononuclear phagocyte system 
Human dendritic cells are defined as antigen-presenting	 leukocytes	 with	 allo-





Counterparts of mouse DC subsets have been described in human based on the 
comparative analysis of their transcriptome along with the identification and assessment 
of subset-specific functions. Like in mouse, human DCs in blood and lymphoid organs 
can be divided in two main subsets: CD11c- plasmacytoid (pDC) and CD11c+ 
conventional DCs (cDC). Plasmacytoid DCs can be further defined as CD33- CD123+ 
CD45RA+ BDCA2/CD303+ BDCA4/CD304+ cells, whereas conventional DCs consist 
of at least two subsets: BDCA3/CD141+ DCs and BDCA1/CD1c+ DCs, corresponding 
to the mouse CD8α+ and CD11b+ cells, respectively25–28. Moreover, several markers 
are conserved between human DCs and their mouse counterparts, such as XCR1, 
CADM1 (Necl2), Clec9a (DNGR1) and Flt3 in BDCA3/CD141+ DCs, CX3CR1, Flt3 
and CD172a (SIRPα) in BDCA1/CD1c+ DCs and CD123 and CD45RA in pDC. 
Dendritic cells, both in human and mouse, are one of the lineages composing the 
mononuclear phagocyte system (MPS). The mononuclear phagocyte system was first 
proposed by van Furth in the late 1960s, to define a group of leukocytes with specific 
abilities to process and present antigens29. The MPS includes monocytes, macrophages 
and dendritic cells; closely related cell types whose existence as distinct lineages has 
represented a source of controversy for many years30,31. Indeed, human monocytes can 
be induced to differentiate into dendritic-like cells (moDCs) and macrophage-like cells 
(moMacs) upon exposure to cytokines such as GM-CSF, IL4 and TNFα or M-CSF, 
respectively32–35. However, it is now clear that this in vitro approach, albeit having 
provided an invaluable tool to study rare and not easily accessible human cells, does not 
faithfully recapitulate the developmental processes occurring in vivo. The hematopoietic 
stem cell (HSC)-independent embryonic origin of tissue-resident macrophages has been 
formally proven in the mouse model36–41, and human tissue-resident macrophages share 
the same properties. In this regard, during HSC transplantation dermal macrophages 




dermal DCs42, and Langerhans cells have been reported to be of donor origin up to ten 
years after limb transplantation43, suggesting that human macrophages are capable of 
self-maintaining or are long lived and are independent from circulating HSC-derived 
monocytes. Furthermore, circulating monocytes and all cDC subsets were absent in 
patents with a mutation in the transcription factor GATA2, whereas Langerhans cells 
and macrophages were present at normal numbers in the skin and lungs. These 
observations supported the independent development of Langerhans cells and tissue-
resident macrophages from monocytes and DCs44. Unlike tissue-resident macrophages, 
human monocytes and DCs both originate from HSCs and they are constantly 
replenished by specific progenitors residing in the bone marrow 45. Independent 
progenitors with restricted potential for either DCs (CDP)45 or monocytes (cMoP)46 
have been identified in human bone marrow, underlining the distinct origin of these 
cells. Moreover, transcriptional analysis further confirmed the separation of DCs from 
monocytes and macrophages both in humans and mice26,47–49, in a more unbiased 
fashion not based only on the expression of partially shared, and therefore potentially 
misleading, surface markers. Moreover, further evidence has been provided in the 
mouse model, where a precursor for moDCs has been identified within the Ly6C+ 
monocytes compartment, characterised by the ability to give rise to CCR2-dependent, 
Flt3L-independent moDC, not labelled in Zbtb46-cre fate mapping experiments and 
strongly dependent on high levels of PU.150.  
A further source of complexity, which characterised the MP system for the past 
decades, was the absence of a unified and consistent nomenclature to describe and 
define the different members of the system. For instance, the partial overlap of the 
surface markers used to identify different cell types as well as their shared functions in 
specific contexts, can greatly affect the ability to unequivocally identify the lineages 




in each cell type within different tissues in the same organism as well as among 
different species can easily represent a source of further confusion. Recently, a novel 
approach has been proposed to define a unified nomenclature for both human and 
mouse MPS, based on the ontogeny of these cells as opposed to their function and/or 
phenotype51 (Figure 1-1). According to this new system, MPS cells have been first 
divided in three main groups based on their ontogeny: macrophages when 
embryonically derived, monocyte-derived cells when cMoP-dependent, and dendritic 
cells when CDP-derived. Furthermore, dendritic cells have been classified in three main 
subsets: cDC1, cDC2 and pDC. Conventional DC1 subset includes the previously 
described human BDCA3/CD141+ cells from both lymphoid and non-lymphoid tissues, 
as well as mouse CD8α+ lymphoid and CD103+ CD11b- non-lymphoid dendritic cells. 
Likewise, cDC2 subset can be used to define human BDCA1/CD1c+ cells in the blood 
and lymphoid organs, the BDCA1/CD1c+ CD1a+ cells present in non-lymphoid organs 
and the mouse lymphoid and non-lymphoid CD11b+ cDCs. Based on this 
nomenclature, all the cells derived from monocytes, even if they partially share their 
phenotype or function with DCs (e.g. CD14+ DCs, inflammatory DCs) and/or 
macrophages, should be considered a distinct lineage and referred to as monocyte-






Figure 1-1. A unified nomenclature for MPS classification (from Guilliams et al., 201451). Three 
main groups of cells can be identified based on their ontogeny: embryonic-derived macrophages (orange), 
monocyte-derived cells (blue) and CDP-derived cells (purple). CDP-derived cells were further divided in 
three subsets (cDC1, cDC2 and pDC, i.e.) based on their subset-specific transcription factor dependency. 
 
1.3 Anatomical classification of human dendritic cells 
Human dendritic cells can be classified based on their anatomical localization in 
lymphoid organs- “resident” cDCs, and non-lymphoid tissues- “migratory” cDCs.   
1.3.1 Non-lymphoid tissue cDC1 and cDC2s 
Several DC subsets can be identified in non-lymphoid tissues. These cells are defined as 
“migratory” cDCs for their ability to acquire antigens, mature and migrate to the lymph 
nodes via afferent lymphatics in a CCR7-dependent fashion. In the lymph nodes, 
“migratory” cDCs can present their antigen to T cells to initiate an antigen-specific 
adaptive response. Two main subsets of cDCs, BDCA3/CD141+ cDC1 and 
BDCA1/CD1c+ CD1a+ cDC2 can be detected in human skin, liver, lung and intestine, 
co-existing with other macrophages and monocyte-derived cells. Additional subsets 
have also been described in mucosal tissues. In the skin, Langerhans cells (LC) and 
CD14+ DCs can be identified in the epidermis and dermis, respectively. These cells 
have been initially included in the dendritic cell lineage based on their ability to 




responses in vitro56,57. However, the presence of LC in patients harbouring a GATA2 
mutation preventing cDC and monocyte development44, as well as the detection of 
donor LC after ten years in transplanted limbs43 defined LC as a distinct lineage from 
cDCs, a concept further supported by mouse evidences describing LC ability to renew 
in the skin58 and their potential embryonic origin37. Likewise, transcriptome analysis of 
CD14+ DCs strongly suggests a monocytic origin for these cells, therefore excluding 
them from the cDC lineage59.  
Human small intestine cDCs differ from other non-lymphoid tissue cDCs, in that the 
integrin CD103 is expressed in both BDCA3/CD141+ cDC1 and BDCA1/CD1c+ 
cDC2, which also express SIRPα/CD172a. Moreover, a third subset can be identified as 
CD103- SIRPα/CD172a+ cells, which was found to cluster with monocytes in 
transcriptional profiling analysis, suggesting their monocytic origin28. Finally, an 
additional subset termed as “inflammatory” DC (InfDC) has been described in human 
inflamed tissues, which has been characterised as a monocyte-derived population60,61. 
1.3.2 Blood and lymphoid organ DCs 
In the blood, human dendritic cells represent approximately 1% of the circulating 
peripheral blood mononuclear cells (PBMCs), and they are classified in three subsets: 
BDCA3/CD141+ cDC1, BDCA1/CD1c+ cDC2 and BDCA2/CD303+ CD123+ pDCs. 
More recently, a new classification has been proposed based on single-cell RNA-seq 
experiments62, which will be described in detail in a dedicated section of this thesis. 
Through the circulation, human DC can seed all lymphoid organs, such as spleen, 
lymph nodes and tonsils, where they reside for their entire life playing a role in tissue 
homeostasis and inflammation. These cells are defined as “resident” DCs, as opposed to 
the “migratory” DCs found in non-lymphoid tissues. Resident DCs represent the only 




be distinguished by their lower expression of MHCII and higher expression of CD11c 
from their “migratory” counterparts also present in the lymph nodes. 
 
1.4 Human DC subsets in blood and lymphoid organs  
Human blood and lymphoid-tissue resident cDCs represent the most relevant 
compartment for the aims of this thesis, and therefore they will be extensively discussed 
in the next sections of this chapter, focusing on their phenotype, function, transcription 
factor dependency and growth factor requirements (Table 1-1). Moreover, two further 
sections will be dedicated to the description of additional DC subsets recently identified 
in human blood62 and to the characterisation of human inflammatory DCs. 
Table 1-1. Human dendritic cell subsets in blood and lymphoid organs 



























































1.4.1 Human DC1 subset 
Human DC1s represent the rarest subset of DCs both in human and mouse, and they 
account for 0.03% of total PBMCs in blood. cDC1s were originally named as 
BDCA3/CD141+ DC, based on their expression of thrombomodulin (CD141). 
However, CD141 does not represent a specific marker for cDC1s and other members of 
the MPS such as monocytes and in vitro cultured cDC2 have been reported to up-
regulate CD141 under certain conditions. Therefore, additional membrane proteins have 
been identified as more reliable markers to identify human and mouse cDC1s, including 
the C-type lectin-like receptor Clec9A65,66 and the chemokine receptor XCR167. 
Consistent with the mouse system, human cDC1 also express fms-like tyrosine kinase 3 
(Flt3/CD135) and strongly depend on Flt3L for their development both in vitro68,69 and 
in vivo70. The transcriptional regulation of human cDC1 is less clear compared to their 
mouse counterparts. Like in mouse, cDC1s express both interferon regulatory factor 8 
(IRF8) and the transcription factor Batf3. Moreover, patients harbouring IRF8 
mutations showed a dramatic reduction in all DC subsets including cDC1, suggesting a 
key role of IRF8 in DC development71. Conversely, conflicting results were reported for 
Batf3, which plays a critical role in mouse cDC1 development and appeared to be 
required for human cDC1 in vitro, but not in vivo in humanised mice66.  
Expression of TLR1, TLR3, TLR6, TLR8 and TLR10 has been reported in human DC1 
either at mRNA or protein level25,63,72–74. TLR3 activation by PolyI:C (dsRNA) or HCV 
infection induces type III interferon (IFN-λ) production by cDC175–77, a feature 
conserved in the mouse system, whereas no cytokine production has been reported in 
response to TLR8 activation in human cDC173,78. Moreover, human cDC1 can 
efficiently secrete TNFα and CXCL10, but very low IL12, a major difference with their 





Like in mouse, human cDC1 are capable of inducing CD8+ CTL response against 
tumors and viral infections67,68,72,79. 
1.4.1.1 Human DC1 in T cell responses 
The most peculiar function of mouse cDC1 is their superior ability to cross-present 
various forms of antigens to CD8 T cells via MHCI80. This aspect is not fully conserved 
in humans, where all blood and lymphoid organs DC are capable of cross-presenting 
antigens to CD8 T cells81, and have comparable efficiency in soluble antigen cross-
presentation regardless of their activation state60,63,64. However, human cDC1 appeared 
to be more efficient than other subsets in cross-presenting dead cell-derived antigens 
upon TLR3 stimulation and antigens delivered via CD205 targeting26,60,67,72,79,82,83. 
Several features of human cDC1 are responsible for their efficient cross-presentation to 
CD8+ T cells. TLR3 and Clec9A, are known to be important in cross-priming82,84–87. 
Moreover, cDC1s express the chemokine receptor XCR167,79, whose ligand XCL1 is 
produced by activated CD8+ T cells, inducing the recruitment of DC1s and supporting 
the establishment of a strong adaptive response88. Finally, mouse cDC1s have been 
shown to play a crucial role in anti-tumor immunity and they accumulate in regressing 
tumors89,90. Supporting a similar role for cDC1s in human, a positive correlation of the 
expression of transcript associated to cDC1 and patient outcome has been reported89. 
In humans, both cDC1s and cDC2s can induce allogeneic CD4+ T cells proliferation in 
vitro28,63,72,73,91. In contrast with mouse data, human cDC1s do not show a subset-
specific ability to induce Th1 polarization of CD4 T cells, and both cDC1s and cDC2s 
can efficiently induce a Th1 response when activated by a variety of stimuli64,72,73,92. 
Moreover, human cDC1s appeared to be superior to cDC2s in inducing Th2 
responses91, in contrast with the mouse system, where CD11b+ cDC2s are known to be 
the most efficient subset promoting Th2 polarisation. However, these observations are 




been reported when an Ag-specific autologous response was measured, suggesting that 
cDC1s and cDC2s are equally efficient in processing and presenting antigens to CD4 T 
cells72,83. Even if a role in tolerance induction has been proposed for mouse cDC1s93, a 
similar function for human CD141+ cDC1 has not yet been reported. 
 
1.4.2 Human cDC2 subset 
Human cDC2s can be identified in lymphoid and non—lymphoid tissues as well as in 
the blood, where they represent approximately 0.3% of total PBMCs. The phenotype of 
human cDC2s in blood and lymphoid tissue can be defined as CD11c+ HLA-DR+ 
CD14- CD16- CD2+ CD1c+ CD45RO+ SIRPα/CD172a+ cells60,63,94,95.	 In addition, 
other markers have reported to be expressed in these cells, such as CD1a in the skin and 
CD103 in the intestine, highlighting tissue-specific discrepancies in the cDC2 
phenotype. Human cDC2 phenotype closely resembles the phenotype described for 
inflammatory monocyte-derived DCs and therefore a re-evaluation of their function, 
especially during inflammation, may be needed60. Moreover, heterogeneity of human 
cDC2s has been recently described based on their phenotype and transcriptomic 
analysis, suggesting the existence of two independent subsets within the cDC2 
population62,96, as previously described in mouse21,22. Human cDC2s also express Flt3 
and accordingly, Flt3L expands this subset in vitro and in vivo34,70,97–99. 
The transcriptional regulation of human cDC2s is not fully elucidated, but the specific 
expression of the interferon regulatory factor 4 (IRF4) may suggest its potential 
involvement in controlling cDC2s development, consistent with the mouse system100. 
However, it has been shown that autosomal dominant mutation of IRF8 in patients 
induces an abnormal phenotype in cDC2s, without affecting the cDC1s, suggesting a 
different transcriptional regulation of DC development between human and mouse71. 




infections71, which is consistent with the specific ability of cDC2s to present glycolipid 
antigens and trigger responses to mycobacteria by virtue of CD1c expression101. 
The expression of TLR1, TLR2, TLR4, TLR5, TLR6 and TLR8 has been reported in 
human cDC2 either at mRNA or protein level25,63,72–74. Activation of TLR2 and TLR8 
can trigger IL12-p70 secretion in blood and lymphoid cDC2s, making them the best 
IL12 producers among all DC subsets60,78,102. Moreover, blood and tissue cDC2s can 
also secrete IL1β, TNFα, IL8 and IL10 in response to specific stimulation56,73, and IL23 
production in skin, lung and intestine by cDC2s has been reported in response to 
Aspergillus fumigatus exposure or TLR8 stimulation92,103.  
1.4.2.1 Human cDC2s in T cells responses 
Human cDC2s from spleen, lymph node, tonsil, skin and lung of humanized mice are 
capable of cross-presenting antigens to CD8+ T cells, in some cases with the same 
efficiency of cDC1s, depending on the source of antigen and the kind of 
stimulation60,63,64,104. Moreover, blood activated cDC2s can induce cytotoxic T 
lymphocytes (CTL) differentiation and trigger higher levels of granzymes expression as 
compare to human cDC1s, possibly due to their ability to secrete IL12-p7078. 
Furthermore, lung cDC2s have been associated with the induction of CD103 acquisition 
by CD8+ T cells, promoting migration and retention of these cells in peripheral 
tissues104. Mouse cDC2s are considered a specialised subset promoting CD4+ T cell 
responses, and the same ability may be predicted for human cDC2s, based on their 
superior ability to express genes associated with MHCII processes72. Indeed, blood, skin 
and lung cDC2s are capable of inducing Th1, Th2 and Th17 polarization of CD4+ T 
cells, depending of the source of antigen and stimulation47,92,105,106. Moreover, lung 
cDC2s are more efficient than cDC1s in promoting Th17 response after A. fumigatus 
exposure76, consistent with their ability to secrete IL23 and with the role of their murine 




blood, lymph nodes and lung appeared to be equally competent in inducing Th1 
responses in the presence91,107 or absence of specific activation stimuli64,91, as well as 
promoting a Th17 response in the intestine28. Emerging evidence supports a role of 
human cDC2s in Th2 response in allergy and asthma, consistent with the mouse 
model108–113. However, mouse moDC have also been associated with allergic 
responses108. Therefore a better characterisation of the phenotype of cDC2s and 
monocyte-derived DCs in humans and their contribution to asthma and allergy is 
required. Finally, gene expression profiles and functional analysis support the idea that 
human cDC2s may be involved in the regulation of tissue homeostasis, consistently 
with their mouse CD11b+ counterparts. Human cDC2s in non-lymphoid tissues express 
high levels of immune regulatory molecules, such as CLEC4A (DCIR), ILT4, ICOS-L 
and PD-L128,114. Moreover, human cDC2s have been shown to secrete IL-10 in response 
to E. coli or LPS stimulation, and to efficiently induce immunosuppressive T cell 
responses115,116.  
 
1.4.3 Human pDCs subset 
In steady state human pDCs localise mainly in blood and lymphoid organs, whereas 
during inflammation, they can migrate and can be detected in non-lymphoid tissues as 
well117,118. pDCs are phenotypically defined as CD11c- HLA-DR+ CD123+ 
BDCA2/CD303+ BDCA4/CD304+ CD45RA+ cells117,119, and they can be further 
subdivided, based on their expression of CD2, in CD2lo and CD2hi pDCs120,121. 
Moreover, a subset of pDCs expressing CD56 have been recently characterised122, 
which also express CD33, CD13, CD2 and CD46 and it has been proposed to represent 
an immature form of pDCs 122. Consistent with the mouse system, human pDC 
development relies on the transcription factors IRF8 and E2-2. Indeed, autosomal 




and impairment in pDC function has been reported in E2-2-deficient patients117,123. One 
of the most peculiar characteristics of pDCs is their ability to sense viral and self nucleic 
acids through the highly expressed Toll-like receptors 7 and 9 (TLR7 and TLR9)124–126. 
Once activated, pDCs can produce massive amounts of type I interferon (IFNα and 
IFNβ) and for this reason they are considered one of the most important effectors of 
antiviral immunity117,120,127–130. The ability of pDCs to	 secrete	 type	 III	 interferon	
further	supports	 this	concept77,131.	 Indeed, pDCs have been shown to play a role in 
the immure response against several pathogenic viruses, of which the most extensively 
characterised is HIV 132. Likewise, the extremely efficient production of type I 
interferon by pDCs has been associated with non-viral pathogen immune responses. The 
contribution of human pDCs has been reported in Aspergillus fumigatus infection by 
producing type I interferon in a Dectin-2 dependent manner133 as well in responses 
against BCG, where pDCs are considered a fundamental mediator of the optimal CD8+ 
T cell response to vaccine134. Moreover, pDCs contribute to the priming of CD4+ T 
cells by DC2s in mycobacterial infection135, and their activation and consequent IFNa 
production has been described in human blood and tonsils in response to numerous 
gram positive and negative bacteria136. The involvement of pDCs in several 
autoimmune diseases has been reported primarily as the major source of IFNα and β126. 
An “IFN signature” has been described in systemic lupus erythematosus (SLE)137–139, 
psoriasis140, Wiskott-Aldrich syndrome (WAS)141 and atherosclerotic lesions142. In all 
these pathologies, the high levels of type I IFN are mainly due to pDC activation in 
response to self nucleic acids via TLR7 and TLR9137–142.	Finally, even if capable of 
initiating a powerful inflammatory response, pDCs have also been associated with 
tolerance and immunoregulation143. Based on experimental evidences and clinical 




transplant tolerance145, induction of regulatory T cells146 and poor prognoses in patients 
with solid tumors147. 
1.4.3.1 Human pDC in T cell responses 
Human pDCs are characterised by superior ability to stimulate naïve T cells as compare 
to their mouse counterparts134. Indeed, blood pDCs have been reported to efficiently 
induce Th1127,143 and Th2143 polarisation of CD4+ T cells.  However, whether this is 
true for lymphoid organ pDCs has not yet been established. Moreover, experimental 
evidence demonstrates that pDCs are also capable of cross-presenting soluble60,63,148–
150,	 viral150–152	 and	 cell-associated148,153	 antigens.	 Nevertheless,	 the	 ability	 of	
human	 blood pDCs to prime T cells has been recently challenged. It has been 
demonstrated that the CD11c- CD123+ BDCA2/CD303+ BDCA4/CD304+ CD45RA+ 
cells originally used in vitro to assess T cell activation by pDCs, are actually a 
heterogeneous population containing a “contaminating” fraction of cells described 
either as DC precursors (pre-DC)154 or as an alternative DC subset (AS DCs)62. These 
cells can be discriminated from pDCs based on the expression of CD33, Siglec6 and 
Axl62,154. More interestingly, when deprived of this additional population of cells, pDCs 
failed to efficiently induce T cell proliferation62,154.  
 
1.4.4 Human DCs in blood: additional subsets 
The existence of additional subsets other than cDC1, cDC2 and pDC has been recently 
described in human blood62. The unbiased analysis of single-cell RNA sequencing data 
in HLA-DR+ lineage- cells from healthy donor PBMCs enabled the identification of ten 
independent populations within the blood HLA-DR+ lin- cells. Six of these clusters 
were described as dendritic cell subsets, based on their gene expression profile, 
phenotype and function, whereas the remaining four populations appeared to be 




human PBMCs consists of three subsets of dendritic cells (cDC1, cDC2 and pDC, i.e.) 
and three subsets of monocytes (CD14+ “classical”, CD16+ “non-classical” and CD14+ 
CD16+ “intermediate”, i.e.). Therefore, three additional DC subsets, named as DC3, 
DC4 and AS DCs as well as one monocyte subset (mono 4) were revealed with this 
approach62.  DC4s were described as poorly characterised CD11c+ CD1c- CD141- cells 
and no further information was provided about their function or phenotype, which 
potentially overlaps with previously described CD16+ SLAN+ “DC-like” monocytes, 
also named as SLAN DCs. DC3s represent a second subset of BDCA1/CD1c+ cells 
characterised by a more “inflammatory” signature of their gene expression profile, 
which can be distinguished from classical DC2s based on the lower expression of CD1c 
and CD11c. Finally, a new population of Axl+ Siglec6+ cells (AS DC) was identified. 
AS DCs shared expression of many genes and surface markers with pDCs, but 
functional characterisation of these cells confirmed their independence from the pDCs 
subset. Indeed, pDCs were uniquely capable of secreting high amounts of type I 
interferon in response to TLR9 stimulation, whereas AS DCs could produce IL12-p70 
when stimulated with TLR4 and TLR7/8 agonists, suggesting a closer relationship with 
conventional DCs62. Moreover, AS DCs have been shown to be able to induce T cell 
proliferation as efficiently as the other cDCs subsets, while pDCs failed to do so when 
deprived from the AS DCs “contamination” due to their partially overlapping 
phenotype62. Based on this unbiased approach a new classification of the human blood 
DC compartment has been proposed62. However, the existence of these subsets in 
lymphoid and non-lymphoid organs and a further characterisation of their phenotype 





1.4.5 Human inflammatory DCs 
Little is known about inflammatory dendritic cells (infDCs) in human, even though 
recent publications have reported the isolation of human infDCs displaying specific 
features consistent with their mouse counterparts60,155. Mouse infDCs have been 
described in vivo in a variety of inflammatory conditions156–166. Mouse infDCs are 
characterised by the expression of surface markers mostly shared with other myeloid 
populations, for instance inflammatory macrophages (infMacs), and therefore their 
isolation may sometimes present a challenge. However, infDC can be clearly 
distinguished from infMacs due to their unique ability to migrate to the lymph nodes in 
a CCR7-dependent fashion108,156,167	 and	 efficiently	 activate	 T	 cells108,161. Moreover, 
infDC have been described as monocyte-derived cells that can differentiate in the 
tissues during inflammation156, and this concept is further supported by their 
dependency on CCR2160,161,168–172.	 InfDC are not affected in Flt3l-/- mice108, suggesting 
their independence from the DC lineage. Although infDCs express the DC-lineage 
specific transcription factor ZBTB46	 in	 vitro173	 and	 in	 vivo174,	 they	 were	 poorly	
labelled	in	Zbtb46cre	x	RosalslYFP	fate	mapping	experiments50.	 
Based on the observation that infDC-like cells can be generated in vitro from mouse	
monocytes	 in	 the	presence	of	GM-CSF175and	 the	 identification	of	 infDC	 in	several	
GM-CSF-dependent	 inflammatory	 settings50,163,166,	 GM-CSF	 has	 been	 proposed	 to	
play	an	essential	role	in	infDC	development.		
More recently, inflammatory cells with similar characteristics have been identified in 
human inflamed tissues in atopic dermatitis patients, arthritis synovial fluid and tumor 
ascites60,155. Human infDCs were characterised by the expression of CD14, CD1c, 
CD11b, CD172α, FcεRI, CD11c, HLA-DR,	 CD1a,	 CD206,	 M-CSFR/CD115	 and	
ZBTB4660,61,176.	 Moreover,	 in	 the	 same	 inflammatory	 conditions,	 infDCs can be 




Transcriptomic profiles of infDCs isolated from human inflamed tissues consistently 
align with GM-CSF-dependent monocyte-derived DCs generated in vitro, supporting 
the monocytic origin of these cells60. Little is known about the function of human 
infDCs in vivo. However, human infDCs isolated from synovial fluid of arthritis 
patients and from tumor ascites have been shown to induce Th17 polarisation of CD4+ 
T cells ex vivo through the secretion of the Th17-polarising cytokines TGFβ, IL1β, IL6 
and IL2360. 
	
1.5 Growth factors involved in the MPS development 
The development of monocytes, macrophages and dendritic cells is a strictly regulated 
process that involves essential growth factors specific for each lineage. Based on in 
vitro and in vivo evidences both in mouse and human, three fundamental cytokines can 
be identified: Flt3L, GM-CSF and M-CSF. 
 
1.5.1 Flt3L 
Flt3 ligand (Flt3L) is a key regulator of dendritic cell commitment during 
hematopoiesis6,177 and it is ubiquitously secreted by a wide range of cells, including 
stromal cells, endothelial cells, activated T cells178 and activated mast cells179. Flt3L is 
produced as a trans-membrane protein biologically active in both soluble and 
membrane-bound forms. Soluble Flt3L is the product of proteolytic cleavage of the 
extracellular domain of the trans-membrane protein180,181. 
The fms-like tyrosine kinase 3 (Flt3), also known as Flk2 or CD135, is the cognate 
receptor for Flt3L. Flt3 is expressed in all early hematopoietic progenitors both in 
human and mouse, including short-term repopulating hematopoietic stem cells 
(HSCs)182–184, common lymphoid and myeloid progenitors (CLP and CMP, 
respectively)185, monocyte and dendritic cell progenitor (MDP)186,187, common dendritic 




is lost in all committed progenitors before entering the circulation and it is maintained 
exclusively in pre-DC and in the terminally differentiated DC subsets8,185. The crucial 
role of Flt3L in dendritic cells development has been fully demonstrated in vivo using 
both Flt3- and Flt3L-deficient mice, which display impaired DC development, without 
affecting monocyte numbers and function8,17. Interestingly, Flt3 knockout mice 
presented a less severe phenotype as compared to the ligand-deficient ones17,186,188,189, 
suggesting that a potential alternative unknown receptor might be involved. Albeit 
limited in number, the few DCs still present in Flt3L-deficient mice appeared to be fully 
functional17. Moreover, the transfer of fully functional DCs into recipients lacking Flt3L 
resulted in reduced proliferation of the cells186, potentially suggesting a more important 
role of Flt3L in DC homeostasis rather than development. In contrast with this 
hypothesis, Flt3L-deficient mice have been reported to display reduced numbers of 
CDPs190 and pre-DCs186. Further studies have supported the fundamental role of Flt3L 
in dendritic cell development and maintenance. For instance, high levels of Flt3L have 
been detected in both mouse188,191 and human44 serum in response to Flt3 inhibition or 
cDC depletion, suggesting a strictly regulated feedback between DC availability and 
Flt3L concentration. Furthermore, the administration of Flt3L was reported to 
selectively expand DCs in vivo in mouse17,186,192,193 and in human34,98,99,194. Likewise, 
Flt3L can successfully support DCs differentiation in vitro from human cord blood-
derived progenitors68,69 or mouse bone marrow cells7. 
Finally, although monocyte development is not affected in vivo in Flt3L-deficient mice, 
the addition of Flt3L to in vitro cultures of human monocytes in the presence of GM-
CSF and IL4 increased the yield of DC-like cells and their ability to stimulate T cells 
proliferation195. Therefore, a potential effect of Flt3L in driving the differentiation of 






Granulocyte macrophage colony-stimulating factor (GM-CSF or CSF-2) is a 
hematopoietic cytokine controlling myeloid cell development, the most prominent role 
of which is granulocyte and monocyte differentiation and maintenance196. GM-CSF 
binds specifically to its receptor GM-CSFR (CSF-2R), which consists of a trans-
membrane protein formed by two subunits, GM-CSFRα and GM-CSFβ1. GM-CSFR 
expression has been reported in committed hematopoietic progenitors (GMP, MDP and 
CDP), as well as terminally differentiated cells, such as monocytes, cDC1s and 
cDC2s158,197. 
GM-CSF, alone or in combination with other factors, has been extensively used to 
induce in vitro differentiation of DC-like cells from either monocytes or hematopoietic 
progenitors, both in human33,198 and mouse199. Indeed, GM-CSF still represents a key 
factor in the generation of DC-based vaccines against cancer using irradiated tumor 
cells, a procedure termed as GVAX200,201. However, even if numerous publications have 
demonstrated that in vitro cultures with GM-CSF give rise to moDC that do not 
resemble the physiologically circulating DC subsets60,202, GM-CSF is still part of the 
cytokine mix most commonly used to differentiate human DCs in vitro from 
hematopoietic progenitors34,45,62,154,203,204. 
In vivo, GM-CSF appeared to be mainly involved in the homeostasis and differentiation 
of myeloid cells in peripheral tissues, especially during inflammation. Indeed, 
conventional DCs are not affected in the lymphoid organs of mice lacking either GM-
CSF or GM-CSFR expression205. Conversely, a reduction of cDC1 and cDC2 in the 
lung, intestine and dermis has been reported in GM-CSF-deficient mice158,197,206, 
suggesting a critical role for GM-CSF in cDC maintenance in non-lymphoid tissues158. 
Importantly, GM-CSF has been also identified as a key regulator of CD103 expression 






Macrophage colony-stimulating factor (M-CSF or CSF-1) is a hematopoietic cytokine 
involved in the regulation of development, proliferation and survival of monocytes and 
macrophages210. Alternative splicing of the M-CSF mRNA gives rise to two forms of 
the translated protein with different fate: a soluble form that is incorporated into vesicles 
and released via the secretory pathways, and a trans-membrane form which can play a 
role in cell-cell interactions or alternatively be released into the extracellular space by 
proteolytic cleavage211,212. 
M-CSF receptor (M-CSFR, CSF-1R or CD115) is a member of the class 3 receptors 
tyrosine kinases (RTK-III) and is expressed in hematopoietic progenitors at different 
stages of myeloid commitment, including GMP and MDP, whereas it is lost in CDP and 
pre-DCs8,45. M-CSFR is also expressed in terminally differentiated cells such as 
macrophages, monocytes and a subset of mouse cDC2s190,213. Therefore, based on the 
pattern of expression of their receptors in monocyte and dendritic cell progenitors, Flt3L 
and M-CSF have been proposed as key mediators in the commitment of MDP towards 
the monocyte or dendritic cell fate178. Moreover, an alternative ligand for M-CSFR has 
been identified in interleukin 34 (IL-34)214. 
M-CSF involvement in macrophages and monocyte development is strongly supported 
by in vivo evidence in the mouse model. Mice lacking M-CSFR display normal DC 
development in lymphoid organs, but they failed to develop monocytes, macrophages 
and Langerhans cells (LCs)215. On the other hand, when the production of the ligand is 
impaired (i.e., in Csf-1-/- or Csf-1op/op), monocytes and macrophages are still absent, but 
LCs develop normally in the epidermis216. This observation suggested the existence of a 




exclusively lack epidermal LCs, whereas dermal DCs and macrophages are not 
affected158,217. 
In vitro evidence further supports the role of M-CSF in macrophages development. 
Indeed, M-CSF alone or in combination with other factors can be used to efficiently 
generate monocyte-derived macrophages from hematopoietic progenitors both in 
humans and in mice32,218. 
 
1.6 Transcriptional regulation of DC development 
The transcriptional regulation of dendritic cell development has been extensively 
investigated in mice93,219,220. Genetic evidence demonstrated the key role of subset-
specific transcription factors in the differentiation, maintenance and function of cDC1s, 
cDC2s and pDCs (Figure 1-2).  
Conventional DC1 (CD8α+/CD103+) development strictly depends on the expression 
of the interferon regulatory factor 8 (IRF8)221–224, the basic leucine zipper transcription 
factor ATF-like 3 (BATF3)90,208 and the inhibitor of DNA binding protein 2 (ID2)225. 
Mouse cDC2 instead, are depleted in the absence of interferon regulatory factor 4 
(IRF4) expression92,100,226–228 and they also rely on interferon regulatory factor 2 
(IRF2)229, RELB230, RBP-J231, NOTCH221 and Kruppel-like factor 4 (KLF4)22.  
Moreover, KLF4 and NOTCH2 dependency discriminate between two subsets of cDC2 
that can be further characterised by the expression of the endothelial cell-selective 
adhesion molecule (ESAM)21. Both cDC1 and cDC2 specifically express the zinc finger 
transcription factor ZBTB46, a conserved feature between mouse173,232 and human47,60. 
However, mouse ZBTB46 is not required for cDC development and appears to be 
involved in the maintenance of a DC specific transcriptional program and in the 
suppression of DC activation173,232. Finally, E2-2 (TCF4) has been identified as a master 




the activation of other transcription factors involved in pDC development (SPIB, IRF8) 
and function (IRF7)123.  
 
 
Figure 1-2. Transcriptional regulation of mouse DC subsets (adapted from Satpathy et al, 2012219). 
Transcription factors sequentially required for mouse cDC and pDC development. Subset specification is 
further defined by their ability to respond differently to pathogen challenges and produce subset-specific 
cytokines involved in the polarization of naïve CD4+ T cell. 
 
1.6.1 IRF8 
In mouse, IRF8 has been clearly identified as a key transcription factor involved in 
cDC1 and pDC development. Two distinct phenotypes have been reported in mice 
carrying dysfunctional IRF8. The Irf8-/- mice display a more severe phenotype 
characterised by the absence of monocytes, pDCs and cDC1s, while impairing the 
functional maturation of cDC2s221,222. A second model providing insightful information 
about IRF8 function in dendritic cell development is the BXH2 mouse. The BXH2 
mouse harbours a spontaneous point mutation in the Irf8 gene (IRF8R294C), which 
impairs exclusively the development of cDC1 subset without affecting pDCs and 
monocytes223. These mice exhibit an immunodeficient phenotype similar to the Irf8-/- 
animals, characterised by enhance susceptibility to Mycobacterium Bovis (BCG), 




leukaemia233. More recently, the involvement of IRF8 in different stages of monocytes 
and dendritic cell development has been assessed in several conditional Irf8-/- mice224. 
This analysis enabled the identification of IRF8 as a key transcription factor involved in 
both cDC1 development and maintenance (terminal selector), whereas its absence in 
terminally differentiated pDCs exclusively affects their function but not their survival. 
Moreover, the deletion of IRF8 in the bone marrow progenitors highlighted a 
fundamental role of this transcription factor in the differentiation of CDPs from MDPs 
as well as the development of monocytes from their cMoP precursors224. IRF8 
expression requires prior autoactivation of IRF8, which is dependent on different 
transcription factors at different stages of DC development. Indeed, it has been 
demonstrated that while IRF8 expression in CDP and pre-DC1 is sustained by its PU1-
dependent autoactivation, the terminal differentiation of these progenitors into DC1 
requires a BATF3-dependent autoactivation of IRF8234. This model is supported by in 
vivo evidences in Batf3-/- mice, which displayed an impaired development of terminally 
differentiated DC1 without affecting the development of CDP and pre-DC1234. 
In humans, the understanding of the transcriptional regulation of DC development relies 
on the identification of specific mutation associated with DC deficiencies. To date, the 
DC deficiency syndromes include well-characterised mutations of IRF8 and GATA2. 
Two different mutations on the IRF8 gene have been reported in patients affected by 
DC deficiency syndrome: the autosomal recessive mutation K108E and the autosomal 
dominant sporadic mutation T80A71, both localised in the DNA-binding domain of 
IRF8. The K108E mutation appeared to recapitulate the absence of functional IRF8 in 
both the Bxh2-/- and Irf8-/- mouse models, and it is characterised by the increased 
susceptibility to Mycobacterium and other bacteria/virus infections and the appearance 
of a striking myeloproliferative syndrome71. This very severe phenotype is explained by 




patients harbouring the K108E mutation. Conversely, patients affected by the autosomal 
dominant sporadic mutation T80A display normal monocytes, pDC and cDC subsets in 
the blood. However, within the cDC compartment a specific loss of CD1c+ DC2s has 
been described, while the CD141+ DC1s were not affected71. This represented a 
completely unexpected observation considering the higher expression of IRF8 in cDC1s 
and pDCs and its essential role in their development and maintenance in the mouse 
model, suggesting a poorly conserved regulation of DC development between human 
and mouse. Moreover, patients harbouring the T80A mutation presented a less severe 
phenotype, displaying an increased susceptibility to mycobacterial infection but normal 
life expectancy and no need for stem cell transplantation therapy71. 
 
1.6.2 GATA2 
The DC, monocyte, B and NK lymphoid (DCML) deficiency syndrome is another 
group of genetic disorders, which provide further evidence of the regulation of DC 
development in human. DCML was described as ‘autosomal dominant and sporadic 
monocytopenia’235 and is characterised by heterozygous mutations in the transcription 
factor GATA2236,237. Many different mutations have been identified, all resulting in the 
loss or mutation of the C-terminal zinc finger domain236. GATA2 mutations are 
considered the cause of dendritic cell, monocyte, B and natural killer lymphoid 
deficiency and correlate with increased susceptibility to infection, leukemic 
transformation and pulmonary alveolar proteinosis, higher incidence of solid tumors and 
in some cases autoimmunity238. Patients harbouring GATA2 mutations completely lack 
circulating monocytes, cDCs and pDCs and the remaining fraction of HLA-DR+ Lin- 
cells were identified as CD34+ progenitors. The lack of circulating B cells, NK cells, 
monocytes and DCs reflects the absence of multilymphoid progenitors (MLP) and 




with increased levels of Flt3L in the serum as well as depletion of regulatory T cells 
(Treg)44. Similar observations have been reported in conditional GATA2 knockout mice, 
which are characterised by significant reduction of the DC population239. GATA2-
deficient progenitors displayed a reduction in myeloid-related gene expression along 
with an increase in T lymphocyte-related genes, suggesting an important role of 
GATA2 in the progenitor commitment to the myeloid rather than lymphoid lineage239. 
 
1.6.3 E2-2 
The basic helix-loop-helix transcription factor E2-2 (TCF4) is a member of the E 
proteins family and it has been identified as a key transcriptional regulator of human 
and mouse pDCs123. Constitutive or inducible knockout of E2-2 completely abrogates 
pDCs development in mice. Moreover, haploinsufficiency of E2-2 led to impaired type 
I interferon responses as well as aberrant gene expression profiles in pDCs both in 
mouse and in the human Pitt-Hopkins syndrome123. The pivotal role of E2-2 in pDCs 
regulation is further supported by its ability to modulate the activation of other 
transcription factors involved in pDC function and differentiation, such as IRF7, IRF8 
and SPIB. Interestingly, E2-2 has been reported to repress the expression of ID2, a 
transcription factor involved in conventional DC1 development. Conversely, ID2 is 
capable of inhibiting E2-2 function, suggesting that a finely regulated balance between 




Genetic experiments in the mouse model enabled the identification of the helix-loop-
helix transcription factor ID2 as an essential factor driving mouse conventional DC1 




and Id2-/- animals completely lack splenic cDC1s as well as Langerhans cells225. The 
role of ID2 in human DCs development has not been evaluated yet and the 
consequences of its abrogation are still unknown. However, ID2 has been identified as a 
key regulator of hematopoietic progenitors commitment and its overexpression in 
human cord blood-derived progenitors resulted in the expansion of the HSC pool as 
well as the modulation of progenitors commitment towards the erythromyeloid lineage, 
at expense of lymphoid differentiation241. 
 
1.6.5 IRF4 
The fundamental role of the transcription factor IRF4 in cDC2 development and 
maintenance has been extensively investigated in mouse92,100,226,227. Irf4-/- mice display 
severe reduction of mouse cDC2s in the spleen100, as well as in peripheral tissues 
including lung, gut and intestine92,226, with the consequent impairment of both Th2 and 
Th17 responses92,226,227. Furthermore, Irf4-/- bone marrow progenitors failed to 
differentiate in vitro in cDC2100. However, even if high expression of IRF4 in human 
DC2s has been reported92, its role in their differentiation and maintenance has not been 
formally proven yet. 
Table 1-2. TF mutations associated to DCs deficiency in human and mouse 










Bxh2 normal absent normal normal 223 
Homo 
sapiens 
K108E absent absent absent absent 
71 




Gata2-/- reduced reduced reduced reduced 
239 
Gata2+/- normal normal normal normal 
Homo 
sapiens GATA2
+/- absent absent absent absent 235 236 
E2-2 Mus musculus 
E2-2-/- normal normal normal absent 
123 












-/- normal absent normal normal 225 
Homo 




-/- normal normal reduced normal 92 226 
Homo 
sapiens n/a unknown unknown unknown unknown - 
 
1.7 Ontogeny of human dendritic cells 
Both mouse and human DCs in the peripheral tissues are constantly replenished by 
specific precursors residing in the bone marrow. In humans, clinical observations 
support this notion, as demonstrated by the complete replacement of dermal DCs after 
bone marrow transplantation47, as well as the total absence of circulating DCs in 
patients undergoing bone marrow suppression in pre-engraftment stage of bone marrow 
transplantation42. 
The ontogeny of monocytes and DCs has been originally described in the mouse model 
based on the identification of clonogenic progenitors with restricted potential to 
differentiate into monocytes, DCs or both. In the mouse bone marrow, a monocyte and 
dendritic cell progenitor (MDP)187 has the ability to differentiate into common dendritic 
cell progenitors (CDP)6–8, which has lost monocyte and macrophage potential, and 
common monocyte progenitor (cMOP)242. CDP can give rise exclusively to 
plasmacytoid DC and precursors of conventional DCs (pre-DC)163, which egress the 
bone marrow and through circulation, seed the peripheral tissues where they give rise to 
both cDC1 and cDC2. DC potential has been described in human CD34+ progenitor 
compartment both in multi-lymphoid progenitors (MLP) and in the granulocyte and 




MDP45, cMoP46, CDP45 and pre-DC34,62,154 have been identified in human cord blood 
and bone marrow. Moreover, precursors committed exclusively to either the cDC1 or 
cDC2 fate have been described both in mice248 and humans154,204 (Figure 1-3). 
Nevertheless, the phenotype of the human circulating pre-DC precursors, including the 
already committed pre-DC1s and pre-DC2s, has not reached a full consensus. Breton et 
al. first identified human pre-DCs in blood, bone marrow and peripheral lymphoid 
organs as lin- CD34- CD45RA+ CD135+ CD116+ CD123int CD117+34, and described 
the existence of pre-committed progenitors for cDC1s (CD172a-) and cDC2s 
(CD172a+) based on the expression of CD172a204. More recently, single-cell mRNA 
sequencing and cytometry by time-of-flight (CyTOF) analysis on human PBMCs were 
used to identify human DC progenitors154. Pre-DCs were described as lin- CD34- 
CD45RA+ CD135+ CD123+ CD33+, a phenotype similar to the one described 
previously34. However, few differences were highlighted such as the higher levels of 
CD123 expression, the inclusion of the CD117- cells as pre-DCs and the need to assess 
CD33 expression to distinguish them from pDC (CD33-)154. Moreover, even if pre-
DC1s and pre-DC2s were defined as CD1c- CADM1+ (pre-DC1) and CD1c+ CADM1- 
(pre-DC2) within the CD123lo/- fraction, the pattern of expression of CD172a was 
consistent with the previously reported phenotype204. Finally, a more divergent 
phenotype for DC progenitors was identified by unbiased transcriptomic analysis of 
blood PMBCs62. CD45RA+ CD34int CD100+ cells were shown to give rise to all DCs 
subsets, including pDCs, which suggests a less committed state of these precursors 
more consistent with CDPs. However, these cells did not express the cytokine receptors 
CD123, CD135, CD115 and CD116 previously reported either in MDP, CDP45 or pre-
DCs34,154. Therefore, it is not clear if these cells might represent a less committed 




morphology and phenotype62. Nevertheless, further studies are needed to clarify 
whether these phenotypically different precursors are related and how. 
 
Figure 1-3. Ontogeny of human mononuclear phagocyte system. Human DCs and monocytes arise 
from a common progenitor, the monocyte and dendritic cell progenitor (MDP) residing in the bone 
marrow. MDPs give rise to both monocyte- and DC-committed progenitors, the cMOP and CDP, 
respectively. CDPs differentiate into circulating pre-DC that can be further subdivided in subset-specific 
precursors, the pre-DC1 and pre-DC2, which can give rise to terminally differentiated DC1 and DC2, 
respectively. Moreover, DC potential has been recently described in early hematopoietic progenitors, 
suggesting that DCs can also originate from human multipotent lymphoid progenitors (MLP)247.  
 
1.8 The bone marrow niche 
Adult hematopoietic stem and progenitor cells are localised in the bone marrow. Since 
its colonisation by hematopoietic stem cells migrating from the fetal liver during 
embryonic development, the bone marrow represents the primary site of hematopoietic 
development throughout adult life. In the bone marrow, HSC and hematopoietic 
progenitors reside in defined regions supporting their maintenance and expansion: the 



















marrow, and its importance for HSC function, was originally postulated in the late 
1970s by Ray Schofield, based on the superior ability of the bone marrow to support 
HSCs as compare to the spleen249. The endosteal surface of the bone was initially 
considered the principal component of the niche, suggesting a regulatory role for the 
osteoblastic lineage in hematopoietic maintenance250–252. More recently, technical 
improvements in the live imaging techniques along with the identification of more 
specific markers to visualise HSCs, enabled the localisation of these cells in proximity 
of the sinusoidal vasculature253, revealing a primary role of perivascular cells in the 
HSC regulation254–257. The conditional knockout of essential niche factors in 
perivascular cells and osteoblasts further supported this hypothesis258–260. However, 
several cell types have been described as important components of the hematopoietic 
niche261	(Figure 1-4).	
	
1.8.1 Cellular composition of the niche 
Perivascular cells have been proposed to be the main regulators of HSC maintenance 
and regeneration in the bone marrow niche. In human, this population of cells has been 
characterised as CD146+ stromal progenitors262, and a fraction of them also express 
platelet-derived growth factor receptor-α (PDGFRα), CD51 (ITGAV) and nestin263,264, 
defining them as bone marrow mesenchymal stem and progenitor cells (MSPCs)263. 
Perivascular stromal cells comprise at least four overlapping and highly redundant cells 
types that can be defined as CXCL12-abundant reticular (CAR) cells265, cells marked by 
the expression of nestin (Nes-GFPdim and Nes-GFPbright)264, leptin receptor-expressing 
cells (LepR)259 and cells expressing the transcription factor osterix (Osx-Cre)258. All 
these populations are the major producers of essential niche factors, such as CXCL12 
and stem cell factor (SCF). Conditional deletion of CXCL12 in all subsets showed an 




their complete depletion258–260,266, confirming an essential role of perivascular stromal 
cells in the regulation of the HSC maintenance. 
Early in vitro studies suggested that osteoblasts could sustain HSCs self-renewal and 
differentiation267. However, mouse genetic experiments have recently demonstrated that 
osteoblasts do not contribute to HSCs maintenance by producing key factors of the 
niche258–260 and they do not associate with hematopoietic progenitors254,255. Endothelial 
cells (ECs) have been reported as a further component of the bone marrow niche. ECs 
isolated from bone marrow can support expansion and differentiation of human CD34+ 
hematopoietic progenitors in vitro268, and the abrogation of angiogenic activity of ECs 
impaired their ability to support long-term HSCs269. More importantly, the selective 
deletion of either CXCL12 or SCF in ECs resulted in decreased numbers of HSCs in the 
bone marrow, highlighting the important contribution of these cells for a functional 
niche259,260. Moreover, other cell types including members of the sympathetic nervous 
system270–273, macrophages274,275, megakaryocytes276,277 and adipocytes278,279 have been 
proposed to actively influence HSCs homeostasis, by directly or indirectly modulating 





Figure 1-4. Key cell types regulating HSC maintenance in the niche (Mendelson et al, 2014280). 
Schematic of the cell types constituting the bone marrow niche. Key growth factors regulating HSC 
maintenance and expansion (e.g. CXCL12 and SCF) are produced by perivascular stromal cells residing 
in the bone marrow, which can be subdivided in four main cell types: CAR cells, Nestindim Lepr+ cells, 
Nestinbright cells and cells expressing the transcription factor osterix (Osx-Cre cells). 
 
1.8.2 Growth factors of the niche 
HSC quiescence, self-renewal and differentiation in the bone marrow niche are finely 
regulated processes that require a balanced contribution of many factors provided by the 
surrounding microenvironment. Genetic experiments in the mouse model allowed the 
identification of essential factors involved in HSC maintenance and mobilization such 
as CXCL12 (SDF1), SCF and Thrombopoietin (TPO). However, other important 
signalling pathways have been associated with HSC regulation and function, even if 







Table 1-3. Essential growth factors of the bone marrow niche 
Growth 
factor Mouse model Localisation/target HSCs Ref. 
CXCL12 
(SDF1) 









Osx-Cre X Cxcl12fl/fl Perivascular/CXCL12 Increased mobilisation 
Tie2-Cre X Cxcl12fl/fl Endothelial cells/CXCL12 Reduced numbers 
Col2.3-Cre 
xCxcl12fl/fl Osteoblast/CXCL12 Not affected 
Vav-Cre X Cxcl12fl/fl Hematopoietic cells/CXCL12 Not affected  
SCF  
c-Kit-/- Global/c-kit Impaired repopulation 
287 
 
Sl/Sld Global/membrane-bond SCF Absent 288 
TPO 
Mpl-/- Global/Mpl Reduced numbers 295 
293 
TPO-/- Global/TPO Reduced numbers 
 
1.8.2.1 CXCL12 
The C-X-C motif chemokine 12 (CXCL12), also known as stromal cell-derived factor 
(SDF1) is a key chemokine involved in HSC maintenance and more importantly in their 
retention in the bone marrow niche265,281–284. Perivascular stromal cells (CAR, LepR-
Cre, Nes-GFP, Osx-Cre) represent the main source of CXLC12 in the bone marrow, by 
expressing 100 to 1000-fold higher levels than endothelial cells and osteoblasts, 
respectively258,260,265,285,286. The critical role of CXCL12 in HSC homing and 
maintenance has been demonstrated in several mouse models. The global deletion of 
CXCL12, as well as its receptor CXCR4, resulted in the depletion of HSCs from 
BM265,281,287. Moreover, conditional knockouts of CXCL12 in perivascular stromal 
subsets (LepR-Cre and Osx-Cre) displayed increased mobilization of HSCs from BM 
258,260, while its deletion restricted to endothelial cells (Tie2-Cre) appeared to 




of CXCL12 produced by other bone marrow tissues is dispensable for HSC 
maintenance, as demonstrated by its conditional ablation in osteoblasts (Col2.3-Cre and 
Sp7-Cre) or hematopoietic cells (Vav1-Cre)258,260 (Table 1-3). 
1.8.2.2 SCF 
Stem cell factor (SCF) is a cytokine expressed by a number of cells types that interact 
with its receptor c-Kit, a class III tyrosine kinase receptor expressed on hematopietic 
stem and progenitor cells. SCF can be produced in both its soluble or membrane-bond 
forms, depending on alternative mRNA splicing and proteolytic cleavage. SCF acts on 
HSCs by promoting their survival288, and its fundamental role in the niche 
microenvironment has been extensively demonstrated in mouse genetic experiments 
(Table 1-3). HSCs lacking c-Kit expression showed an impaired repopulation 
potential288. On the other hand, HSCs are absent in mice exclusively expressing the 
soluble form of SCF (Sl/Sld), highlighting the essential role of membrane-bond SCF for 
HSC maintenance289,290. This was further demonstrated by the preferential localisation 
of HSCs in proximity of trans-membrane SCF-expressing cells in a niche containing 
both wild-type and Sl/Sld stromal cells281. Moreover, membrane-bound SCF plays a role 
in the retention of HSCs in the niche. Indeed the proteolytic cleavage of SCF mediated 
by the receptor activator of nuclear factor NF-kB (RANK) ligand and cathepsin K 
produced by osteoclasts, increases mobilisation of HSCs in the niche291. Since cell-cell 
contact is required for a functional SCF signalling, SCF expression has been used to 
identify the most important cell components of the niche. 
1.8.2.3 TPO 
Thrombopoietin (TPO) is a cytokine primarily involved in megakaryocyte and platelet 
development, even if an important role of TPO and its receptor Mpl in the maintenance 
of hematopoietic progenitors has been described292–295. Indeed, mice lacking the 




the bone marrow296 (Table 1-3). Furthermore, TPO has been shown to contribute to the 
generation and expansion of definitive HSCs in the developing embryo, and to promote 
HSC survival in vitro297,298. Liver and kidney represent the main source of TPO in vivo, 
even though low levels of expression were also detected in the bone marrow 
stroma299,300. However, the conditional knockout of TPO in niche stromal cells is 
needed to assess the importance of their contribution. 
1.8.2.4 Other factors 
Other factors have been implicated in the regulation of HSC homeostasis in the bone 
marrow niche, even if the experimental demonstration of their involvement is still a 
source of controversy. 
Notch signalling was initially proposed as an important pathway for HSC regulation in 
the bone marrow niche301, and this was supported by the observations that Notch is 
capable to expand HSCs ex vivo in gain-of-function experiments. Moreover, Notch 
activity was detected in transplanted HSPCs302 and Notch ligands were detected in the 
endosteal surface and associated with increased HSC activity250. However, in vivo 
knockout models failed to confirm these observations303,304. 
Wnt/β-catenin represents a very complex signalling pathway, whose involvement in the 
hematopoietic niche has not been fully elucidated. Early studies suggested that HSC 
maintenance in the bone marrow is not affected by the absence of Wnt signalling305,306. 
However, later studies revealed the osteoblast-specific expression of important 
mediators of the pathway, such as dikkopf homolog 1 (DKK1), secreted frizzled-related 
protein 1 (SFRP1) and Wnt inhibitor factor 1 (WIF) and reported a consistent effect of 
their modulation on HSC self-renewal and exhaustion307,308. Based on these 
observations, Wnt appeared to be involved in HSC maintenance by promoting 





1.9 DCs and cancer immunotherapy 
The series of events characterising the immune response against cancer have been 
recently summarised in the concept of “Cancer-Immunity Cycle” by Chen and 
Mellman309, and in this context dendritic cells play a major role in the initiation and 
maintenance of an antitumor immune response (Figure 1-5). The Cancer-Immunity 
Cycle is defined by seven major steps leading to the establishment of a self propagating 
immune response and ending with the killing of cancer cells. The process starts with the 
release of cancer cell antigens (step1) that can be engulfed and transported to the lymph 
nodes by antigen presenting cells (APCs) (step 2). Here, APCs efficiently prime and 
activate antigen-specific cytotoxic T cells (CTLs) (step 3), which migrate through 
circulation (step 4) and infiltrate the tumor (step 5). Once at the tumor site, CTLs can 
recognise (step 6) and kill the cancer cells309. 
Dendritic cells play a fundamental role in this process by capturing and processing 
tumor-associated antigens (TAA) and presenting them to T cells. In order to induce an 
efficient cytotoxic T cell response, antigen phagocytosis is followed by DC maturation. 
Matured DCs reduce their phagocytic ability, express co-stimulatory molecules and 
migrate in a CCR7-dependent fashion toward the lymph nodes, where they are capable 
of secreting key cytokines to efficiently promote T cells activation310–314. For this 
reason, in the last two decades several DC-based strategies have been proposed for the 
therapeutic vaccination against cancer, including (i) non-targeted protein- and nucleic 
acid-based vaccines that can be captured by DCs in vivo, (ii) peptides/proteins coupled 
to antibodies targeting DCs specifically and (iii) ex vivo generated dendritic cells loaded 
with tumor antigens310. Two main approaches have been tested so far as a source of ex 
vivo generated DCs: the in vitro differentiation of DC-like cells from monocytes 
(moDCs) and the isolation, expansion, activation and re-injection of naturally 




promising source of clinically relevant cells, mainly due to the high numbers of 
monocytes that can be easily isolated from blood and differentiated into moDCs by the 
exposure to GM-CSF and IL-4. For this reason, numerous clinical trials have been 
performed in the last twenty years, and a quite extensive knowledge of the efficacy of 
this approach is now available310,315. Unfortunately, although moDC-based vaccination 
appeared to be safe and to successfully induce the expansion of circulating tumor-
specific CD4+ and CD8+ T cells, they failed to demonstrate a long-lasting beneficial 
effect on the overall clinical responses315,316. A better understanding of the mechanisms 
by which DCs interact with T cells and contribute to establish an efficient immune 
response highlighted important aspects that can explain the disappointing outcomes of 
moDC-based vaccination. Indeed, many limitations of moDC-based therapy have been 
identified, such as the poor migration to lymph nodes, the expression of inhibitory 
signals (IL-10, PD-L1 and PD-L2, e.g.) and an inefficient antigen loading and 
presentation314,317–320. For this reason, more recently the paradigm of DC-based 
vaccination shifted towards the use of naturally circulating subsets315. Indeed, 
preliminary results on patients affected by metastatic melanoma and treated with ex vivo 
expanded, activated and antigen-loaded pDCs, demonstrated that despite the limited 
magnitude of a melanoma-specific immune response, the pDC-based therapy resulted in 
a consistent increase of the patients overall survival321. Supporting this concept, a cell-
based therapy consisting in the ex vivo activation and antigen loading of isolated 
antigen-presenting leukocytes, showed a significant increase in the overall patients 
survival322, and received FDA approval for the treatment of prostatic cancer in 2010 
(Sipuleucel-T/Provenge®). These clinical studies contributed to the understanding that 
tumor growth is closely associated to one or more dysfunctional steps of the cancer-
immunity cycle, preventing a durable anti-tumor response. Several aspects may concur 




paucity and immaturity, subversion of DC function by tumors, lack of T cell infiltration 
and inhibition of T cell effector functions. Therefore, therapeutic approaches that aim at 
re-establishing a functional cycle may represent a successful strategy to induce tumor 
regression. Supporting this hypothesis, a recent publication demonstrated how an 
efficient expansion and activation of DCs in the tumor site along with PD-L1 blockade 
therapy can successfully improve the immune response against mouse melanoma and 
protect the animals from secondary tumors323.  
In this regard, the use of genetically modified iPSC-derived DCs may represent a 
valuable alternative to overcome some of the previously described limitations by 
providing an efficient platform to produce patient-specific DCs that (i) resemble the 
physiologically circulating subsets, (ii) can be in vitro manipulated to constitutively 
express tumor-associated antigens, (iii) can be in vitro activated by TLR stimulation to 
promote immunogenic responses and efficient T cell priming, (iv) can be genetically 
modified to abrogate signalling pathways negatively regulating different phases of the 
cancer-immunity cycle, such as antigen presentation (IL-10, IL-13 or IL-4, e.g) or T cell 
priming and activation (PD-L1 and PD-L2, e.g.). The PD-1/PD-L1 pathway represents a 





Figure 1-5. The Cancer-Immunity Cycle (Cheng and Mellman, 2013309). The Cancer-Immunity Cycle 
represents the series of events characterising the immune response against cancer. Antigen presenting 
cells, including DCs, pick up cancer cell antigens in the tumour site (1) and migrate towards the lymph 
nodes (2) where they are capable of presenting tumour-associated antigens (TAA) to T cells (3). 
Activated T cells can then migrate through the circulation (4) and infiltrate into the tumour (5), where 
they recognise and kill cancer cells (6-7). 
 
1.9.1 PD-1/PD-L1 axes 
Programed death 1 (PD-1) is an immune-checkpoint receptor known to negatively 
regulate T cell activity. When engaged by its specific ligands PD-L1 and PD-L2, PD-1 
induces apoptosis of the effector cell and therefore promotes tolerance by limiting T cell 
activity324–328. The expression of PD-L1 and PD-L2 can be induced in dendritic cells 
and macrophages as well as in activated B and T lymphocytes. Despite its predominant 
role in suppressing the immune system to prevent autoimmune diseases, PD-1 plays an 
essential role in responses against cancer 329,330. Indeed, many types of malignant cells 
express its ligands and can therefore prevent tumor eradication by inhibiting cytotoxic T 
cells activity329,331. Therefore, the PD-1/PD-L1 pathway represents one of the most 
successful targets of the immune checkpoint blockade in cancer therapy332–334. In this 




pre-clinical studies, targeting both the receptor and the ligand (Table 1-4). Noteworthy, 
two anti-PD-1 antibodies (Nivolumab and Pembrolizumab) have been lately approved 
by the FDA to treat metastatic melanoma, non-small cell lung cancer (NSCLC), head 
and neck squamous carcinoma (HNSCC) and Hodgkin lymphoma335–340. Furthermore, 
three anti-PD-L1 antibodies (Atezolizumab, Durvalumab, Avelumab) were recently 
approved for the treatment of bladder cancer341. Moreover, a recent publication has 
shown that the anti-PD-L1-mediated immunity in mouse melanoma is strictly dependent 
on the presence of dendritic cells, suggesting a major involvement of the PD-1/PD-L1 
pathway in the interaction of T cells with DCs in the lymph nodes, rather than with 
cancer cells in the tumor site323. For all these reasons, targeting PD-L1 in iPSCs may 
represent a potential strategy to increase the immunogenicity of iPSC-derived DCs 
against cancer. 
 
Table 1-4. PD-1 and PD-L1 antibodies in clinical development 




























1.10 Modelling human DCs development 
Human circulating DCs represent a very rare population of cells accounting for 
approximately 1% of blood PBMCs. For this reason, the use of ex vivo isolated DC 
subsets to better understand human DC function, regulation and development has 
proven to be a very challenging task. Therefore, the development of in vitro and in vivo 
systems to faithfully recapitulate DC differentiation from hematopoietic progenitors 
represents a fundamental tool for the study of human DC biology. For instance, the 
establishment of an in vitro platform supporting human DC differentiation enabled the 
identification of human MDP, CDP and pre-DC34,336 as well as the characterisation of 
human BATF3-dependent Clec9A+ cDC1 cells, equivalent to the mouse cDC1 
subset66,68. Moreover, the in vitro generation of DC-like cells (moDCs) from easily 
accessible human blood monocytes33, has provided an extensively used and invaluable 
platform to study human antigen presenting cells (APCs) and their interactions with T 
lymphocytes.  
Based on their unique ability to engulf, process and present antigens to T cells15, DCs 
represent an essential component of therapeutic vaccination against cancer. Therefore, 
the idea of developing reliable approaches to obtain patient specific DCs in order to 
induce a strong and specific response against cancers has gained increasingly interest in 
the last decades. However, the absence of a significant clinical benefit of the moDC-
based therapy316 and the very limited number of circulating DCs preventing their 
extensive use in anticancer immunotherapy, represent important drawbacks of this kind 
of approaches. 
In conclusion, the need to further elucidate the mechanisms underlying human DC 
biology as well as their potential clinical application in cancer immunotherapy, 
highlight the importance of establishing a reliable system to faithfully recapitulate 





1.10.1 Modelling human DC development in vitro 
Many attempts to generate human DC subsets in vitro have been performed in recent 
years, based on the use of growth factors known to be important in DC maintenance and 
differentiation (Table 1-5). 
The first experimental evidence that human monocytes can be induced to differentiate 
into DC-like cells upon exposure to GM-CSF and IL-4 in vitro, was provided by 
Sallusto and Lanzavecchia in 199433. This culture system represented an important 
technical advancement, enabling the study of key aspects of human APC functions in 
vitro. However, it is now commonly accepted that moDCs do not represent a faithful 
model of the naturally circulating subsets, due to important differences on their 
phenotype and function50,202. 
Pioneering work from Caux et al. also demonstrated the feasibility of differentiate 
human Langerhans cells and moDCs from cord blood-derived CD34+ hematopoietic 
stem and progenitor cells (HSPCs), paving the way for the development of more refined 
approaches to induce cDC and pDC differentiation form hematopoietic 
progenitors198,342,343.  
More recently, several methods have been reported to support the differentiation of 
human DC subsets from HSPCs (Table 1-5). All these approaches were based on the 
use of recombinant growth factors involved in HSPC maintenance and expansion, as 
well as DC differentiation. In some of the protocols mouse stromal feeder lines were 
used34,203,344, whereas others provided an extra step of HSPC expansion68,202. More 
importantly, all these methods were based on the use of GM-CSF, a cytokine 
dispensable for DC development in vivo205 and know to induce moDC differentiation 
both in vitro33 and in vivo50. Based on their phenotype, subset-specific TLR 




cDC2s and pDCs were reported. pDCs were characterised by the expression of 
CD123+, CD303+ and CD45RA+ in most of the protocols, and they were further 
validated by their ability to produce massive amounts of type I interferon in response to 
TLR7 and TRL9 stimulation34,203,344. cDC1s were also identified based on their specific 
expression of Clec9A (DNGR1), even if some discrepancies in their phenotype were 
observed when compared to blood DC1s, including the lack of CD141 expression69 or 
the presence of markers expressed in tissue DC1s such as CD1c, CD1a and 
CD172a34,68,69,202,203. Nevertheless, gene expression profiles of in vitro generated cDC1s 
aligned them to their human blood counterparts34,202,203. Finally, the differentiation of 
cDC2s was described in most of the protocols34,69,203. However, an extensive evaluation 
of the observed heterogeneity (CD14 expression, e.g.) was not performed34,203 and the 
potential contribution of monocyte-derived cells to the CD1c+ subset was not assessed. 
Indeed, when compared to in vitro generated moDCs, the gene expression profile of 
XCR1- CD1c+ DC2-like cells was consistent with their monocytic origin202. 
 













































































1.10.2 Modelling human DCs development in vivo 
The generation of mouse models supporting DC differentiation in vivo represents an 
essential tool for the study human DC development and functions in a more 
physiological environment, allowing the evaluation of their interactions with other cell 
compartments. In this regard, the generation of humanised mice models enabled a wide 
range of possibilities for the study of human immune system. Indeed, humanised mice 
have been extensively used as a model to study human hematopoietic hierarchy, human 
malignancies (mostly hematopoietic), and to perform preclinical studies on newly 
generated therapeutic approaches345. The “humanisation” process is achieved by 
transplantation of human hematopoietic progenitors into recipient mice. The successful 
engraftment relies on some fundamental features of the hosting animal: i) the absence of 
innate and adaptive immune responses, ii) the availability of a niche to favour human 
progenitors persistence and expansion and iii) the presence of cross-reacting signals 
supporting human cells maintenance and differentiation. 
Several mouse strains permissive to human hematopoietic cells engraftment have been 
generated in the last 30 years346. The abrogation of the mouse immune system has been 
achieved by targeting the main effectors of the innate and adaptive responses, including 
B and T lymphocytes, NK cells and macrophage phagocytosis. The absence of mouse B 
and T cells is a consequence of the defective V(D)J recombination, which occurs 
naturally in mice harbouring the severed combined immunodeficiency (SCID) (as a 




alternative can be induced by targeting one of the recombination activating genes RAG1 
or RAG2352–356. Moreover, deficiency of NK cells can be achieved by mutation of the 
Il2rγ gene, coding for the common gamma chain of cytokine receptors, which is share 
among different member of the IL-2 family, including IL-15 and resulting in the 
complete abrogation of NK cells development354,355,357–359. Furthermore, phagocytic 
tolerance against human cells can be induced by triggering the CD47-SIRPα pathway, 
also known as “don’t eat me” signal. SIRPα is trans-membrane protein expressed in 
phagocytic cells, whose interaction with the endogenous CD47 results in phagocytosis 
inhibition. In most mouse strains, mouse SIRPα does not bind to human CD47 thus 
mediating phagocytosis of human cells. In mouse models permissive to human 
hematopoietic cells, this interaction is achieved either by introducing the human SIRPA 
gene as a bacteria artificial chromosome (BAC) or by replacing its mouse homologous 
(knock-in)360,361, or by generating the humanized mouse in the non-obese diabetic 
(NOD) background, whose Sirpa allele is very similar to the human one and interacts 
with human CD47362. The combination of these different strategies allowed the 
generation of numerous humanised mice models over the years, which are listed in 
Table 1-6. 
Table 1-6. Humanized mice models 
Strain Name Features Ref. 
CB17-Scid SCID T and B cells deficiency 346, 347 
NOD-Scid  T and B cells deficiency phagocytic tolerance 348, 349, 350 
NOD-Scid Il2rg-/-  NSG T, B and NK cells deficiency phagocytic tolerance 356, 357, 358 
BALB/c-Rag2-/- Il2rg-/- BRG T, B and NK cells deficiency 354 
Tg(hSIRPA)Rag2-/- Il2rg-/- SRG T, B and NK cells deficiency phagocytic tolerance 360 
  
A second requirement for a successful engraftment is the availability of a hematopoietic 




achieved by sub-lethal irradiation of the recipient mice. However, alternative 
approaches have been reported recently, based on generation of genetically modified 
animals characterised by impaired HSC maintenance, which confers	 a	 competitive	
advantage	 to	 human	 progenitors	 homing	 in	 the	 bone	 marrow	 niche363–365.	
Furthermore,	 the	development	of	a	human	immune	system	in	humanized	mice	 is	
strictly	 dependent	 on	 external	 growth	 factor	 provided	 by	 the	 surrounding	




the	 human	 hematopoietic	 cells	 generated	 in	 humanised	 mice346,366,367.	 This	
includes	 the	 limited	 differentiation	 of	 functional	myeloid	 and	 NK	 cells368,369,	 the	
lack	 of	 B	 cells	 maturation370,371	 and	 the	 impaired	 selection	 and	 maturation	 of	
human	 T	 cells372,373.	 To overcome this issue, a new approach has been developed, 
based on the generation of transgenic animals expressing human hematopoietic factors 
either by replacing their mouse counterparts or under the control of a constitutively 
active promoter. This strategy has been used to generated	 humanised	 models	
expressing	 human	M-CSF374,	 membrane-bond	 SCF375,376,	 TPO365,	 GM-CSF	 and	 IL-
3377,378	 and	 the	 combination	 of	 M-CSF,	 IL-3,	 TPO	 and	 GM-CSF379.	 The	 most	
representative	example	of	 this	 cohort	of	models	 is	 the	generation	of	 the	MISTRG	
mouse379.	 Indeed,	 the	 combinatorial	 expression	 of	 human	M-CSF,	 IL-3,	 TPO	 and	
GM-CSF	 resulted	 in	 the	 ability	 of	 these	 mice	 to	 develop	 a	 functional	 myeloid	
compartment,	 capable	 of	 triggering	 an	 effective	 innate	 response	 against	 viruses	
and	bacteria379. However, even if the full characterisation of human DC subsets has not 
been reported for this model, the observed myeloid compartment mainly comprised 




effect of Flt3L may be required to induce an efficient DC differentiation. In fact, 
successful generation of all human DC subsets has been described in humanised mice 
treated with human Flt3L70,179 (Table 1-7), providing experimental evidences that 
functional DCs can be generated in vivo from human hematopoietic progenitors. 
 
Table 1-7. Differentiation of human DC subsets in humanized mice 
Strain Treatment Irradiation DC subsets Time Ref. 








NSG DNA encoding huFlt3L Yes n/a 12 weeks 
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2 Hematopoietic system during embryonic development 
Embryonic hematopoiesis represents a very organised and finely regulated 
developmental program, extremely conserved among the different animal models used 
to study early embryo development, such as zebrafish, frog, chick and mouse382,383. 
Hematopoietic cells originate from mesoderm, one of the three embryonic germ layers 
from which muscle and connective tissues are also generated. This process is strictly 
regulated and organised in space and time, and it occurs both in extra- and intra-
embryonic sites: the yolk sac and the embryo proper384. The first wave of hematopoietic 
cells with limited potential originates from the yolk sac and support the early phases of 
embryo development385. Afterwards, the first hematopoietic stem cell (HSC) showing 
self-renewal capability and multi-lineage potential is detected in the aorta-gonad-
mesonephros (AGM) region of the mouse embryo proper386. HSCs then migrate to the 
fetal liver where they undergo maturation and expansion before seeding the bone 
marrow, where they reside in a specialised niche to support the hematopoietic system 
during adulthood. The spatio-temporal organisation of embryonic hematopoiesis is a 
conserved feature of human and mouse embryonic development, even if the duration of 
each step is considerably different. In mouse, the subsequent stages occurring during 
embryogenesis can last less than a day, and are defined by specific embryonic days (E). 
On the contrary, in humans these intervals last significantly longer, and a different 
classification, known as Carnegie stages (CS), is used to describe the external 
morphological changes during embryo development387. The fact that embryonic 
hematopoiesis takes place in different sites led to the idea of a primitive program taking 
place in the yolk sac, as opposed to a definitive program occurring in the intra-
embryonic tissues. More recently this oversimplified view has been challenged and the 
identification of further programs (EMPs, LMPPs, i.e.) with “definitive” features 




separation of these two processes. Moreover, the temporal organisation of 
hematopoietic cell generation in the embryo led to the concept of an embryonic 
hematopoiesis organised in waves, which consist in the sequential activation of distinct 
programs in very defined intervals of time. 
 
2.1 Primitive versus Definitive Hematopoiesis. 
The terms “primitive” and “definitive” hematopoiesis have been used in a rather broad 
sense, and this may sometimes represent a source of confusion in the interpretation of 
the available literature. In this regard, Medvinsky et al. pointed out that the term 
“definitive” hematopoiesis refers to all hematopoietic cells originating from a definitive 
HSCs (dHSCs), historically defined as a stem cell that can give rise to all the mature 
blood lineages in the adult hematopoietic system388. However, the authors acknowledge 
that the term definitive hematopoietic cells has been used to define cells that can give 
rise to myeloid and adult enucleated erythroid cells, in a less accurate way388. 
On the other hand, Lacaud and Kouskoff underlined that primitive hematopoiesis is 
most commonly defined as the first wave of hematopoietic cells that takes place in the 
yolk sac and generates primitive erythrocytes, megakaryocytes and macrophages389–392. 
Conversely, definitive hematopoiesis includes all the alternative hematopoietic 
programs occurring in the embryo after the primitive one, including Erythromyeloid 
progenitors (EMPs) in the yolk sac, Lymphoid-primed multipotent progenitors (LMPPs) 
in the yolk sac and para-aorta splanchnopleura (P-Sp) and definitive HSC (dHSC)389. 
The relationship between these two programs is not fully elucidated, but the more 
accepted model supports the idea that embryonic (primitive) and adult (definitive) 
hematopoiesis are independently generated. Embryonic hematopoiesis serves to 
maintain the embryo until the definitive program arises through the specification of 




development can be hypothesised, where the yolk sac and AGM are considered sites for 
the primitive and definitive programs, respectively. Observations from non-mammalian 
vertebrates support this view384,393,394. An alternative hypothesis relies on the existence 
of a common ancestor (not detected in experimental assays) that gives rise to sequential 
waves of hematopoiesis: a first wave generating primitive hematopoietic cells (but no 
dHSC) and a second one where dHSCs are generates and mature in the AGM. On these 
premises, the yolk sac appears to be the only tissue where the hematopoietic system 
originates, and AGM represent an intermediate “educational” site where HSC develop 
prior to colonisation of the fetal liver395. 
 
2.2 Waves of Hematopoiesis. 
In human and mouse embryo, hematopoietic cells originate in subsequent waves 
characterised by their time of appearance, localisation and potential. 
 
2.2.1 Primitive hematopoiesis  
The primitive hematopoietic program occurs in the yolk sac in a very precise stage of 
embryo development, corresponding to E7.5 in mouse and CS 7-8 in human385,396. 
Progenitors	generated	during	primitive	hematopoietic	program	originate from blast 
colony-forming cells (BL-CFC) through an intermediate precursor expressing 
endothelial markers397–399 and show	 a	 very	 restricted	 potential,	 giving	 rise	
exclusively	to	embryonic	erythrocytes,	megakaryocytes	and	macrophages385,391,400. 
Embryonic erythrocytes can be easily distinguished from their adult counterparts by 
their larger size, nuclear retention (eventually lost)385,396 and the expression of specific 
isoforms of globin. In human, primitive erythrocytes express ε-globin, whereas 
definitive erythrocytes express either γ-globin before birth or β-globin after birth401. 




hematopoiesis and β-globin if they originate from the definitive program402. Conversely, 
embryonic megakaryocytes and macrophages are substantially indistinguishable from 
their definitive counterparts, even if they present some peculiar features, such as 
reduced ploidy and platelets production for megakaryocytes391,400 and the non-
monocytic origin of primitive macrophages403,404. 
 
2.2.2 EMP hematopoiesis 
A second wave of hematopoietic cells arises in the mouse yolk sac at E8.25. These cells 
are distinct from the primitive program but they appear before the establishment of 
circulation and the identification of the first definitive HSC385,405. Based on their 
restricted potential to differentiate exclusively into erythroid, megakaryocytic and 
myeloid lineages, these cells were named as erythro-myeloid progenitors (EMPs) and 
they originate from endothelium via endothelial-to-hematopoietic transition 
(EHT)406,407. Originally identified as the onset of definitive hematopoiesis in the yolk 
sac385,408,409, EMPs are now considered as a separate hematopoietic program distinct 
from primitive and definitive hematopoiesis. The most relevant experimental evidence 
supporting this notion is the ability to separate EMPs from both primitive and definitive 
progenitors based on the expression of cKit, CD41 and CD16/32 and the lack of SCA1 
in the mouse embryo410,411. When cultured in vitro, EMPs isolated from mouse embryo 
have the potential to differentiated into erythrocytes, megakaryocytes, macrophages, 
neutrophils, eosinophils and basophils. More importantly, no lymphoid potential has 
ever been reported for these cells. In vivo transplantation experiments have shown that 
EMPs provide only a short-term erythroid, myeloid and platelets engraftment when 
compared to HSCs. Moreover, erythrocytes originating from EMPs can be distinguished 
from the definitive ones by their simultaneous expression of low levels of embryonic 




observed in mouse embryogenesis occurs at CS13-15, and even if it has not been 
formally proved yet, early studies support this observation412. 
 
2.2.3 LMPP hematopoiesis 
Concurrently to EMPs appearance, B and T cells can be observed in the yolk sac and 
para-aortic splanchnopleura (P-Sp) before the establishment of circulation and the 
generation of the first dHSC413–415. Lymphoid-primed multipotent progenitors (LMPPs) 
have been identified in the yolk sac at E9-9.5416. LMPPs originate from Ve-Cadherin+ 
Tie2+ CD41- endothelial cells413,415 and are characterised by their potential to generate 
T lymphocytes (both αβ and γδ)413,414, B lymphocytes (type B1 and marginal 
zone)413,417 and myeloid cells416, partially overlapping the EMP hematopoietic program. 
In the yolk sac, EMP and LMPP programs together give rise to a great variety of 
hematopoietic lineages comparable to the HSC-derived cells in the definitive 
hematopoiesis. However, the existence of a common progenitor linking these two 
programs has not been reported, and the ontogeny of EMPs and LMPPs requires further 
investigation to elucidate the underlying mechanisms regulating these pre-HSC 
programs418.  The main function of EMPs and LMPPs is to actively support embryo 
early life during development. However, there are several examples of cells in the adult 
that have an EMP- or LMPP-origin, suggesting that these embryonic-derived cells fulfil 
functions other than supporting early embryo development. Of note, the EMP-origin of 
most of tissue resident macrophages has been extensively demonstrated, even though 
some controversy still remains on the major path of ontogeny followed by the 
development of microglia in the brain36,37,41,419,420. Furthermore, type1 B cells in mouse 






2.2.4 Definitive hematopoiesis and dHSCs 
Definitive hematopoietic stem cells (dHSCs) can be detected in the AGM, vitelline and 
umbilical arteries from E10.5 in mouse386,423 and CS13 in human424–427. Definitive 
hematopoiesis takes place following the primitive program in the embryo proper and 
ultimately gives rise to definitive hematopoietic stem cells (dHSCs). The transfer of 
quail	embryos	to	chicken	yolk	sac provided the first experimental evidence supporting 
the intra-embryonic origin of dHSC384,428.	 Afterwards,	 the	P-Sp/AGM	 region	 of	 the	
mouse	 embryo	 has	 been	 identified	 as	 the	 major	 site	 of	 dHSC	 generation	 in	
vertebrates,	 including	 human386,426,427,429,430.	 However,	 alternative	 locations	 have	
been	described	as	sites	of	dHSC	differentiation	such as yolk sac vessels407,423,431–433, 
vitelline and umbilical arteries434,435, placenta436, head vasculature437, and 
endocardium438. It has been clearly established that dHSCs originate from the 
endothelial layer of the dorsal aorta424,439,440 and this is supported by lineage tracing 
experiments in mice, using a Ve-Cadherin-specific cre-mediated fate mapping 
approach441–444, and in human ESC-based in vitro evidences399,445. Hematopoietic cells 
bud off from the endothelium and enter the circulation. This specialised endothelium 
with hematopoietic potential has been named Hemogenic Endothelium (HE), and the 
transformation of flat aortic endothelium to hematopoietic cells (endothelial-to-
hematopoietic transition or EHT) has been characterised in chicken embryos440, mouse 
embryos441 and observed in live microscopy444,446,447.  
The self-renewing HSC are localised in intra aortic hematopoietic clusters (IAHC) 
along with non self-renewing progenitors. In mouse, IAHC are localised in the ventral 
floor of the dorsal aorta and correlates with the presence of functional HSCs448. 
Similarly, humans IAHC are located in the ventral AGM region and the presence of 
functional human dHSC within the IAHC has been confirmed by immunophenotype 




the number of cells in the IAHC of the AGM region largely exceeds the number of 
HSCs426, which supports the idea that developing not-yet-transplantable HSCs with 
immature phenotype constitute part of the clusters450–452.  
 
2.2.4.1 Definitive HSCs phenotype and maturation  
Definitive hematopoietic stem cells (dHSCs) are defined by their ability to give rise to 
all blood lineages (multipotency) as well as to daughter HSCs (self-renewal). In mice, 
HSCs were first identified by the ability of bone marrow cells isolated from a donor 
mouse to undergo clonal expansion in the spleen of an irradiated recipient453,454. For this 
reason, the progenitor originating the clone (dHSC) was called colony-forming-unit-
spleen (CFU-S). The observation that single CFU-S can give rise to both differentiated 
cells and new CFU-S progenitors established the self-renewability behaviour of these 
multipotent progenitors455,456. 
Substantial efforts have focused on the identification of the precise phenotype of dHSCs 
both in humans and mice. During embryonic hematopoiesis the first dHSC originates in 
the AGM region of the embryo and these newly generated dHSCs can be identified as 
CD150- VE-Cadherin+ CD45+ CD117+ CD34+ CD41+/- cells in mouse408,457,458, and 
VE-Cadherin+ CD45+ CD117+ CD34+ CD90+ CD105+ CD38- CD45RA- cells in 
human449.  
The ability of dHSC to engraft and provide long-term reconstitution (LTR) in lethally 
irradiated recipients represents an extremely powerful assay to evaluate the 
differentiation and maturation potential of newly generated dHSC. In mice, the first 
dHSC capable of repopulating an adult recipient appears in the AGM at 
E10.5386,423,426,457. Similarly, cells isolated from human AGM at CS 14 can successfully 
provide multi-lineage long-term engraftment in immunodeficient mice (NSG)426. 




neonatal recipients459,460, suggesting that dHSCs precursors are already available at E9 
in these sites, even if a further maturation step is required to acquire repopulation 
activity. Further evidences supporting this notion were provided by in vitro co-cultures 
of VE-Cadherin+ cells isolated from AGM at E9.5-10 on OP9 or endothelial feeder 
cells. After co-culture AGM-derived cells, named as pre-HSCs, acquired the ability to 
engraft adult recipient mice, even if yolk sac-derived cells isolated at the same stage of 
development failed to do so450,451,461,462. These experimental evidences led to a more 
precise classification of the maturation steps that dHSCs precursors undergo before 
acquiring a fully functional phenotype. In a three-step process, VE-cadherin+ CD45- 
pro-HSC first differentiate into VE-cadherin+ CD45- CD41+ type1 pre-HSC followed 
by the acquisition of CD45 expression and the consequent appearance of the VE-
cadherin+ CD45+ CD41+ type2 pre-HSC which further mature in fully functional HSC 
with LTR capability451,461. Finally, the acquisition of MHCI expression marks the 
appearance of a fully functional matured dHSCs, characterised by LTR activity in 
conventional recipients463. An important role in promoting pre-HSC maturation is 
played by endothelial cells, a key component of the hematopoietic niche. Indeed, 
overexpression of adenoviral protein E4ORF1 in endothelial cells activates the AKT 
pathway promoting survival and inducing a state that closely resemble the endothelial 
cells in the hematopoietic niche464. AKT-activated endothelial cells have been shown to 
support maintenance and expansion of HSCs isolated from mouse AGM by inducing 
the expression of Notch ligands462, as well as supporting the generation of engraftable 
HSCs from monkey iPSCs465.  Moreover, extracellular matrices also play an important 
role in the hematopoietic niche. Sub-aortic mesenchyme underneath the IAHC produces 
extracellular matrix rich in Tenascin C466. Tenascin C is produced by overgrown OP9 in 
vitro, which appeared to be superior in promoting hematopoietic differentiation. 




chemically defined conditions, and supports the generation of progenitors with 
multilineage potential but limited self-renewal467. 
 
2.3 Spatiotemporal progression of embryonic hematopoiesis  
2.3.1 The yolk sac  
The first appearance of hematopoietic cells in the embryo occurs in the yolk sac (YS) 
around E7.5 as a consequence of extra-embryonic mesoderm ingress through the 
posterior primitive streak and the subsequent differentiation into hematopoietic cells468. 
In the yolk sac, hematopoietic as well as endothelial progenitors are localised in the YS 
blood islands469.   
Based on the observation that the yolk sac is the site where the first hematopoietic cells 
appear, it was initially proposed that HSCs originate from YS progenitors. Supporting 
this hypothesis, the injection of donor cells isolated from the YS into embryonic 
circulation of a recipient mouse resulted in the detection of donor T cells in the recipient 
thymus470. However, experiments performed in the avian model and in Xenopus led to 
the opposite conclusion. In fact, the generation of quail-chicken and congenic chicken 
chimeras clearly showed that YS hematopoietic cells only transiently contribute to the 
hematopoietic compartment and the definitive hematopoietic program has an intra-
embryonic origin384,471. Likewise, experimental evidence in Xenopus laevis established 
that YS and intra-embryonic blood compartments are independently generated and 
originate from different blastomers393. Moreover, additional evidence in the mouse 
model support this idea. Yolk sac cells at E8 (pre-circulation) are restrained to produce 
short-lived myeloid cells472 and they lack CFU-S before E9.5427 and dHSCs earlier than 
E11.5386,429. Only at E11.5 true dHSCs are detected in the mouse YS, which acquires 
the ability to expand them starting from E12.5473. Based on these observations it is 




dHSCs388. In addition, even though it is impossible to entirely exclude the ability of the 
YS to independently generate true multipotent dHSCs, their presence in the later stages 
of embryo development might represent the consequence of tissue repopulation by 
dHSCs of exogenous origin. The anatomical organisation of the human yolk sac 
significantly differs from the mouse. The mouse YS consists of a whole structure that 
surrounds the embryo, whereas in human it is a balloon-like formation of mesoderm 
origin, which is localised in front of the embryo and later differentiates into endothelial 
and hematopoietic erythroblast to support embryo formation. However, like in mouse, 
the human yolk sac is the first site of hematopoietic cell formation. At CS7-8 large 
embryonic erythrocytes arise, along with rare primitive macrophages and 
megakaryocytes396,474. Subsequently, at CS 10 the first erythroblast can be observed in 
the cardiac cavity followed by the appearance of the first CD45+ cells425, underling the 
establishment of circulation, a further aspect shared with the mouse developing 
embryo475. 
 
2.3.2 The AGM  
In the mouse embryo, the first CFU-S is identified in the AGM at E9.5 in higher 
numbers than in the yolk sac427. Also, the AGM has been described as a powerful 
source of dHSC activity386 and AGM-derived cells are capable of long-term 
reconstitution as early as E10429. All together this experimental evidence support the 
notion of an intra-embryonic origin of mammalian hematopoiesis384,430. However, based 
on these results, it is not possible to completely rule out the potential contribution of the 
yolk sac to adult hematopoiesis by providing some sort of dHSC precursor not detected 
in the assays performed so far. The formation of the AGM in the embryo follows a 
defined set of events and it has been best described in non-mammalian vertebrates. In 




mesoderm476, which corresponds to the dorsolateral plate (DLP) in amphibian and the 
posterior lateral mesoderm (PLM) in zebrafish, two animal models extensively used to 
decipher early embryo development. The adult hematopoietic program in the AGM 
starts with the specification of DLP cells into endothelial (expressing Flk1 and Fli1) and 
hematopoietic (marked by SLC, GATA2 and LMO2 expression) cells prior the 
migration to the midline477,478. Subsequently, DLP cells migrate towards the midline and 
give rise to the dorsal aorta. At this stage VEGF signaling plays a key role in the 
modulation of SCL and GATA2 expression as well as the migration of Flk1+ 
endothelial cells to the midline479,480. Finally, arterial specification occurs coinciding 
with the emergence of adult hematopoietic cells. It has been demonstrated that 
morphogenesis of the aorta is linked to arterial and hematopoietic development 481–483. 
In zebrafish, arterial and hematopoietic programs are both controlled by Hedgehog, 
VEGF and Notch, whereas BMP4 appeared to be essential for the hematopoietic 
development only484. In mice, BMP4 and Sonic-hedgehog (Shh) play a role in the 
expansion of dHSCs in the AGM485,486. An extensive amount of experimental evidence 
support the pivotal role of the AGM as a source of dHSCs in the developing embryo. 
AGM explants can autonomously generate bona fide CFU-S in vivo427 and cells isolated 
from the AGM after E10 have been shown to successfully provide long-term 
reconstitution in adult mice429. Likewise, in vitro culture of AGM cells confirmed their 
ability to generate dHSC after E10.5473, which expand up to 150-fold when exposed to 
recombinant growth factors450,487. Moreover, in vitro analysis of embryonic tissues 
before the establishment of circulation (E7-8.5) showed that only cells originating from 
the P-Sp/AGM region have the ability to generate multipotent progenitors both in 
mice488 and in humans489. Conversely, only erythro-myeloid progenitors were detected 
from yolk sac-derived cells488,489. Furthermore, no LTR activity was reported for any of 




were capable of long-term reconstitution when engrafted into immunodeficient Rag γc-/- 
mice, supporting the idea that immature dHSC precursors are localised in the AGM, 
even though a further maturation step, including the acquisition of MHCI expression, is 
needed to become fully functional472. 
Several lines of evidence support the idea that hematopoietic progenitors are generated 
in a short window of development. Fate mapping of labelled cells expressing VE-
Cadherin441 or RUNX1395 showed labelling of 100% of adult HSCs only when cre 
recombinase was provided between E8.5 and E9.5. Moreover, the number of 
progenitors in AGM massively increases at E9 and E10, reaching a peak at E10.5 and 
decreasing thereafter. In the AGM, newly generated dHSCs are localised in intra-aortic 
hematopoietic clusters (IAHC) on the ventral floor of the dorsal aorta. IAHC have been 
observed in many species and they are characterised by the expression of both 
endothelial and hematopoietic markers386,424,434,440,490. In humans, the intra-embryonic 
hematopoietic wave is marked by the appearance of IAHC at CS13 on the ventral wall 
of dorsal aorta in the AGM region491. This formation lasts until CS17 and as opposite to 
mice development, it is restrained in the floor of dorsal aorta in the pre-umbilical 
area424,425. 
 
2.3.3 Alternative sites of embryonic hematopoiesis 
2.3.3.1 Placenta 
In mice and humans the placenta has been described as a hematopoietic niche, 
favourable to dHSC maintenance and expansion436,487. However, it is unclear whether 
the detected cells are newly generated dHSCs or circulating progenitors colonising the 
tissue.  
In mice, dHSC are detected in the placenta simultaneously to dHSC emergence in the 




Nevertheless, fully functional dHSCs showing repopulating potential arise only at 
E10.5-11 and after a rapid expansion around E12.5 they reduce in numbers by E15.5, 
suggesting potential translocation to the fetal liver436,492. Furthermore, hematopoietic 
clusters have been identified in the placenta of Ncx1-/- mice, a model lacking functional 
circulation and therefore suggesting an independent generation of dHSCs in this site493. 
However, placenta explants cultures failed to give rise to definitive HSCs494. In the 
human placenta, hematopoietic cells are detected as early as week 4-5, and they include 
CD34hi CD45lo CD38- progenitors containing high CFU-Cs and CD34+ CD45lo 
progenitors committed to erythroid and myeloid lineages495. At this stage human 
placenta represent also a site for erythrocytes maturation496. Transplantation 
experiments using immunodeficient mice (NSG) have demonstrated that the first human 
definitive HSC can be detected in the placenta as early as week 9487,497. As opposite to 
mice development, the appearance of dHSC in human placenta occurs significantly later 
than AGM, implying that human placenta is not a site for HSCs generation. However, 
the exact location, contribution and significance of HSCs in this site are not known. 
 
2.3.3.2 Umbilical cord 
An additional site that has been evaluated as a source of dHSC generation is the 
umbilical cord. RUNX1-expressing cell clusters have been detected in the murine 
umbilical cord498,499. Also, very rare dHSCs can be identified in umbilical cord vessel 
by E10.5423. Nevertheless, explants culture of murine umbilical cord cells did not give 
rise to any definitive HSC. 
 
2.3.3.3 Fetal liver 
The fetal liver is considered the main site for dHSC maturation and expansion. 




between E11.5 and E12.5, coinciding with their appearance in the embryonic 
circulation. Here, dHSCs undergo a massive expansion mediated by angiopoietin-like 
factors and SOX17500,501. From E16.5, dHSCs start migrating from the fetal liver and 
colonise the bone marrow, where they will localise in the hematopoietic niche, which 
represents the only source of HSCs in the adult and supports their maintenance and 
expansion throughout life.  
Very little is known about human fetal liver and most of the knowledge about its 
organization and function is based on experimental evidence obtained from the murine 
model. Human fetal liver emerged as a diverticulum of the embryonic gut at CS10. 
Starting from CS10 the liver contains primitive yolk sac-derived erythrocytes and 
CD45+ hematopoietic cells. Afterwards, by CS13, the human fetal liver contains 
CD34+ CD45+ cells425, most likely originating from the second wave of yolk sac-
derived EMP hematopoietsis410,412, even if strong experimental evidence is missing to 
fully support this hypothesis.  A fraction of these cells might also migrate from the 
IAHC in the AGM, which are known to emerge at the same stage of embryo 
development (CS13). However, the first human dHSC with transplantable potential 
appears in the fetal liver only at CS17426. 
 
2.3.3.4 Fetal spleen  
In mice, the fetal spleen is an organ of mesoderm origin502, which shows hematopoietic 
capacity exclusively during embryonic life, and subsequently become a secondary 
lymphoid organ in the adult. From E12 hematopoietic cells can be detected in the fetal 
spleen. This pool of hematopoietic cells consists in F4/80+ macrophages and large 
nucleated basophilic erythroblast503. The time of appearance and their independency 
from the transcription factor MYB support their primitive origin37. After circulation is 




and repopulation potential closely resemble their fetal liver counterparts253. However, 
HSCs in the fetal spleen are infrequent504: at E15.5 the HSC frequency of engraftment is 
5 HSCs per spleen and this value increases between E16.6 and E18.5253,505. Finally, no 
hematopoietic niche has been described in the fetal spleen, supporting the maintenance, 
expansion and survival of HSCs. 
 
2.4 Circulation in hematopoietic development  
The contribution of circulation in the emergence of definitive HSCs and its involvement 
in the spatiotemporal organisation of the embryonic hematopoietic system has not been 
fully elucidated yet. In mice, yolk sac vasculature connects to the embryo body at E8 
and a fully functional circulation starts to be established at E10. Originally, the role of 
circulation has been investigated mainly using two mouse models: the Ncx1-null 
embryos, which fail to initiate heart beating and die by E10392, and the Rac1 mutant 
embryos, in which cell migration is impaired475. Ncx1-null embryos showed normal 
erythrocytes and CFC-C count in the yolk sac but no hematopoietic progenitors were 
detected in the embryo body392. Likewise, Rac1 mutant embryos had normal CFU-C in 
the yolk sac, but no IAHC formation or fetal liver hematopoiesis was detected475. 
These results led to the hypothesis that intra-embryonic hematopoiesis is strictly 
dependent on migration of yolk sac-derived progenitor that colonise the AGM and give 
rise to multipotent dHSCs. However, an alternative approach was later proposed, and 
the attention was focused on the contribution of physical and mechanical forces 
produced by the blood flow and their ability to influence and modulate endothelial cells 
function. Indeed, initial observations supported the idea that endothelial cells express 
mechanical receptors that induce transcriptional and phenotypic changes in response to 
heart beating and blood flow506. Furthermore, nitric oxide (NO) showed to be involved 




cells could be modulated by shear stress508. On these premises, a new hypothesis was 
proposed, based on the idea that biochemical forces resulting from blood flow may be 
responsible for the induction of the aortic endothelium to generate hematopoietic cells 
through NO signalling509,510. It was demonstrated that shear stress can induce RUNX1 
and MYB expression and increase CFU-C production in vitro, both in AGM cells and 
embryonic stem cells (ESC), and this effect was abrogated by NO signalling 
inhibitors509. Moreover, in vivo administration of NO inhibitors abrogated intra-aortic 
clusters formation and reduced CFU-S, CFU-C and dHSC production in the AGM509. In 
addition, further in vivo evidence was provided from the “silent-heart” mutants in 
zebrafish, where the absence of heart beating induces a reduction of RUNX1+ and 
CD41+ hematopoietic progenitors. The re-establishment of a regular NO signalling by 
the administration of NO donors was sufficient to revert the phenotype510,511.	 
In conclusion, even if mouse models lacking a functional circulation/migration 
suggested that the translocation of a yolk sac-derived hematopoietic ancestor might be 
needed to initiate AGM hematopoiesis, the modulation of NO signaling, both in vitro 
and in vivo, appeared to play an essential role in the establishment of a definitive 
hematopoietic program. More interestingly, evidence was provided demonstrating that a 
yolk sac-independent hematopoiesis in the AGM was achieved in the absence of 
circulation by re-establishing a functional NO signaling. 
 
2.5 Endothelial origin of hematopoietic cells 
It is commonly accepted that blood cells originate from embryonic endothelium and this 
has been demonstrated in many experimental models, including, zebrafish, frogs, 
chicks, mice and humans411,444,446,512,513. The hemogenic endothelium (HE), a 
hematopoietic precursor with endothelial features present in hematopoietic niches in the 




process called endothelial-to-hematopoietic transition (EHT)445. In mice, EHT is a 
multistep process characterised by different stages of maturation of the hematopoietic 
progenitors388,450,461. Mouse hematopoietic progenitors in the embryo or differentiated in 
vitro from embryonic stem cells (ESCs) initially express the endothelial marker VE-
Cadherin, and subsequently acquire the expression of CD41 and CD45399,445,514,515. Even 
if expressing several endothelial markers, these cells do not display any endothelial 
potential anymore, and they are fully committed to the hematopoietic lineage. In mice 
AGM, EHT is a process driven by the co-operation of several transcriptional programs, 
including the transcription factors RUNX1 and SOX17, and it is antagonised by the 
expression of HOXA3442,516,517. 
In humans, KDR+ CD34- mesoderm derived precursors give rise to the endothelial cells 
forming the dorsal aorta upon acquisition of CD34+ expression518. From CS13, CD34 is 
expressed in both the aortic endothelium and the intra-aortic hematopoietic clusters 
(IAHC)425. These CD34+ CD45- cells isolated from AGM and umbilical vein give rise 
to both myeloid and lymphoid progeny when cultured in vitro519. Therefore, 
hematopoietic precursors (HE) are present in the CD34+ CD45- fraction of the aortic 
endothelium and they undergo EHT to give rise to fully committed hematopoietic cells. 
However, the CD34+ CD45- cells are an heterogeneous population that contain cells 
other than endothelial, as shown in in vitro differentiation experiments using human 
pluripotent stem cells (PSCs), where the expression of CD43 marks a subset of CD34+ 
CD45- cells already committed to the hematopoietic fate520. Therefore, CD34+ CD45- 
cells in human AGM may contain a fraction of precursors already committed to the 
hematopoietic lineage, and even if some of the mechanisms responsible for EHT have 
been described393, further studies are needed to clarify the set of events leading to 





In conclusion, even if the endothelial origin of the first definitive HSC in the human 
embryo represents the most commonly accepted hypothesis, further experimental 
evidences are missing to unequivocally rule out alternative scenarios388,426. For instance, 
the observed penetration of human IAHC into the endothelial lining of the dorsal aorta 
425 might be explained by: i) excessive EHT in the aortic endothelium; ii) migration of 
cells undergoing EHT towards the umbilical vein, as observed in zebrafish443,444; iii) 
trans-endothelial migration of hematopoietic precursors sitting underneath the 
endothelium towards the lumen of the dorsal aorta (no EHT)408,451 (Figure 1-6). 
Moreover, the expression of angiotensin converting enzyme (ACE), a feature of 
hematopoietic cells in the fetal liver, has been reported on few cells scattered beneath 
the endothelium of the human dorsal aorta in CD34- cells. These cells might represent 
precursors of IAHC that acquire CD34+ expression when integrated in the endothelium 
(potential non-endothelial origin)521. 
 
 
Figure 1-6. Potential mechanisms of dHSC origin in the intra-aortic hematopoietic clusters (from 
Medvinsky et al, 2011). (a) An endothelial precursors give rise to hemogenic endothelium (HE) that 
undergo EHT and differentiate into pre-HSC and dHSC. (b) The hemangioblast gives rise to 
hematopoietic precursors and endothelial cells independently. (c) Non-endothelial pre-HSC lying 
underneath the endothelial lining matures into dHSC and enters the circulation. (d) A pre-HSC of non-





2.5.1 The hemangioblast 
In 1932, Murray first described the existence of a mass of cells of mesoderm origin 
containing both endothelial and hematopoietic cells and named it hemangioblast522. This 
concept arose as opposed to the Angioblast described earlier by Sabin, a similar mass of 
mesoderm cells constituted exclusively of endothelial cells348. This idea was consistent 
with the hypothesis that blood islands in the yolk sac might consist in clonal structures 
and that a bi-potent progenitor with both endothelial and hematopoietic potential should 
exist348. More recently, even if the clonal origin of the yolk sac blood islands has been 
revised, the existence of the hemangioblast as a clonal progenitor for endothelial and 
hematopoietic cells gained more and more interest. Early attempts to demonstrate the 
existence of such progenitor in mice and avian in vivo, were unsuccessful523,524. 
However, in the late 90s a clonal multi-potent precursor was identified as a blast 
colony-forming cell (BL-CFC) in in vitro differentiation assays using mouse embryonic 
stem cells (ESCs)397,525. The phenotype of this BL-CFC was established as KDR+ Bry+ 
VE-cad- CD31- KIT- CD45- CD34-, and these cells displayed primitive hematopoietic 
cells potential, introducing the idea that the hemangioblast might represent the 
progenitors of primitive hematopoiesis526. Subsequently, BL-CFCs were identified in 
murine posterior primitive streak at E7398, in zebrafish527 and in human ESC-derived 
mesoderm528. Nevertheless, conclusive experimental evidence that the hemangioblast 
can give rise to both endothelial and hematopoietic cells in vivo in higher vertebrates is 
still missing. Of note, lineage tracing experiments based on Flk1-cre or Tie2-cre mouse 
models failed to demonstrate the existence of the hemangioblast in vivo469,529, even 






2.5.2 The hemogenic endothelium  
The term hemogenic endothelium (HE) refers to cells with endothelial phenotype, gene 
signature and morphology, which in vivo localise to the endothelial layer of blood 
vessels and have the unique ability to give rise to HSPCs. It has been formally proven, 
both in vitro and in vivo, that blood cells originate from HE399,440,441,444–447,530 via 
endothelial-to-hematopoietic transition (EHT)445. HE cells express the endothelial 
markers Ve-Cadherin458,513 and CD31458 as well as transcription factors involved in 
hematopoietic differentiation such as RUNX1513 and GATA2531,532. Moreover, HE cells 
localise in specific sites in the developing arterial vasculature including the ventral wall 
of the dorsal aorta in the AGM and other hematopoietic niches (umbilical cord veins, 
brain vasculature, e.g.).  All these aspects suggest that the HE might originate from 
endothelial cells, even though this has not been formally proven yet. In fact, the original 
model describing the HE was based on the idea that HE cells are bi-potent progenitors 
with both endothelial and hematopoietic potential (Figure 1-7). However, this concept 
has been recently challenged by showing that HE cells are already committed to the 
hematopoietic fate and no endothelial potential was observed both in vivo533 and in vitro 
using mouse and human PSCs cultures533–535. The lack of endothelial potential in 





Figure 1-7. Potential models of blood cells specification from hemogenic endothelium (from I. 
Slukvin, 2016537). (a) Alternative models proposing the hemangioblastic potential of the HE that gives 
rise to both endothelial and hematopoietic cells (top) or the HE as a transitional stage of progenitors 
already committed to the hematopoietic fate (bottom). (b) Potential scenarios of blood cells specification 
from HE. HE differentiates into HSCs that give rise to all other lineages (1). HE is heterogeneous and 
specification of blood cells occurs at the HE stage (2). HE can generate all hematopoietic lineages 
including HSC (3). 
 
Further insights on the development and heterogeneity of the human hemogenic 
endothelium have been provided by the in vitro differentiation of human PSCs. During 
in vitro differentiation of human PSCs, hematopoietic cells follow the same path 
observed in vivo during embryonic development and EHT happens in Flk1+ 
mesodermal cells, from which hematopoietic cells have been observed to 
originate399,445. In human PSC in vitro cultures, HE and arterial endothelium are already 
specified at day 8 of differentiation and	HE	and	non-HE	can	be	reliably	discriminated	
by	 the	 expression	 of	 specific	 surface	 markers:	 CD43	 marks	 the	 appearance	 of	
hematopoietic	 committed	 cells520,526,	 whereas	 CD73,	 DLL4	 and	 CXCR4	 are	
exclusively	 expressed	 in	 non-HE	 cells	 only534,538,539.	 Furthermore,	 in	 human	 PSC	
differentiation	 cultures	 a	 precursor	 with	 endothelial	 but	 not	 hematopoietic	
potential	 can	 be	 detected536	 and	 a	 subset	 of	 mesoderm	 lacking	 blood-forming	
potential	that	gives	rise	exclusively	to	endothelial	cells	can	be	identified	based	on	
the	expression	of	KDR534. Therefore, the exact origin of hemogenic endothelial cells 
has not been completely elucidated. Further observations in mice have shown that 
endothelial progenitors can migrate from the yolk sac to intra-embryonic sites in the 




RUNX1 silencing540. Moreover, RUNX1 expressing cells labelled at E7.5 showed to 
contribute to the dorsal aorta formation and HSC generation395,541. All together these 
evidences might suggest an extra-embryonic origin of HE389.  
HE is heterogeneous and it can vary among different hematopoietic niches as well as 
within the same site. For instance, only the ventral domain of the dorsal aorta generates 
definitive HSCs, whereas the dorsal domain gives rise only to multipotent progenitors, 
but no dHSCs448. Further evidences of HE heterogeneity have been provided by in vitro 
differentiation of human PSCs. In this experimental setting, the fate of different HE 
cells appeared to be already defined in the early mesoderm. APLNR+ PDGFRα+ 
mesoderm expressing primitive streak genes gives rise to the hemangioblast, which 
subsequently differentiate to primitive erythrocytes (expressing embryonic globin) 
through an intermediate HE step via EHT534,536. Conversely, HE originating from 
mesoderm expressing TAL1, ETV2 and GATA2 but lacking expression of primitive 
streak genes, has shown a broad myelo-lymphoid differentiation potential467,534,542. In 
addition, continuous imaging of human PSCs cultures showed that at least two waves of 
EHT occur during in vitro differentiation543 and the overexpression of specific 
transcription factors in human PSCs can drive the differentiation of HE with different 
potential544 (Figure 1-7). It has been clearly demonstrated that the hemogenic 
endothelium is not specific for any embryonic hematopoietic program, and experimental 
evidences have been provided to prove the hemogenic endothelial origin of mouse 
E8.25 yolk sac EMPs407, E9.5 yolk sac LMPPs413,414 and E10.5 AGM-derived definitive 
HSCs447. However, the presence of hemogenic endothelium in the yolk sac and its 
involvement in the primitive hematopoietic program is not fully elucidated yet. HE has 
been identified in the yolk sac529, but primitive hematopoietic cells arise in the yolk sac 
as early as E7.5 from masses of cells expressing endothelial markers399,545. Moreover, at 




expressing endothelial markers cannot be considered bona fide hemogenic endothelium. 
For this reason the term hemogenic angioblast has been proposed for these yolk sac-
derived cells with primitive blood cells potential only389. 
In conclusion, the co-existence of hemangioblast and hemogenic endothelium in a 
unified model has been proposed399, by which the hemangioblast	 gives	 rise	 to	
hemogenic	 endothelium	 in	 a	 SCL-dependent	 fashion	 and	 subsequently	 the	 HE	
differentiates	 into	 definitive	 hematopoietic	 cells	 in	 a	 process	 dependent	 on	 the	
transcription	factor	RUNX1.		
	
2.6 Signalling pathways involved in embryonic hematopoiesis 
Embryonic development of endothelium and hematopoietic cells are closely related and 
shared common signalling pathways. Experimental evidences support the idea that the 
fate of nascent HSCs is not strictly pre-determined at the HE state, but is consistently 
dependent on external signals provided by the surrounding microenvironment. Newly 
generated blood cells budding from the endothelial layer in the AGM is a step-wise 
process controlled by factors provided by the surrounding mesenchyme, endothelial 
cells and IAHC444. Moreover, the disruption of sub aortic mesenchyme blocks initiation 
of RUNX1 expression and the formation of IAHC without affecting vessels formation 
and arterial identity in the avian model546.  
Based on in vitro and in vivo studies, several signalling pathways have been shown to 
play a role in the activation of specific transcriptional programs driving hematopoietic 
cells specification. 
 
2.6.1 The KDR/VEGF axes 
KDR (also known as VGFR2/Flk1) is a class IV receptor tyrosine kinase (RTK), which 




various intracellular signalling pathways547. KDR is mainly expressed in blood vascular 
endothelial cells and plays a crucial role in the formation and maintenance of the 
vasculature547. 
During embryogenesis, KDR plays a fundamental role in the formation of dorsal aorta 
in various species548. In humans, KDR+ CD34- cells were detected at CS10518, a 
phenotype resembling the hemangioblast described in other contexts528,537,548. 
Moreover, endothelial cells and IAHCs in the dorsal aorta at CS14-15 express KDR and 
produce its ligand VEGF466. KDR is also expressed in early mesoderm in human PSCs 
cultures in vitro. KDR expression can be used to discriminate between mesoderm with 
hematopoietic potential (KDRbright) and mesoderm giving rise exclusively to endothelial 
cells (KDRdim)534. Within the KDR+ mesoderm two subsets can be identified based on 
the expression of CD235a (glycophorin A) as early as day 3 of differentiation. Further 
analysis KDR+ mesoderm revealed that KDR+ CD235a+ fraction is enriched in cells 
with primitive hematopoietic potential, whereas T lymphocytes potential was detected 
in the KDR+ CD235a- population535.  
 
2.6.2 The KIT/SCF axes 
KIT is a member of RTK-III (class III receptor tyrosine kinases). KIT is express in 
hematopoietic stem and progenitors cells (HSPCs) in the bone marrow, as well as in 
melanocytes and mast cells. The interaction of KIT with its cognate ligand stem cell 
factor (SCF) is crucially involved in hematopoiesis, melanogenesis, spermatogenesis 
and mast cell development547.  
SCF is expressed by fibroblast, stromal cells and endothelial cells and exists both in 
soluble and membrane bond form. Differential effects of the two isoforms have been 




The emergence of dHSC in the early embryo requires SCF signalling259,461, and the 
interaction with its cognate receptor KIT plays an important role in HSC maturation in 
the mouse AGM461,550. Indeed, addition of recombinant SCF to explants culture of 
mouse dorsal aorta increases HSC generation from the ventral compartment and induces 
HSC formation in the dorsal one550. In human embryo, KIT is expressed in the IAHC 
and in newly generated HSCs449,551, suggesting the same important role for SCF/KIT 
signaling in human embryonic hematopoiesis. 
 
2.6.3 The FLT3/FLT3L axes 
The receptor tyrosine kinase Flt3 (also known as Flk2) is expressed in HSPCs in the 
bone marrow both in mice and humans. However, mouse long-term reconstituting stem 
cells (LTR-HSC) do not express Flt3 and its up-regulation is accompanied by loss of 
self-renewal capacity182,552. Conversely, a fraction of LTR-HSCs in human bone 
marrow and cord blood express Flt3 and most of the CD34+ HSCs capable of 
reconstitute immunodeficient mice (NOD/SCID) are Flt3+183,184. The interaction of Flt3 
with its cognate receptor Flt3L has a fundamental role in HSPC and B cell progenitors 
expansion in the bone marrow, and it represents an essential regulator of DC 
development and homeostasis17,34,45,185,186. During embryogenesis, FLT3 expression 
marks mouse embryonic HSC precursors553 and both FLT3 and its ligand FLT3L are 
expressed in the IAHCs and surrounding endothelium in human AGM466. However, 
there is no evidence of a specific role of FLT3/FLT3L in the development of the 






Bone morphogenic protein 4 (BMP4) is a member of the transforming growth factor 
beta (TGFβ) superfamily. BMP4 is involved in bone and cartilages formation as well as 
in the early stages of human embryonic development. 
During embryonic hematopoiesis, the emergence of definitive HSCs strictly requires 
BMP4, which has been shown to contribute to the formation of the AGM niche in the 
early embryo484,550.  
Moreover, BMP4 promotes hematopoietic differentiation from human PSCs in 
vitro554,555 and induces the expression of tenacin C and fibronectin556, which further 
contribute to the establishment of the hemato-endothelial program in human PSCs 
cultures467,557. In vivo, BMP4 is highly expressed in the ventral mesenchyme underneath 
the dorsal aorta and it is regulated by FGF485,558. Indeed, the inhibition of FGF signaling 
in zebrafish enhances BMP4 expression triggering the definitive hematopoietic 
program558. However, BMP4/TGFβ signaling appeared to be crucial for hematopoietic 
induction in a very short window of time. In fact, it has been shown that BMP4 
negatively regulates HSC maturation550 and its inhibition occurs in the IAHC after 
endothelial-to-hematopoietic transition550,559. Inactivation of BMP4 signalling during 
hematopoietic development is achieved by expression of the antagonist Noggin, which 
is potentiated by a positive feedback loop by the expression of Sonic-Hedgehog 
(Shh)550. 
 
2.6.5 Notch signalling pathway 
During embryogenesis the dependency on Notch signalling represents a very reliable 
approach to discriminate between the different hematopoietic programs. Many 
experimental evidences clearly established that Notch signalling plays a fundamental 




confirmed in various models, such as zebrafish, chicks and mice406,446,560. Conversely, 
Notch appeared to be dispensable for the initiation and progression of the yolk sac as 
well as EMP-dependent hematopoiesis. Its role in the LMPP program has not been 
addressed yet. Notch-/- mouse embryos develop normal CFC-C in the yolk sac but very 
limited in the embryo body560,561. Furthermore, wt:Notch-/- chimera did not show any 
hematopoietic cells with Notch-/- genotype in the adult mouse560. Notch and its ligands 
Jag1 and Jag2 are preferentially expressed in the ventral floor and in intra-aortic clusters 
on the dorsal aorta of E10.5 embryos562,563. It has also been demonstrated how Notch 
control GATA2 expression562,563, which control RUNX1 expression564. Indeed, 
overexpression of GATA2 or RUNX1 could partially restore AGM hematopoiesis in 
Notch and Jag1 knockout mice562,563. In addition, Notch signalling plays a role in the 
specification of arterial and venous endothelium565. In chicks, uncontrolled activation of 
Notch leads to “arterialization” of the venous endothelium406. Murine PSC-derived 
hematopoietic progenitors lack the expression of Notch when compared to embryonic 
hematopoietic niches, an observation that might explain the limited potential of these in 
vitro generated cells 566. However, human PSCs culture showed that even if important 
for blood formation, Notch signalling is not sufficient to successfully induced the 
generation of self-renewing definitive HSCs539,567. The precise mechanism by which 
Notch promotes definitive hematopoiesis is not fully elucidated, but recent publications 
may suggest a potential role in the development of the hemogenic endothelium in the 
AGM195,568. 
 
2.6.6 Activin/Nodal and Wnt/β-catenin pathways 
Nodal/Activin	and	Wnt/β-catenin are two very important signalling pathways involved 
in the development of the early embryo. The establishment of active Nodal and Wnt 




embryo are specified and differentiate. Based on these observations, the effect of the 
modulation of Nodal/Activin and Wnt/β-catenin signalling on embryonic hematopoiesis 
has been tested in human PSCs differentiation experiments. This in vitro approach 
demonstrated how Nodal/Activin signalling pathway promotes primitive hematopoiesis 
and inhibits the establishment of a definitive program535,569. Conversely, Wnt/β-catenin 
pathway appeared to promote definitive hematopoiesis while abrogating the primitive 
hematopoietic program535,569. Very interestingly, the modulation of both pathways was 
effective only in a very narrow temporal window of 72 hours of differentiation, 
suggesting a direct effect on mesoderm formation and patterning. These observations 
were consistent with previously reported evidence of a fundamental role of Wnt in the 
emergence of HSCs in vivo570,571. More importantly, these results are compatible with 
the spatial organisation of the developing embryo, where the mesoderm cells committed 
to the primitive hematopoietic fate are exposed to an active Nodal signalling as well as a 
Wnt inhibition572. 
 
2.6.7 Inflammatory cues 
A further example of extrinsic factors involved in hematopoietic development during 
embryogenesis is the contribution of pro-inflammatory mediators to the generation of 
definitive HSCs in the AGM. Several examples have been reported in different models. 
Interferon produced by embryonic myeloid cells and retinoic acid signalling play an 
important role in the formation and specification of hematopoietic progenitors in mouse 
yolk sac and AGM573–575. Moreover, TNF-mediated activation of NF-kB and Notch 
signalling pathways has been reported to be involved in HSC development both in 
zebrafish and mice576,577. Finally, the use of retinoic acid in human PSC cultures in vitro 




cluster genes, a key feature of dHSC maturation and expansion578. However, no positive 
effect on self-renewal and repopulation capability has been reported. 
 
2.7 Transcription factors involved in embryonic hematopoiesis 
2.7.1 RUNX1 
The transcription factor RUNX1 is a master regulator of dHSC development in many 
species481,579,580. RUNX1 is preferentially expressed in hematopoietic cluster in the 
dorsal aorta499 where it plays a fundamental role in the regulation of EHT442. Indeed, 
RUNX1 activates its downstream target GFI1, which contributes to the suppression of 
the endothelial program and promotes hematopoietic differentiation581. RUNX1 
promotes EHT in combination with the transcription factor GATA2582, and it is 
negatively regulated by the expression of HOXA3516. Runx1-/- mice display a normal 
yolk sac erythropoiesis but no dHSC generation and embryos die around E12.5583,584. 
IAHCs are absent in Runx1-/- mice499,585, and an accumulation of mesanchymal cells has 
been observed beneath the dorsal aorta, suggesting a potential impairment of EHT499. 
Impaired EHT has been reported in Runx1 knock out zebrafish444, and a dysfunctional 
hemogenic endothelium with no hematopoietic potential has been described in in vitro 
differentiation of Runx1-/-  mouse embryonic stem cells (ESCs)399. Moreover, the 
overexpression of RUNX1 is sufficient to re-establish functional definitive 
hematopoiesis in ex vivo cultures586. Dose and time of RUNX 1 expression is also a key 
aspect, as demonstrated by the decreased hematopoietic differentiation in the AGM and 
the early appearance of dHSC in the yolk sac in RUNX 1 or GATA2 haploinsufficient 
mice531,587. Furthermore, the induction of RUNX1 expression has been reported in 
response to biomechanical forces both in AGM cells and in ESC-derived hematopoietic 






Another transcription factor intimately involved in the establishment of the definitive 
hematopoietic program during embryogenesis is MYB. The dependency on MYB 
represents a reliable approach to discriminate between the primitive versus the 
definitive origin of differentiated hematopoietic cells. Indeed, MYB expression has 
been reported in definitive progenitors and in EMPs419, but not in cells originating from 
the primitive hematopoietic program385. Primitive hematopoiesis is not affected in Myb-
/- mice588–590, and primitive erythroblast, megakaryocytes591 and EMP-derived 
macrophages37 develop normally in these animals. However, the absence of MYB 
completely abrogates the establishment of the definitive hematopoiesis and the embryos 
die at E16588,590. Moreover, MYB expression has been identified as a key event 
following EHT during dHSC differentiation from arterial endothelium in zebrafish446. 
Of note, hematopoietic differentiation of human PSCs using a MYB-reporter line has 
shown that in vitro differentiated cells do not express high levels of MYB after EHT, 
which might limit the differentiation of proper dHSCs592. 
 
2.7.3 SOX17 
SOX17 is a member of the SOX (SRY-related HMG-box) family of transcription 
factors, mainly involved in regulating pluripotency, self-renewal and differentiation 
processes in embryonic development.  SOX17 has been shown to play a critical role in 
the emergence of HSCs during embryonic development and to promote arterial and 
hemogenic endothelium specification516. Once EHT occurred, SOX17 expression is 
abrogated in order to allow the initiation of the hematopoietic program593. In mouse and 
human PSC-derived hemogenic endothelium, SOX17 has been used to identify the 
emergence of the definitive hematopoietic program569,594. In human PSCs in vitro 




differentiation of Ve-Cadherin+ CD43+ CD45- hematopoietic progenitors with blood 
cells potential upon down-regulation of SOX17 expression595.  
 
2.7.4 HOXA genes 
HOX genes are a group of very conserved genes that code for transcription factors 
involved in the regulation of the early embryo development. HOX genes are part of the 
homeobox transcription factors genes, and in human they are classified in four different 
clusters (HOXA, HOXB, HOXC and HOXD). 
HOXA genes are already expressed at the primitive streak stage in the embryo596 and 
they mark intra-embryonic hematopoiesis during mesoderm patterning. Hematopoietic 
progenitors isolated from umbilical cord or fetal liver express high levels of HOXA 
genes, whereas in vitro generated PSC-derived hematopoietic progenitors failed to do 
so578,597, suggesting an inefficient activation of the definitive hematopoietic program. 
However, it has been recently reported that HOXA genes expression can be induced in 
human PSC-derived hematopoietic progenitors by modulating the Activin/Nodal as well 
as Wnt/β-catenin signalling pathways, more closely recapitulating the definitive 
hematopoietic program taking place in the early embryo597. Furthermore, lineage 
conversion studies, an approach by which the re-programming of pluripotent as well as 
terminally differentiated cells is achieved by forced expression of specific transcription 
factors, have significantly contributed to highlight the importance of HOX genes in the 
development of definitive hematopoiesis. Activation of HOXA genes appeared to have a 
strong impact on the expansion of mouse bone marrow HSCs598,599 and in the temporal 
regionalisation of embryonic mesoderm600. Moreover, the overexpression of HOXB4 in 
mouse ESCs in association with Notch signalling activation conferred multilineage 
long-term repopulation abilities to in vitro differentiated hematopoietic progenitors601. 








HOXA3 is one of the members of the HOXA genes, which plays a pivotal role in the 
cell fate decision between the endothelial and the hematopoietic lineages. 
Overexpression of HOXA3 has been shown to inhibit the pro-hematopoietic 
transcription factor RUNX1 and promote the endothelial program516. Conversely, the 
down-modulation of HOXA3 allowed the RUNX1-mediated activation of the 
hematopoietic program at the expense of the endothelial pathway516.  
 
2.8 The study of embryonic hematopoiesis: a technical perspective 
The understanding of the key events driving hematopoietic development in the human 
embryo as well as the spatiotemporal organisation of the embryonic hematopoietic 
system is closely related to the availability of reliable in vitro and in vivo assays. 
Advances in technology enabled a more accurate interpretation of the early events 
driving embryonic hematopoiesis and the appearance of the first definitive HSC. For 
instance, the use of human induced pluripotent stem cells (iPSCs) provided a potential 
inexhaustible source of human embryonic tissues overcoming bioethical concerns. 
Moreover, the generation of immunodeficient mouse models capable of supporting 
human hematopoietic cells maintenance and differentiation (e.g. NSG, NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ), allowed the in vivo assessment of the function and 
repopulation potential of ex vivo isolated or in vitro generated hematopoietic 
progenitors.  Finally, the development of very powerful gene targeting techniques, such 
as CRISPR/Cas9, enabled the very rapid and efficient generation of human knock-out 




genetically tractable environment. The following section will provide an overview of 
the different technical approaches, both in vivo and in vitro, that contributed to a better 
understating of the human embryonic hematopoiesis. 
 
2.8.1 Studying human embryonic hematopoiesis: in vitro approaches  
Using an in vitro culture system in semi-solid matrices (Methylcellulose), colony-
forming-units culture (CFU-C) were identified in the human embryo as CD34+ 
hematopoietic progenitors425. However, technical limitations prevented an accurate 
evaluation and identification of the embryonic tissues giving rise to these cells425. To 
overcome this issue, mouse embryonic hematopoiesis was studied using an ex vivo 
expansion of tissues explants before assessing hematopoietic potential386,488. The same 
approach was then transferred to the study of human embryos. Tissues isolated at CS10, 
before the establishment of a functional circulation, demonstrated that while the yolk 
sac has the potential to generate myeloid and NK cells only, a broader spectrum of 
hematopoietic cells (including B and T lymphocytes) originate from the P-Sp/AGM 
region of the human embryo489. However, even if consistent with other models, the 
lympho-myeloid precursor identified in vitro in the p-Sp/AGM may not correspond to 
definitive HSCs. Therefore, to test the long-term repopulation ability of these cells and 
identify the true, rare HSC in the human embryo, in vivo studies needed to be 
performed, and the generation of a mouse model highly permissive for human cells 
(NSG) enabled this experimental approach.  
 
2.8.2 Studying human embryonic hematopoiesis: in vivo approaches  
The in vivo repopulation assay represents the gold standard technique to evaluate self-
renewal and differentiation potential of hematopoietic progenitors in order to identify 




evaluation of the hematopoietic potential in the different tissues of the human embryo 
has been performed426. As a result, the first transplantable definitive HSC was identified 
in the AGM at CS14. Conversely, the yolk sac did not show any repopulation activity 
except for very rare events detected as early as CS16 (at least five days later than the 
AGM). Definitive HSCs were detected in the fetal liver after 7-8 weeks of gestation. 
These cells were still expressing the endothelial marker Ve-Cadherin, supporting the 
notion of an endothelial origin of the hematopoietic system602. After liver colonisation, 
which occurs between CS14 and CS17, HSCs can be detected in the placenta from 9 
weeks of gestation487 and in the umbilical cord, suggesting that they represent secondary 
sites for HSC development and they are colonised only after maturation and expansion 
in the liver. As compared to the mouse model where dHSCs appear almost at the same 
time in many tissues, the clear temporal separation of subsequent events leading to 
human dHSC generation represents a great advantage of performing in vivo studies with 
human embryonic tissues. Moreover, the differences in the time of HSC appearance 
observed comparing the in vivo426 and in vitro425,487,495 approaches, highlight the 
importance of in vivo experiments for the study of human embryonic hematopoiesis. 
 
2.8.3 Modelling embryonic hematopoiesis using human PSCs 
A substantial contribution to the understating of human embryonic hematopoiesis was 
made by the use of pluripotent stem cells (PSCs), in order to reproduce the early events 
of human embryogenesis. With the discovery of iPSCs by Prof. Yamanaka in 2006603 
and the successful re-programming of most of the human adult cell types to a 
pluripotent state amenable to in vitro differentiation604, the establishment of reliable 
protocols to generate hematopoietic cells in vitro gained increasingly amounts of 
interest. In fact, besides acquiring a better understanding of the processes driving human 




HSPCs, and virtually all the cells types of the human immune system, for clinical 
purposes. In vitro differentiation of hematopoietic cells from mouse PSCs has shown a 
remarkable consistency with the mechanisms described in vivo in the embryo. 
Therefore, it is reasonable to consider human PSCs as a reliable approach to study 
hematopoiesis in the early stages of human embryonic life605. However, not all the 
aspects of in vitro differentiation of hematopoietic cells have been fully elucidated yet, 
and some conflicting evidence has been reported. For instance, while many publications 
support the idea that in vitro generated hematopoietic cells arise with different timing, 
mimicking the wave-like kinetic described in vivo606–608, others reported the emergence 
of all blood cells types in the same time frame609. 
 
2.8.3.1 PSC-derived HSPC in vitro: differentiation potential and limitations  
Two main strategies have been adopted to differentiate human PSCs into hematopoietic 
cells:  
- co-culture of human PSCs with mouse bone marrow-derived stromal cell lines, 
among which OP9 demonstrate to be the most efficient option610 
- induction of hematopoietic differentiation through embryoid bodies (EBs) 
formation by providing specific factors in a more controlled experimental 
setting528,554,569  
From both approaches, a very extensive spectrum of hematopoietic lineages have been 
differentiated in vitro from human PSCs: erythroblast, macrophages, DC-like and 
monocyte-derived DCs, NK cells, neutrophils, eosinophils, basophils, megakaryocytes, 
B and T cells610,611. However, the main drawback of both approaches resides in the 
absence of reliable markers to firmly establish the primitive or definitive origin of these 
cells. Indeed, primitive and definitive hematopoiesis in vivo can be easily distinguished 




reproducible in vitro. Due to the lack of specific markers identifying the primitive or 
definitive origin of the cells, the potential of the in vitro generated HSPCs is a 
commonly used approached. However, the fact that different hematopoietic programs 
can give rise to the same lineages adds a further layer of complexity to the reliable 
evaluation of the differentiated progenitors. Based on the evidence that most of the 
hematopoietic lineages, including T cells414, can originate in an HSC-independent 
process, the most reliable indication of a successful induction of the definitive program 
is the appearance of Type2 adaptive B cells, a cell type exclusively derived from HSC. 
To date, most of the in vitro-based protocols to generate HSPCs from PSCs appeared to 
mainly resemble primitive yolk sac hematopoiesis, providing a possible explanation for 
the absence of self-renewal and long-term repopulation observed in these PSC-derived 
progenitors. Indeed, in vitro generated cells have never shown repopulation ability 
comparable to dHSC isolated from AGM426. This comparison might suggest that not 
only the differentiation process still needs to be optimised and fully understood, but also 
other aspects, such as the maturation of pre-HSC into fully functional stem cells, have 
to be taken into account. 
 
2.8.3.2 Embryonic hematopoietic programs in PSC-based in vitro cultures 
So far, numerous approaches have been developed to generate HSPCs in vitro from 
human PSCs, which appear to be mimicking different stages of the embryonic 





Figure 1-8. In vitro approaches to generate human hematopoietic cells (from Rowe et al., 2016612). 
The diagram summarise some examples of different approaches used to generate hematopoietic cells in 
vitro. Hematopoietic development was induced either by exposing pluripotent cells (PSCs) to 
morphogens/growth factors (Kennedy et al., 2012; Sturgeon et al., 2014) or by over-expressing defined 
sets of hematopoietic transcription factors in human PSCs (Doulatov et al., 2013) or terminally 
differentiated fibroblast (Batta et al., 2014), endothelial cells (Sandler et al., 2014) and mouse 
hematopoietic precursors (Pereira et al., 2016). The different methods were capable of recapitulating 
several stages of embryonic hematopoiesis, including the onset of primitive and definitive hematopoietic 
progenitors with variable engraftment and differentiation potential. 
 
2.8.3.2.1 Mesoderm specification 
In mammalian embryo mesoderm specification and hematopoietic differentiation are 
driven by the activation of several signalling pathways and specific factors are involved 
in this process, such as BMP4, FGF, WNT, TGFβ, Hedgehog, retinoic acid and Notch 
signalling482,483,548,574,593. In vitro, mesoderm patterning has been shown to recapitulate 
quite faithfully the in vivo process, and it depends on the presence of specific factors 
such as BMP4, FGF, Activin and canonical Wnt pathway570,613–618. 
Mesoderm committed to the hematopoietic fate is defined by the expression of specific 




PDFGRα, i.e.)418,537,619 and its specification to the different hematopoietic programs 
(primitive versus definitive) occurs in these early phases of mesoderm patterning. 
Indeed, mesoderm differentiated providing Activin and BMP4 signals appeared to 
resemble primitive hematopoiesis by the efficient generation of hematopoietic 
progenitors without repopulation potential, as described for yolk sac derived cells in 
vivo570. Moreover, the exposure of BMP4-driven in vitro-generated mesoderm to 
Activin inhibitors569, Wnt agonists535,620 and the combination of the two597 resulted in 
the inhibition of the erythroyd-biased primitive program and the induction of more 
“definitive-like” progenitors, characterised by their potential to generate T lymphocytes. 
The commitment to different programs was already detectable at the mesoderm level 
based on the expression of KDR and CD235a535.  
 
2.8.3.2.2 Yolk Sac/Primitive hematopoiesis 
PSC-derived BMP4-dependent mesoderm can be further differentiated into blast 
colonies (BL-CFC) by the presence of VEGF and bFGF in the culture medium. BL-
CFCs represented the first identification of the hemangioblast in vitro397,525, marking the 
onset of hematopoiesis528,536,619. In vitro PSC-derived hemangioblast is characterized by 
the expression of KDR, PDGFRα, apelin receptor534,536,621 and CD235a535, and has the 
potential to differentiate into the hematopoietic, endothelial and smooth muscle 
lineages621. The hematopoietic potential of these cells is limited to primitive 
erythrocytes, megakaryocytes and macrophages, and the terminal differentiation occurs 
through an hemogenic endothelium intermediate, as described previously in mice399. All 
together, these observations are consistent with the induction of a primitive 
hematopoietic program, resembling yolk sac-derived embryonic hematopoiesis. The 
same result can be achieved in alternative culture settings by exposing human PSCs, 




cytokines cocktails, or by co-cultures of PSCs with OP9 mouse stromal cells520. When 
co-culture with OP9, a subset of PSC-derived CD34+ cells acquires expression of 
CD43, which has been identified as a reliable marker to discriminate by hematopoietic 
and endothelial cells in this experimental settings520. CD34+ CD43+ hematopoietic cells 
can be detected in all the described differentiation approaches and they showed to be 
capable of giving rise to a wide spectrum of erythroid and myeloid cells534,569,597. This 
would suggest that CD34+ CD43+ hematopoietic progenitors differentiated in vitro 
have a broader potential than in vivo primitive yolk sac-derived cells (limited to 
erythroblast, magakaryocytes and macrophages), but the absence of lymphoid progeny 
would exclude their definitive origin. These cells might correspond to yolk sac-derived 
EMPs described in mouse410, and less extensively in humans412. However, the primitive 
or definitive origin of these cells has not been fully elucidated yet, even though the 
absence of expression of HOXA genes578,597, a marker of AGM-derived definitive 
progenitors in vivo, would support the first option. Of note, even if EMPs are usually 
associated with the yolk sac, cells with the similar restricted potential can be detected 
within the Ve-Cadherin+ CD45+ population of the human AGM449. Therefore, these 
cells might be distinguishable from the yolk sac-derived EMPs only by the expression 
of HOXA genes.  
 
2.8.3.2.3 AGM/definitive hematopoiesis and dHSC 
The first definitive HSCs in vivo originates from the hemogenic endothelium localised 
in the dorsal aorta. Numerous publications reported the generation of PSC-derived 
hemogenic endothelium in vitro, whose phenotype has been identified as CD34+ 
CD31+ Ve-Cadherin+ CD73- CXCR4- DLL4- CD43-534,539. In vitro-generated 
hemogenic endothelium express RUNX1 and GFI1 in both mouse499,581 and human 




derived hemogenic endothelium expressing HOXA genes, as described in vivo in the 
AGM597. HOXA+ hemogenic endothelium could also be subdivided in SOX17hi cells, 
transcriptionally similar to the dorsal aorta endothelium, and SOX17dull cells giving rise 
to hematopoietic progenitor. This pattern was consistent with previous reports608,622,623, 
supporting the idea the SOX17 is down-regulated during EHT. Nevertheless, 
hematopoietic progenitors generated in this protocol, even if closely resemble their 
AGM-derived counterparts, failed to support long-term repopulation in vivo597. There is 
no reliable marker enabling an accurate separation of definitive AGM-like progenitors 
from primitive yolk sac-derived cells in vitro418,537. Therefore, the potential of the in 
vitro generated progenitors has consistently been used to try to establish the primitive 
versus definitive origin of the PSC-derived cells. Based on this approach, many 
publications in the recent years reported the generation of progenitors defined as 
“definitive” based on their potential to generated T lymphocytes467,539,569,597,624. 
However, it is widely accepted that T lymphocyte emergence cannot be consider as a 
reliable indication of the definitive origin of the cells, since T and B lymphocytes arise 
in vivo during embryonic development prior AGM formation, suggesting that primitive 
lymphoid progenitors exists, and T cell potential cannot rule out primitive 
hematopoietic origin410,413,414. In fact, the only cell type that has been shown to originate 
exclusively from definitive HSCs is the mouse type2 B cells413,417, an aspect that 
appeared to be conserved in humans as well625,626. So far, few protocols generating 
human B cells from PSCs have been reported542, and in most of these cases the 
discrimination between the HSC-independent type1 and the HSC-dependent type2 B 
cells have not been assessed. More recently, the generation of mouse PSC-derived 
progenitors with the ability to engraft irradiated recipients and give rise to multilineage 
progeny, including type2 B cells, has been reported609. In this protocol, the combination 




repopulation potential when injected intra-femur into lethally irradiated NSG mice609. 
However, these progenitors displayed a limited self-renewal capacity and the same 
approach has not been tested with human PSCs.  
 
2.8.4 Generation of human PSC-derived HSPCs: alternative approaches 
Even if a broad spectrum of hematopoietic cells have been successfully differentiated 
from human and mouse PSCs, the generation of bona fide dHSCs is still an unachieved 
goal. Very few studies reported the generation of PSC-derived progenitors, which can 
successfully be transplanted into immunodeficient recipients, and even in these cases 
they only show a poor, short-term engraftment occasionally restricted to the myeloid 
lineage and secondary transplantation is rarely evaluated465,627–629. The successful 
generation of transplantable hematopoietic cells was achieved in mouse PSCs by over-
expressing the transcription factor HOXB4630,631 and by intra-femoral injection of cKit+ 
progenitors differentiated in vitro in a very limited window of time609. However, at least 
for the second approach, the observed engraftment was limited in time and no 
secondary transplantation potential was provided. For this reason, alternative 
approaches have been tested in the last decade, based on the forced expression of 
specific transcription factors to induce the reprogramming of somatic cells632–634 or 
iPSC635,636. Moreover, based on the intrinsic ability of PSCs to differentiate in 
potentially all tissues of the body, the presence of hematopoietic cells within 
disorganised embryonic tissues (teratoma) generated by injecting human PSCs into 
immunodeficient mice have been evaluated637,638 as a potential source of human PSC-





2.8.4.1 Reprogramming strategies by transcription factor overexpression  
The idea of using forced expression of transcription factors to reprogram the cell fate of 
different cell types to hematopoietic progenitors has been considered since the early 
nineties639,640, but it is only after the advent of iPSC technology603,641 that this sort of 
approach gained increasingly more interest. Several approaches have been tested both in 
human and mouse cells, ranging from the lineage conversion of adult somatic cells and 
iPSC, to the forced induction of EHT in endothelial cells (Table 1-8). 
 
2.8.4.1.1 Lineage conversion from somatic cells or pluripotent stem cells (PSCs) 
The feasibility of the lineage conversion approach applied to the hematopoietic system 
was first demonstrated by showing that the forced expression of RUNX1, HLF, LMO2, 
PRDM5, PBX1, ZFP37 in mouse lymphoid and myeloid committed progenitors was 
able to reprogram the cells into HSCs with multi-lineage engraftment potential in 
primary and secondary recipients642.	Expression profile studies comparing PSC-derived 
hematopoietic progenitors with ex vivo isolated progenitors, highlighted the fact that the 
in vitro generated cells present higher levels of HOXB genes and lower expression of 
HOXA genes578,643,644.	 Based	 on	 these	 observations,	 the	 combined	 expression	 of	
transcription	 factors	 involved	 in	hematopoietic	differentiation	has	been	 tested	 in	
human	 PSCs.	 Elcheva et al. demonstrated that the overexpression of only two 
transcription factors could induce the differentiation to either endothelial or 
hematopoietic cells from PSCs. More precisely, the authors showed that the forced 
expression of ETV2 and ERG was able to drive the differentiation of endothelial cells. 
Conversely, ETV2 and GATA2 overexpression induced the emergence of CD43+ 
hematopoietic progenitors with pan-myeloid potential through an endothelial 
intermediate step. Moreover, the expression of GATA2 and TAL1 was enough to 




However, none of these progenitors were able to sustain long-term engraftment in 
vivo544. Doulatov and colleagues proposed an alternative approach by demonstrating 
that the forced expression of five transcription factors (HOXA9, ERG, RORA, SOX4 
and MYB) in human iPSCs was sufficient to trigger the differentiation of CD34+ 
CD45+ CD38- hematopoietic progenitors capable of transient erythro-myeloid 
engraftment when injected in vivo645. More recently, the simultaneous expression of 
seven transcription factors (ERG, HOXA5, HOXA9, HOXA10, LCOR, RUNX1 and 
SPI1) in human iPSC-derived hemogenic endothelium was reported to be successful in 
generating hematopoietic progenitors with long-term repopulation ability646. Moreover, 
the overexpression of HOXA9 appeared to promote hematopoietic differentiation in 
vitro, even if no improvement was observed on the engraftment potential in vivo644. 
Likewise, the forced expression of HOX9, HOX7 and HOX5 did not show any effect on 
the repopulation ability of iPSC-derived progenitors578. Finally, despite the efficient 
induction of hematopoietic cells differentiation by the overexpression of HOXB4 in 
mouse PSCs630, the same approach failed to generate hematopoietic progenitors from 
human iPSC629. Reprogramming strategies have been also applied to cells other then 
PSCs, such as human and mouse fibroblasts. A successful generation of hematopoietic 
progenitors capable of efficient myeloid engraftment was obtained by overexpressing 
OCT4 in human adult fibroblasts647.  Moreover, the forced expression of GATA2, 
GFI1b, ETV6, c-FOS was able to induce a transcriptional hematopoietic program in 
mouse fibroblast633, whereas the combination of ERG, GATA2, LMO2, RUNX1c, SCL 
expression enabled the differentiation of hematopoietic colony-forming cells with 





2.8.4.1.2 Induction of EHT in endothelial cells by TF overexpression  
The use of endothelial cells (ECs) reprogramming to induce hemogenic endothelium 
conversion and hematopoietic differentiation avoiding a pluripotent intermediate step 
has been proposed as an alternative system. The forced expression of four transcription 
factors in combination with the exposure to an instructive vascular niche induced by the 
expression of adenoviral E4ORF1 gene in endothelial cells appeared to be a successful 
approach. Indeed, human umbilical vein endothelial cells (HUVEC) and mouse adult 
endothelial cells were efficiently converted into HSCs by the overexpression of FOSb, 
GFI1, RUNX1 and SPI1634,648. The generated EC-derived HSCs displayed multi-lineage 
long-term engraftment in both primary and secondary recipients as well as a 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































2.8.4.2 Human PSC-derived HSPCs in vivo: teratoma formation 
Along with in vitro differentiation and reprogramming, an alternative approach to 
generate PSC-derived hematopoietic progenitors consists in the in vivo generation of 
teratomas. In vivo teratoma formation is achieved by injecting human PSCs into 
immunodeficient mice. Pluripotent cells give rise to disorganised tissues (teratoma) 
belonging to the three different germ layers, including structures resembling the bone 
marrow environment637,649. To date, two publications have tested the ability of human 
PSCs to differentiate in definitive HSCs by injecting them in NSG mice along with 
OP9-DLL1/WNT3a stromal cells637 or by providing the human cytokines SCF and 
TPO638. As a result, human CD45+ cells were generated in the teratoma, which showed 
the ability to home to the bone marrow and seed other lymphoid organs through 
circulation637,638. Moreover, generated CD34+ CD45+ progenitors were capable of 
engrafting primary recipients up until 12 weeks, as well as secondary recipients for up 
to 4 weeks after transplantation637. Finally, teratoma-derived	B	and	T	cells	appeared	
to	 be	 functionally	 normal	 and	 erythrocytes	 expressing	 adult	 globin	 could	 be	
detected.	 However, even if promising results were reported, a longer period of 
incubation is needed to clearly establish if those generated progenitors have the same 
long-term repopulation ability of bona fide dHSCs426.	
 
2.9 Human iPSCs as a source of functional immune cells 
The differentiation of human hematopoietic cells from iPSC not only represents a very 
powerful approach to better understand the mechanisms involved in the early events of 
human embryonic haematopoiesis, but it also enables the opportunity to generate in 
vitro the whole spectrum of cells composing the human immune system. The potential 





from modelling of haematological diseases to cell immunotherapy and drug discovery. 
Therefore, the establishment of reliable protocols to efficiently differentiate most of the 
hematopoietic lineage represents an important goal that has not been achieved yet, even 
though the successful generation of many types of hematopietic cells, such as T 
cells650,651, B cells652, NK cells653, red blood cells654,655 and myeloid cells656 has been 
reported to date. However, the lack of an efficient approach to generate definitive 
human HSCs represents a fundamental limitation of this process, and an in-depth 
characterisation of the hematopoietic programs involved in the generation of the 
aforementioned cells is strongly required. 
 
2.9.1 PSC-derived mononuclear phagocytes: successes and unachieved goals 
Among all the immune cell types that have been successful generated from human PSCs 
to date, of particular interest for this project are the members of the mononuclear 
phagocyte system (MPS), such as monocytes, macrophages and DCs (Table 1-9).  
 
2.9.1.1 Human PSC-derived monocytes 
The differentiation of monocytes from human embryonic stem cells (ESC) or induced-
pluripotent stem cells (iPSC) has been reported in several publications657–660. However, 
in most cases monocytes are generically described as CD45+ CD14+ cells that arise in 
the latest stages of PSC differentiation. Only few studies reported a more accurate 
characterisation of these cells658,659, showing that they also express the chemokine 
receptor CX3CR1, the scavenger receptors CD36 and CD163, the cytokines receptors 
CD116 (GM-CSFR) and CD115 (M-CSFR) and the Fc receptors CD32 and CD64658, 
all known to be expressed in human monocytes. However, these PSC-derived 





derived from adult CD34+ progenitors. Furthermore, these cells have been shown to 
migrate in response to the chemokine CX3CL1 and to produce IL1β when stimulated 
with LPS and ATP659. Finally, PSC-derived monocytes could be differentiated into 
moMacs and moDCs by exposing them to M-CSF and GM-CSF/IL-4, 
respectively658,659.  
 
2.9.1.2 Human PSC-derived macrophages 
The generation of human PSC-derived macrophages has been reported in several 
publications526,657–659,661,662, using both a feeder-free EB-based approach and OP9 co-
cultures. However, only recently a more extensive analysis of the embryonic origin of 
those cells has been performed661,662, revealing their primitive origin. Overall, the PSC-
derived macrophages obtained with different protocols shared a consistent penothype, 
based on the expression of monocyte-macrophages markers such as CD14, CD16, 
CD163, CD115, CD11b and CD11c, among others656–659. Moreover, most of these 
protocols appeared to generated functional cells, as measured by their ability to 
efficiently take up antigens and they could also undergo polarisation towards the M1 or 
M2 phenotype, when exposed to IFN-γ and IL-4, respectively658,659. Nevertheless, all 
these aspects did not provide any information about the embryonic origin of these cells, 
since the terminally differentiated macrophages arising from primitive or definitive 
hematopoietic program are indistinguishable. Only recently two papers were published 
trying to identify the hematopoietic program involved in the generation of PSC-derived 
macrophages661,662. Buchriser et al. performed genetic experiments by knocking out 
transcription factors involved in the early steps of hematopoietic differentiation in the 
embryo using CRISPR/Cas9. This approached resulted in the characterisation of the 





independent, RUNX1 and SPI1-dependent cells661, demonstrating a primitive HSC-
independent origin of those cells. At the same time, Takata and colleagues were able to 
monitor the differentiation of mouse and human iPSC-derived macrophages from in 
vitro generated EMPs through a hemangioblast intermediate step, supporting their 
primitive origin. More interestingly, mouse iPSC-derived macrophages had the ability 
to respond to environmental cues and to terminally differentiate in vivo in tissue resident 
macrophages, as demonstrated for alveolar macrophages and microglia662. Finally, 
transcriptome analysis of these cells confirmed their close relationship with yolk sac-
derived macrophages, and highlighted significant differences when compared to bone 
marrow-derived ones662. 
 
2.9.1.3 Human PSC-derived dendritic cells (DCs) 
In 2004 the generation of human ESC-derived antigen presenting cells was first 
reported. However, an extensive characterisation of the differentiated cells was not 
performed, and the exact identity of the HLA-DR+ leukocytes able to induce allogeneic 
T cells activation was not assessed663. In the following years, several other publications 
described the differentiation of human DC-like cells from both ESCs and 
iPSCs656,659,664–666. Most of these protocols were able to generated DC-like cells 
characterised by their ability to migrate, take up antigens and mature in response to 
activation stimuli such as LPS and TNFα, which were also able to trigger the 
production of pro-inflammatory cytokines. Moreover, their potential to induce 
allogeneic as well as antigen-specific autologous T cells proliferation was 
reported656,659,664–666. However, the extensive use of GM-CSF in the culture medium and 
the expression of monocytic markers such as CD14, CD11b, CD1a and CD209 strongly 





therefore they do not represent a reliable model of human circulating dendritic 
cells656,659,664,665. Conversely, Silk et al. reported for the first time the generation of 
XCR1+ CD141+ human dendritic cells differentiated from iPSC666. The phenotype of 
these cells, even if not fully characterised, coincides with the human conventional cDC1 
subset and this was further supported by their ability to efficiently cross-present tumor-
associated antigens (TAA) and initiate an antigen-specific T cell response666, the main 
functional feature of cDC1s. Finally, a recent publication described the generation of all 
human DC subsets (cDC1s, cDC2s and pDCs) from human iPSC in a two-step 
protocol660. A first differentiation of hematopoietic progenitors was performed in an 
EB-based protocol, and the generated progenitors, marked by the expression of CD31, 
CD43, and CD45, were subsequently differentiated to dendritic cells on OP9 feeders 
with the addition of the human recombinant cytokines GM-CSF, Flt3L and SCF. More 
interestingly, iPSCs knockout for the transcription factor IRF8 were generated, 
demonstrating that in vitro generated monocytes and DCs rely on IRF8 expression660. 
However, the phenotype of the PSC-derived DCs was not fully elucidated and the 
functional validation of the terminally differentiated cells was not provided, for instance 
by assessing their ability to present antigens or to produce subset-specific cytokines in 
response to TLR. Moreover, their dependency on IRF8, even if consistent with in vivo 
data from patients harbouring disease-causing mutations in IRF871, does not represent a 
strong validation of their identity, failing to exclude, for instance, a potential monocytic 






Table 1-9. In vitro differentiation of human MPS cells from iPSC. 
Cell origin Method Cell product Hematopoietic progenitors Ref 
hESC EB moDC  n/a 660 
hiPSC monolayer macrophages primitive/EMP 658 



































hESC EB APCs n/a 659 







3 Overall aims and objectives 
3.1 Rationale of the study 
Due to their unique ability to efficiently process and present antigens to T lymphocytes, 
dendritic cells play a fundamental role in the establishment of a successful immune 
response. Most of the available knowledge about DCs development, regulation and 
function stem from genetic experiments performed in vivo in the mouse model.  
However, the paucity of easily accessible human DCs and the consequent inability to 
genetically manipulate these cells, has greatly limited the validation of these discoveries 
in the human system. Moreover, a better understating of the mechanisms driving an 
efficient immune response against cancer and the pivotal role of DCs in this context led 
to increased interest on their application in cell-based cancer immunotherapy310. 
However, even though numerous clinical trials have been performed using monocyte-
derived DC this approach failed to provide a significant improvement in the overall 
clinical response in cancer patients315,316, and evidences have been provided suggesting 
that the use of naturally circulating DC subsets may represent a more promising 
approach315,321. Hence, the establishment of a reliable system to generated DCs from 
induced-pluripotent stem cells may represent a major improvement both for the study 
and the potential clinical application of human dendritic cells. In this regard, several 
approaches have been proposed in the last decade656,659,660,664–666, but the absence of a 
complete characterisation of the differentiated subsets and the lack of an exhaustive 
understanding of the embryonic hematopoietic program driving their differentiation in 
vitro greatly limited their application. Indeed, in order to achieve the successful 
differentiation of bona fide human DCs from iPSCs, it is essential to recapitulate the 
developmental processes leading to the generation of definitive hematopoietic 





approach to recapitulate in vitro and in vivo the development of human DCs from 
hematopoietic stem and progenitors cells.  This knowledge will be practically 
implemented in the generation of DC subsets from human iPSCs. Once established, this 
approach may represent an invaluable tool to study human DC biology as well as their 
potential application in cellular immunotherapy, providing an unlimited source of 
patient-specific and genetically comparable cells, amenable to genetic manipulation. 
 
3.2 Objectives 
To this end, the following objectives will be pursued: 
- to establish an experimental platform recapitulating DC differentiation from 
human hematopoietic stem and progenitor cells in vitro and in vivo.   
- to promote the establishment of a definitive hematopoietic program in iPSC-
derived progenitors enabling their terminal differentiation into functional human 
DCs; 
- to generate genetically modified iPSC lines in order to study the transcriptional 







Chapter 2 Materials and Methods 
1 Flow cytometry 
1.1 Antibodies and reagents 
Extracellular staining of cells was preformed in FACS buffer, consisting in PBS 
(GIBCO® Life Technologies) 1% BSA (Apollo Scientific) 2mM EDTA (Life 
Technologies). Antibodies used in all experiments are listed in Table 2-1. 
Table 2-1. List of antibodies used in flow cytometry 
Marker Fluorochrome Clone Supplier 
huCD45 APC-Cy7/APC HI30 Biolegend 
muCD45 PerCP-Cy5.5 104 eBiosciences 
CD14 Pe-Cy7/BV786 HCD14/M5E2 Biolegend 
CD16 BV421 3G8 Biolegend 
CD141 PE/PE-Cy7 M80 Biolegend 
CD1c FITC/PE-Cy7 L161 Biolegend 
Clec9A PE/APC 8F9 Biolegend 
HLA-DR BV510 L243 Biolegend 
CD123 PerCP-Cy5.5/APC 6H6 Biolegend 
CD303 APC 201A Biolegend 
CD304 APC 12C2 Biolegend 
CD163 FITC GHI/61 Biolegend 
CD206 PE/PerCP-Cy5.5 15.2/6H6 Biolegend 
CD83 FITC HB15E Biolegend 
CD86 PE IT2.2 Biolegend 
CD3 BV786 OKT3 Biolegend 
Siglec6 FITC 767329 R&D 
Axl PE 108724 R&D 
CD15 BV510 W6D3 Biolegend 
CD19 PE HIB19 Biolegend 
CD34 APC 561 Biolegend 
CD4 PerCP-Cy5.5 OKT4 Biolegend 
CD8 APC-Cy7 HIT8A Biolegend 
PDL1 APC 29E.2A3 Biolegend 
CD43 PE 1G10 BD Bioscience 
CD73 APC-Cy7 AD2 Biolegend 
CD90 BV510 5E10 Biolegend 
CD41 FITC/PE-Cy7 A2A9/6 Biolegend 
CD31 BV421 WM59 Biolegend 
CD184 BV786 12G5 Biolegend 





Marker Fluorochrome Clone Supplier 
CD45RA BV510 HI100 Biolegend 
α-tmSCF biotin polyclonal R&D 
α-Flt3L biotin polyclonal R&D 
CD2 PE RPA-2.10 Biolegend 
CD5 PE L17F12 Biolegend 
CD1a APC HI149 Biolegend 
CD172a PE SE5A5 Biolegend 
CD88 PE S5/1 Biolegend 
CD64 APC 10-1 Biolegend 
CD11b PE ICRF44 Biolegend 
CD33 APC P67.6 Biolegend 
NKp46 biotin 9E2 Biolegend 
CD3 biotin OKT3 Biolegend 
CD19 biotin HIB19 Biolegend 
CD20 biotin 2H7 Biolegend 
CD15 biotin MC-480 Biolegend 
CD203c biotin NP4D6 Biolegend 
Streptavidin APC-Cy7 - Biolegend 
 
1.2 Cell preparation and staining 
Antibody staining for flow cytometry or fluorescence-activated cell sorting (FACS) was 
performed by incubating the cells for 20 minutes in FACS buffer containing the mix of 
antibodies at the appropriate concentrations. Samples were kept on ice and protected 
from light. After incubation, cells were washed twice in FACS buffer and analysed 
using BD LSR Fortessa or sorted on a BD FACS Aria running BD FACSDIVA (BD 
Biosceinces). DAPI 1µg/ml (PromoKine) was used for live/dead discrimination. Both 
instruments were housed at the Biomedical Research Centre (BRC) Flow Core Facility 
(Guy’s and St Thomas’ NHS Foundation Trust and King’s College London). Analysis 
of flow cytometry data was performed using FlowJo software (TreeStar, version 10.2). 





1.3 Intracellular staining 
Intracellular staining for human Flt3 (CD135) was performed using BD 
Cytofix/Cytoperm Fixation kit (BD Biosciences) as per manufacturer’s instructions. 
 
2 Cell culture and primary cell isolation 
2.1 Cell lines maintenance 
Human iPSC lines iKCL4 and iKCL11 (courtesy of Dr. Dusko Ilic - KCL) were 
cultured in Matrigel-coated plates (BD Biosciences) in mTeSR1 medium (Stemcell 
Technologies) and maintained at 37°C 5% CO2 5%O2. Cells were washed with DMEM 
(Gibco® Life Technologies) and detached using PBS (Gibco® Life Technologies) 
0.8mM EDTA (Gibco® Life Technologies) solution. When re-plated iPSC were 
incubated in medium supplemented with 10µM Rho-kinase inhibitor (Y-27632, - Santa 
Cruz Biotechnology) for 6-12 hours. 
MS5 stromal cells were cultured in IMDM (Gibco® Life Technologies) supplemented 
with 10% heat-inactivated FBS (Gibco® Life Technologies), penicillin/streptomycin 
(Gibco® Life Technologies), 50µM β-mercaptoethanol (Gibco® Life Technologies) and 
maintained at 37°C 5% CO2 20%O2. Cells were washed with PBS and detached using a 
solution of PBS 0.25% trypsin (Gibco® Life Technologies) 0.5mM EDTA. 
OP9 stromal cells were cultured in α-MEM (Gibco® Life Technologies) supplemented 
with 20% non heat-inactivated FBS, penicillin/streptomycin, 50µM β-mercaptoethanol 
and maintained at 37°C 5% CO2 20%O2. Cells were washed with PBS and detached 
using a solution of PBS 0.25% trypsin 0.5mM EDTA. 
B16 mouse melanoma cells were cultures in RPMI (Gibco® Life Technologies) 





mercaptoethanol and maintained at 37°C 5% CO2 20%O2. Cells were washed with PBS 
and detached using a solution of PBS 0.25% trypsin 0.5mM EDTA. 
HEK 293T human embryonic kidney cells 293 were cultures in DMEM supplemented 
with 10% heat-inactivated FBS, penicillin/streptomycin, 50µM β-mercaptoethanol and 
maintained at 37°C 5% CO2 20%O2. Cells were washed with PBS and detached using a 
solution of PBS 0.25% trypsin 0.5mM EDTA. 
SK-MEL28 human melanoma cells RPMI supplemented with 10% heat-inactivated 
FBS, penicillin/streptomycin, 50µM β-mercaptoethanol and maintained at 37°C 5% 
CO2 20%O2. Cells were washed with PBS and detached using a solution of PBS 0.25% 
trypsin 0.5mM EDTA. 
2.2 Human iPSC co-cultures 
For in vitro differentiation of human iPSCs, MS5 or OP9 cells were seeded in 6-well 
plates at a density of 105 cells/well and allowed to grow over confluent for 3-4 days. 
Medium was then changed to differentiation medium consisting in α-MEM 
supplemented with 10% not heat-inactivated FBS, penicillin/streptomycin, 100µM 
MTG (Sigma-Aldrich) and 105 iPSC/well were added. Every 3 days half of the medium 
was replaced with fresh differentiation medium. Cells were incubated at 37°C 5% CO2 
20%O2. On the experiment end-point medium was collected in a 15ml Falcon tube and 
cells were incubated at 37°C for 30 minutes in 1mg/ml Collagenase D solution (Roche) 
in PBS. Supernatant was collected in the same 15ml Falcon tube and cells were 
incubated for 10 minutes at 37°C in 0.05% trypsin 0.5mM EDTA solution in PBS. Cells 
were collected, spun down, re-suspended in PBS and passed through a 100µm cell 





2.3 Cord blood-derived CD34+ progenitors co-cultures 
For in vitro differentiation of human HSPCs into DCs, MS5 or OP9 feeders were 
seeded in a 96-well plate (flat bottom) at a density of 104 cells/well. The day after, 104 
cord blood-derived CD34+ cells/well were seeded on top of stromal cells in IMDM 
supplemented with 10% heat-inactivated FBS, penicillin/streptomycin, 50µM β-
mercaptoethanol and maintained at 37°C 5% CO2 20%O2. Half of the medium was 
replaced at day 5 and 10, and cells were collected with a solution of PBS 5mM EDTA 
(at 4°C) at day 15 for flow cytometry analysis. For recombinant FSG samples, human 
Flt3L (Celldex) 100ng/ml, human SCF (Peprotech) 20ng/ml and human GM-CSF 
(Peprotech) 10ng/ml were added. 
2.4 Isolation of human PBMC by Ficoll-Paque gradient 
Human blood samples (both cord and peripheral blood) were diluted in warm PBS and 
layered on 15ml of Ficoll-Paque (GE Healthcare) in 50ml Falcon tubes. Tubes were 
than centrifuged for 30 minutes at 2000 rpm and 37°C without brake. The mononuclear 
cell layer was collected at the interphase and washed several times with warm PBS. 
Cells were then counted and used in down-stream applications. 
2.5 Isolation of CD34+ cells by magnetic separation 
PBMCs isolated from cord blood or cell suspensions from iPSC/OP9 co-cultures were 
incubated for 30 minutes at 4°C with CD34 Microbeads (Miltenyi) in FACS buffer 
according to manufacturer instructions. Cells were washed in FACS buffer and passed 
through a pre-washed MACS LS column (Miltenyi) placed in the magnetic field of a 
MACS separator. CD34+ cells retained in the column were washed three times with 
FACS buffer, the column was removed from the separator and cells were flushed into a 






3 Molecular cloning 
3.1 Cloning of human growth factors into retroviral vectors 
Vectors, enzymes and primers for the generation of retroviral vectors for human growth 
factor expression are listed in Table 2-2. For all constructs, vectors were linearized by 
restriction enzymes digestion (New England Biolabs) (Table 2-2) and purified from 
agarose gel using QIAquick gel extraction kit (Qiagen) according to manufacturer’s 
instructions. Human factors were amplified by PCR with specific set of primers using 
Q5 high-fidelity Taq Polymerase (New England Biolabs) (Table 2-3) and digested in 
order to create complementary overhangs for subsequent ligation into retroviral vectors. 
Digested amplicons were run on 1.5% agarose gel and purified as previously described. 
Linearized vector and insert were incubate at room temperature for 30 minutes in a 
reaction mix containing T4 DNA ligase (New England Biolabs) and provided buffer. 
Chemically competent bacteria DH-10 were transformed with the ligation product by 
heat-shock (30 minutes on ice, 30 seconds at 42°C, 5 minutes ice). Bacteria were then 
plated in LB agar plates containing 100µg/ml of Ampicillin at 37°C overnight. Selected 
colonies were expanded in LB at 37°C overnight and plasmid DNA was extracted using 
a Qiagen Miniprep kit (Qiagen). Successful ligation was assessed by Sanger 
sequencing.  
 
Table 2-2. List of retroviral vectors used for human cytokines expression 
Vector Reporter Selection Restriction enzymes 
pMX  - Puromycin BamHI/NotI 
pMX IRES GFP GFP Puromycin EcoRI/XhoI 






Table 2-3. Primers for the amplification of human growth factors 
Cytokine cDNA vector Genebank ref Primers 
Flt3L pCMV6-XL5 NM_001204502.1 
GAATTCGCCACCATGACAGTGCTGGCGCC 
CTCGAGTCAGTGCTCCACAAGCAG 
GM-CSF pCMV6-XL4 NM_000758.3 
GAATTCGCCACCATGTGGCTGCAGAGCCT 
CTCGAGTCACTCCTGGACTGGCTC 
tmSCF pCMV6-KITL NM_003994.4 
GGATCCGCCACCATGAAGAAGACACAAACTTGGA 
CTCGAGTTACACTTCTTGAAACTCTCTCTC 




3.2 Cloning of sgRNA into CRISPR/Cas9 vectors  
CRISPR/Cas9 vectors (Table 2-4) were digested with FastDigest BsmBI restriction 
enzyme (Life Technologies) in a 30 minutes reaction at 37°C. Linearized vectors were 
run on 1% agarose gel and purified using QIAquick gel extraction kit (Qiagen). Single 
guide RNA specific for each gene of interest (Table 2-5) were designed using an online 
tool from Zhang Lab (http://crispr.mit.edu). When possible, guides were directed to the 
first exon of the gene and high scored sequences based on the presence of off-targets 
were chosen. Oligos coding for sgRNA specific for each gene were annealed and 
phosphorylated by using the T4 PNK enzyme (New England Biolabs). The following 
parameters were used for successful annealing: 37°C for 30 minutes, 95°C for 5 
minutes, rump down to 25°C at 5°C/min rate. Annealed oligos diluted 1/200 in sterile 
water were used. A ligation reaction with the linearized vector using T4 DNA ligase 
(New England Biolabs) was incubated for 30 minutes at room temperature. Chemically 
competent bacteria DH10 were transformed with the ligation product and plated on LB 
agar containing 100µg/ml Ampicillin overnight. Resulting colonies were amplified in 
LB at 37°C overnight and plasmid DNA was extracted using a Qiagen Miniprep kit 






Table 2-4. CRISPR/Cas9 lentiviral vectors 
Vector Selection Restriction enzymes Ref. 
LentiCRISPR v1  Puromycin BsmBI 667 
LentiCRISPR v2 Puromycin BsmBI 668 
LentiGuide-Puro Puromycin BsmBI 668 
LentiCas9-Blast Blasticidin BsmBI 668 
 
Table 2-5. Single-guide RNA and validation primers for CRISPR/Cas9 targeting 
Target 
gene Single-guide RNA Validation primers 
Id2 CACCGGCTCATCGGGTCGTCCACA AAACTGTGGACGACCCGATGAGCC 
AAGCTTTCGGGCTTCATTCTGAGC 
GAATTC TGCTGATATCCGTGTTGAGG 
IRF8 CACCGTGGTCGGCGGCTTCGACAG AAACCTGTCGAAGCCGCCGACCAC 
AAGCTTTTTCAGTTTGCACTCAGGGC 
GAATTCCGACCACAAAAGTGACTCCG 
IRF4 CACCGCAAGCAGGACTACAACCGCG AAACCGCGGTTGTAGTCCTGCTTGC 
AAGCTTTGCGTTACAGGAGAGCAGG 
GAATTCGCAAAACCCCTCAAGCCTTT 
GATA2 CACCGCTTCAATCACCTCGACTCGC AAACGCGAGTCGAGGTGATTGAAGC 
AAGCTTCCGCCTTCCTTTCGTTTTGA 
GAATTCAGTGGCATAGAAGGAACCCC 
E2-2 CACCGCCCAACATTCCTGCATAGCC AAACGGCTATGCAGGAATGTTGGGC 
AAGCTTCAGTTCAATTTTTACCAAGAAC 
GAATTCAGGCACAGAGCAAAACACAA 




4 Genetic modification by Lenti/Retroviral approaches  
4.1 Lenti/Retrovirus production 
A second-generation lentiviral packaging system psPAX2 (Gag/Pol/Rev) and pMD2.G 
(Envelop), and the retroviral packaging plasmid pCL-Ampho were used to produce viral 
particles for cells transduction. HEK-293T cells were seeded at a density of 3x106 
cells/plate in a 10-cm tissue culture dish and were co-transfected with lenti/retroviral 
vectors along with the corresponding packaging system using a calcium phosphate 
transfection method. Culture medium was re-placed 24 hours after transfection. 





hours of incubation, filtered through a 45µm syringe filter and used fresh or stored in 
1ml aliquots at -80°C. 
4.2 Lenti/Retrovirus transduction 
All cell lines were transduced based on the following protocol. Cells were seeded in a 6-
well plate the day before transduction in order to reach approximately 70% confluence 
within 24 hours. The following day the medium was removed and 2 ml of medium-
containing virus were added along with 4µl of polybrene 4µg/µl (Sigma). Cells were 
centrifuged for 2 hours at 1600 rpm (spinoculation) and then incubated overnight at 
37°C. The day after, medium-containing virus was removed and pre-warmed complete 
culture medium (specific for each cell line) was added to the plate. According to the 
selection marker carried by the lent/retroviral vector, cells were selected either by 
fluorescent activated cell sorting (FACS) or by antibiotic selection (concentrations 
specific for each cell line are reported in Table 2-6). 
 
Table 2-6. Antibiotic concentrations for selection of transduced cell lines 
Cell line Puromycin (24hours) 
Blasticidin  
(7 days) 
iKCL4/iKCL11 0.5µg/ml 5µg/ml 
MS5 15µg/ml - 
OP9 15µg/ml - 
SK-MEL28 0.5µg/ml 18µg/ml 
 
5 Validation of CRISPR/Cas9 targeted cells 
In order to validate the CRISPR/Cas9 targeting of human iPSC lines, genomic DNA 
was extracted from either monoclonal or polyclonal population of cells using GeneJET 
genomic purification kit (Thermo Fisher) according to manufacturer’s instructions. The 





amplified by PCR using Q5 high-fidelity Taq Polymerase (New England Biolabs) with 
primers listed in Table 2-5. The resulting PCR products were purified from agarose gel 
and sent for sequencing (Eurofins Genomics). Sequencing results were analysed with 
the Track of Indels by Decomposition (TIDE) online tool 669.  
When clones displaying heterozygous mutations were identified, the same PCR 
products were cloned into the vector pUC19 and competent bacteria were transformed 
(as described above). At least 10 independent colonies were analysed by Sanger 
sequencing, in order to identify the precise mutation characterising each allele. 
6 Quantitative Polymerase Chain Reaction (qPCR) 
Messenger RNA (mRNA) isolation was performed using RNeasy purification mini kit 
(Qiagen). Genomic DNA contaminations were eliminated from the samples by DNase I 
treatment (Roche) and mRNA was reverse transcribed into cDNA using a RevertAid 
RT kit (Thermo Fisher Scientific), according to manufacturer’s instructions. Finally, the 
levels of expression of specific genes were evaluated by qPCR using the SensiMix 
SYBR kit (Bioline) and ABI Prism 7900HT (Applied Biosystems) analyzer. Relative 
quantification was performed using a ΔCt method, and raw data were normalized to an 
internal control (human GAPDH). 
The following primers were use to detect the genes of interest: 
Table 2-7. Primers for qPCR 
GENE Fwd Primer (5'-3') Rev Primer (5'-3') 
CEBPa TGGACAAGAACAGCAACGAGTA ATTGTCACTGGTCAGCTCCAG 
PU1 GGAAGGGTTTCCCCTCGTC GGTCGCTATGGCTCTCCCC 
Pax5 TCCCAGCTTCCAGTCACAG TGCTGCTGTGTGAACAAGTC 
MPO AGCGAGGAGCCCCTGGCCAGGAACCTG GAGCTCGGGCATCTCACTGGAACGG 
Id2 GCAGATCGCCCTGGACTCGC AGCCACACAGTGCTTTGCTGTCA 
IRF8 CTTCGACACCAGCCAGTTCTTC ACAGCTCTTCCCAGCCTCTTCT 
Flt3 CAAGTGCTGTGCATACAATTCCC ACCTGTACCATCTGTAGCTGG 





SOX17 CGCCGAGTTGAGCAAGAT GGTGGTCCTGCATGTGCT 
RUNX1 CTGCTCCGTGCTGCCTAC AGCCATCACAGTGACCAGAGT 
GATA2 CAAGATGAATGGGCAGAAC CTTCTTCATGGTCAGTGGC 
Ve-Cadherin CAGCCCAAAGTGTGGAGAA TGTGATGTTGGCCGTGTTAT 
GATA1 CCAAGCTTCGTGGAACTCTC ACTGACAATCAGGCGCTTCT 
MYB GCCAATTATCTCCCGAATCGA ACCAACGTTTCGGACCGTA 
NANOG ACAACTGGCCGAAGAATAGCA GGTTCCCAGTCGGGTTCAC 
GAPDH CAGCCTCAAGATCATCAGCA GGGCCATCCACAGTCTTCT 
 
 
7 Enzyme-Linked Immunosorbent Assay (ELISA) 
In order to validate the generation of B16 melanoma lines expressing human Flt3L and 
human GM-CSF, the supernatant of cultured cells as well as the serum of tumor-bearing 
mice were analysed by ELISA. Protein expression was measured using a human Flt3L 
Quantikine Kit (R&D) and human GM-CSF ELISA MAX kit (Biologend) as per 
manufacturer’s instructions. 
 
8 Animal model (NSG) 
NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice between 8 and 12 weeks old were used in 
all experiments. Animals were maintained under pathogen-free conditions in 
accordance with the UK Animal (Scientific Procedures) Act, 1986. 
8.1 In vivo human DCs differentiation 
Human cord blood-derived or iPSC-derived CD34+ hematopoietic cells were injected 
subcutaneously along with engineered stromal cells in 200µl of Matrigel (BD 
Biosciences). Mice were sacrificed at day 12 of differentiation by cervical dislocation 





In tumor experiments, B16 melanoma cells expressing human cytokines were injected 
intravenously (i.v.). At day 6 and 8, human PBMC were also injected i.v. and mice were 
sacrificed at day 10 by cervical dislocation. Lungs displaying tumor metastasis were 
collected, processed and analysed.  
8.2 Preparation of cells from Matrigel plugs 
Subcutaneous Matrigel plugs were recovered, cut in pieces and incubated in HBSS 
(GIBCO® Life Technologies) 1% FBS, 0.37U/ml Collagenase D (Roche), 10mg/µl 
DNaseI (Roche) and 1mg/ml Dispase (Sigma-Aldrich) for 30 minutes at 37°C. After 
digestion, plugs were smashed on a 100µm strainer (Corning) and cells were collected, 
spun down at 1600rmp for 5 minutes and re-suspended in FACS buffer for flow 
cytometry analysis.   
8.3 Preparation of cells from mouse spleens 
Mouse spleens were collected, cut in small pieces and incubated for 20 minutes at 37°C 
in digestion buffer, consisting of HBSS (GIBCO® Life Technologies) 1% FBS, 
0.37U/ml Collagenase D (Roche) and 10mg/µl DNaseI (Roche). The reaction was 
stopped by transferring the samples on ice and adding EDTA at a final concentration of 
2mM. Spleens were then smashed on a 100µm strainer (Corning) and the resulting cells 
suspension was spun down at 1600 rpm for 5 minutes. Red blood cells were then lysed 
with Ack lysis buffer (Life Technologies) for 5 minutes at room temperature and 
samples were spun down and re-suspended in FACS buffer for flow cytometry analysis. 
8.4 Preparation of cells from lung metastasis 
Lungs were harvested and transferred in a solution of 0.4mg/ml Collagenase IV (Sigma-
Aldrich) in HBSS. Lugs were cut in small pieces and incubated at 37°C for 45 minutes. 





filtered through a 70µm cells strainer (Corning). Cells were then centrifuged for 5 






Chapter 3 Modelling human dendritic cells development  
1 Introduction and objectives 
Dendritic cells (DCs) are key effectors of the immune system for their central role in the 
initiation of antigen-specific immunity and tolerance. Dendritic cells have the unique 
ability to sense exogenous antigens and make them “visible” to T cells, promoting the 
initiation of a specific immune response and acting as a bridge between innate and 
adaptive immunity.  Human DCs are a very rare population of circulating cells in the 
blood, and the paucity of easily accessible cells has represented a major limitation for 
their study. Therefore, the differentiation of human DCs, in vitro and in vivo, represents 
a fundamental tool to better understand their development and function. Moreover, of 
specific interest for this project, the generation of a reliable platform to induce the 
differentiation of HSPCs into human DCs can also be translated to iPSC-derived 
progenitors, to assess their differentiation potential and to open up new avenues for the 
study of human DCs in genetically tractable settings. 
DC progenitors reside in the BM niche, and therefore the recapitulation of the niche 
microenvironment may represent an efficient approach to model DC development in 
vitro. To date, all the available protocols to differentiate human DCs are based on the 
use of GM-CSF203. However, experimental evidences from the mouse model 
demonstrated that GM-CSF is dispensable for DCs development in vivo205. Moreover, 
GM-CSF has been reported to strongly promote the differentiation of monocyte-derived 
cells in vitro33,198 and in vivo50,163,166, which only phenotypically resemble conventional 
DCs. 
In vivo generation of human DCs has been achieved by treating fully reconstituted 
humanised mice with high doses of human Flt3L66,70,179. However, the establishment of 





this approach, such as the exposure of the animals to radiations as well as the time 
consuming process of successfully generating a fully reconstituted animal.  
Therefore, the aim of this chapter was the establishment of an alternative approach to 
generate human DCs from HSPCs both in vitro and in vivo, by recapitulating the bone 
marrow niche microenvironment physiologically supporting DC development. 
 
1.1 Objectives  
In order to achieve this goal the following objectives were pursued: 
- to generate a “humanised” stromal niche supporting human DC development, 
mimicking the bone marrow microenvironment; 
- to identify the optimal combination of niche factors for human DC subset 
generation in vitro from hematopoietic progenitor cells; 
- to investigate the heterogeneity of in vitro generated DC2s and the contribution of 
GM-CSF to their development; 
- to improve human DCs differentiation in vivo by recreating an artificial niche-like 
environment in immunodeficient mice; 
 
2 Results 
2.1 MS5 stromal cells expressing human Flt3L are more efficient than OP9 
in supporting human DC differentiation 
In physiological conditions, human DCs are constantly replenished by progenitors 
residing in the hematopoietic niche of the bone marrow. Therefore, recreating a niche-
like microenvironment in vitro may represent an efficient approach to expand dendritic 
cell progenitors and subsequently induce their differentiation into fully functional DC 





generation of an in vitro “humanised” niche by expressing human growth factors 
involved in hematopoietic progenitor maintenance as well as DC differentiation in bone 
marrow-derived murine stromal cell. Four factors were identified as potential 
candidates, including human Flt3L, CXCL12, SCF and TPO. Flt3L was chosen due to 
its fundamental role in DC development both in vitro and in vivo. CXCL12, SCF and 
TPO were selected based on mouse genetic evidences demonstrating their essential role 
in the maintenance and expansion of hematopoietic progenitors in the bone marrow 
niche. The genomic sequences coding for all these factors were amplified by PCR and 
subsequently cloned into retroviral vectors (pMX) carrying a selection marker (GFP, 
mCherry and PuroR, i.e.) downstream an internal ribosome entry site (IRES). Flt3L was 
cloned into pMX-IRES-GFP vector, TPO was cloned into pMX-IRES-mCherry and 
SCF was clones into a pMX vector not expressing any reporter gene. Finally an already 
available pBABE-Puro vector carrying the genomic sequence of human CXCL12 was 
used (Figure S3-1).  
Two different mouse bone marrow-derived stromal cells lines were initially compared, 
MS5 and OP9. Both lines were transduced with retroviral vectors to constitutively 
express human Flt3L (MS5_Flt3L and OP9_Flt3L) and their ability to support human 
DCs differentiation was tested in a 15 days co-culture with cord blood-derived CD34+ 
hematopoietic stem and progenitor cells (HSPCs). Flow cytometry analysis of the 
terminally differentiated cells from three independent cord blood donors demonstrated 
the superior ability of MS5_Flt3L to support DCs differentiation, as expressed by the 
significantly increased number of CD141+Clec9A+, CD14-CD1c+ and 
CD123+CD303/4+ cells generated (Figure 3-1a). Furthermore, to test the advantage of 
generating stromal cells constitutively expressing the membrane bound form of Flt3L, 





HSPCs was compared with MS5 supplemented with recombinant Flt3L (100 ng/ml). 
Flow cytometry analysis of DC subsets at day 15 resulted in a significant increase of the 
frequency of CD141+Clec9A+ and CD14-CD1c+ cells in the total CD45+ population 
and consistent but not statistically significant increase of the total number of generated 
DCs. Conversely, pDC were efficiently generated in both systems (Figure 3-1b). Based 
on these observations, MS5 were subsequently used to test the ability of the identified 
growth factors to improve DCs differentiation. Therefore, seventeen lines expressing all 
the combinations of the four growth factors Flt3L, CXCL12, SCF and TPO were 
generated by retroviral transduction (Figure S3-1d). CXCL12-expressing lines were 
first generated and selected based on their resistance to Puromycin and the expression of 
human CXCL12 mRNA was confirmed by qPCR (Figure S3-1c). The validation of the 
FACS-sorted engineered lines was performed by flow cytometry by assessing the 
expression of fluorescence reporters (GFP and mCherry, i.e.) as well as trans-membrane 






Figure 3-1. MS5 stromal cells expressing human Flt3L support DCs differentiation more efficiently 
than OP9. (a) Flow cytometry plots and quantification of human DC subsets differentiated in vitro from 
CD34+ cord blood-derived hematopoietic progenitors cultured with mouse stromal cell lines MS5 and 
OP9 expressing human Flt3L (MS5_Flt3L and OP9_Flt3L) at day 15. (b) Flow cytometry analysis at day 
15 of CD34+ progenitors cultured with MS5 expressing human Flt3L or MS5 supplemented with 
recombinant human Flt3L. Summary of n=3 independent donors (mean ± SEM; * p<0.05, **p<0.01, 
***p<0.001, Mann-Whitney U test). 
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2.2 Human DC differentiation strictly depends on Flt3L and it is improved 
by SCF and CXCL12 
In order to identify the best combination of factors supporting human DCs 
differentiation in vitro, cord blood-derived HSPCs from three independent donors were 
seeded on the generated engineered MS5 lines and co-cultured for 15 days. Terminally 
differentiated cells were analysed by flow cytometry and the presence of 
CD141+Clec9A+, CD14-CD1c+ and CD123+CD303/4+ cells was assessed.  
As expected, the presence of Flt3L was essential for DCs differentiation, as 
demonstrated by the absence of cells expressing DC-specific markers in all the 
conditions lacking Flt3L (Figure S3-2). Moreover, statistical analysis comparing the 
absolute number of cells as well as their frequency within the CD45+ gate resulted in 
the identification of MS5 expressing Flt3L, SCF and CXCL12 (MS5_FS12) as the best 
condition to generate both CD141+Clec9A+ and CD123+CD303/4+ cells. On the 
contrary, neither the numbers nor the frequency of CD14-CD1c+ cells was significantly 
different in all the tested conditions (Figure 3-2). On the other hand, a consistent and 
statistically significant reduction of both CD141+Clec9A+ and CD123+CD303/4+ cells 
was observed in all the condition expressing TPO, suggesting its inhibitory effect on the 
development of the two subsets. Conversely, the number and frequency of CD14-
CD1c+ cells were not affected by the presence of human TPO (Figure 3-2). In 
conclusion, while the differentiation of CD141+Clec9A+ and CD123+CD303/4+ cells 
was modulated by the same combination of factors, CD14-CD1c+ cells development 
appeared to be unaffected in the same experimental conditions, in apparent contrast with 






Figure 3-2. Human DC differentiation strictly depends on Flt3L and it is improved by the presence 
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2.3 In vitro differentiated CD1c+ cells are heterogeneous 
In order to investigate the different regulation observed for CD1c+ cell development as 
compare to CD141+Clec9A+ and CD123+CD303/4+ subsets, a more extensive 
characterisation of these population was performed. 
Further phenotypic analysis of the in vitro generated cells revealed the presence of two 
populations of cells within the CD14-CD1c+ subset, which can be separated based on 
the expression of CD206. More interestingly, while CD1c+CD206- cells were 
significantly increased in the MS5_FS12 condition, in accordance with the 
CD141+Clec9A+ and CD123+CD303/4+ subsets, the development of CD1c+CD206+ 
cells appeared to be promoted by the presence of TPO (Figure 3-3a and Figure S3-3a). 
In order to characterise the different populations of CD1c+ cells, the phenotype of cord 
blood-derived HSPCs differentiated in vitro on MS5_FS12 was compare to blood DCs 
by flow cytometry. Three subsets of CD1c+ cells were identified in the in vitro 
generated cells: the previously described CD14-CD1c+CD206- and CD14-
CD1c+CD206+ cells along with a third subset of CD14+CD1c+CD206+ cells. On the 
contrary, only the CD14-CD1c+CD206- cells were detected in PBMC samples, 
corresponding to the human DC2 subset (Figure 3-3b). A more extensive analysis of the 
phenotype of these cells was also performed (Figure S3-3b) and the hierarchical 
clustering of mean fluorescence intensity (MFI) values of the selected markers 
measured by flow cytometry suggested a closer relationship of in vitro generated CD14-
CD1c+CD206- and CD14-CD1c+CD206+ cells with blood DC2. In addition, CD14+ 
cells generated in vitro consistently aligned with human blood CD14+ monocytes 
(Figure 3-3c). To further characterise the different population of CD1c+ obtained in 
MS5_FS12 cultures, the ability of in vitro generated cells to respond to TLR stimulation 





and CD86 by flow cytometry. When incubated overnight in the presence of LPS 
(TLR4), all the described CD1c+ subsets were able to significantly up-regulate the 
expression of HLA-DR, CD83 and CD86 (Figure 3-3d). Moreover, a preliminary 
experiment (n=1) using the TLR8 agonist VTX-2337 suggested that both CD14-
CD1c+CD206- and CD14-CD1c+CD206+, but not CD14+CD1c+CD206+ and CD14+ 
cells, are equipped to respond to TLR8 stimulation (Figure 3-3d). Overall these 
experiments revealed the existence of two different subsets within the in vitro 
differentiated CD14-CD1c+ cells, which closely align to CD14-CD1c+CD206- blood 
DC2s based on their immunophenotype and their expression of functional TLR4 and 
TLR8. Moreover, the differentiation of CD14-CD1c+CD206- cells, a phenotype closely 
resembling blood bone fide DC2s, was significantly increased in MS5_FS12, further 







Figure 3-3. In vitro differentiated CD1c+ cells are heterogeneous. (a) Representative flow cytometry 
plots and quantification of n=3 independent donors assessing CD1c+ cells heterogeneity in CD34+ 
progenitors co-cultures with engineered MS5 (mean ± SEM; * p<0.05, one-way ANOVA test). (b) 
Phenotype comparison of in vitro generated CD1c+ cells (MS5_FS12) with their ex vivo isolated 
counterparts (blood). (c) Hierarchical clustering of flow cytometry data comparing mean fluorescence 
intensity (MFI) values from in vitro and ex vivo CD1c+ cells using GENE-E analysis platform (Broad 
Institute) (mean of n=4 independent cord blood and PBMC donors).  (d) Assessment of in vitro generated 
DCs maturation in response to TLR4 (LPS) and TLR8 (VTX) agonists by measuring the up-regulation of 
the activation markers CD86, CD83 and HLA-DR by flow cytometry (n=5 for LPS and n=1 for VTX. 
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2.4 CD14-CD1c+CD206- cells differentiated in vitro cannot be generated 
using GM-CSF alone 
Previous experiments demonstrated how CD14-CD1c+CD206- and CD14-
CD1c+CD206+ cells differentiated in vitro using MS5_FS12 stromal cells share several 
features, such as their dependency on Flt3L (Figure 3-2 and Figure S3-2), their 
phenotypic proximity to circulating blood DCs (Figure 3-3c) and their responsiveness to 
TLR4 and TLR8 (Figure 3-3d). Therefore, to further characterise the in vitro generated 
CD14-CD1c+CD206- and CD14-CD1c+CD206+ cells, their dependency on human 
GM-CSF, a cytokine extensively used to generate human DCs and moDCs in vitro, was 
assessed. 
MS5 stromal cells expressing human GM-CSF (MS5_GM) were generated by retroviral 
transduction (Figure S3-1b) and their ability to induce DCs differentiation was 
compared to MS5_FS12 in 15 days co-cultures of cord blood-derived CD34+ 
progenitors.  
Unlike the other CD1c+ subsets generated in vitro, CD14-CD1c+CD206- cells strictly 
require Flt3L for their generation and cannot be detected in presence of GM-CSF only 
(Figure 3-4a-b). Conversely, CD14-CD1c+CD206+ and CD14+CD1c+CD206+ cells 
can be generated in both conditions (MS5_FS12 and MS5_GM), and appeared to be 
induced more efficiently in MS5_GM, even though the observed difference did not 
reach statistical significance (Figure 3-4a-b). Moreover, two additional populations of 
CD1c- cells were observed exclusively in presence of GM-CSF: the CD14-CD1c-
CD206+ and the CD14+CD1c-CD206+ subsets (Figure 3-4a). More interestingly, the 
induction of these populations by GM-CSF correlates with a statistical significant 
decrease of CD14+CD1c-CD206- monocytes in MS5_GM samples (Figure 3-4b).  
In conclusion, even if all the in vitro generated CD1c+ cells depend on Flt3L for their 





CD14+CD1c+CD206+ subsets can also be induced by using GM-CSF alone. 
Conversely, CD14-CD1c+CD206- cells exclusively rely on Flt3L for their 
development. 
 
Figure 3-4. MS5_FS12 support the differentiation of CD1c+ CD206- cells that cannot be generated 
with GM-CSF alone in vitro. (a) Representative flow cytometry plots and quantification of CD34+ 
progenitors co-cultured with MS5, MS5 expressing human Flt3L, SCF and CXCL12 (MS5_FS12) and 
MS5 expressing human GM-CSF for 15 days. (b) Quantification of differentiated cells from n=5 
independent cord blood donors in 3 independent experiments (mean ± SEM; * p<0.05, ** p<0.01, *** 
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2.5 MS5_FS12 are superior to MS5+recombinant FSG to support human 
DC differentiation in vitro 
The most commonly used protocol to differentiate human DCs in vitro from 
hematopoietic progenitors is based on the co-culture of CD34+ HSPCs with Mitomycin 
C-treated MS5 supplemented with the recombinant human cytokines Flt3L, SCF and 
GM-CSF (recFSG) 203. In order to compare the efficiency of this approach with the 
MS5_FS12 stromal cells generated, the two systems were tested in a 15 days co-culture 
experiment using cord blood-derived CD34+ progenitors. Flow cytometry analysis of 
the cells generated at day 15 highlighted the superiority of MS5_FS12 in supporting the 
differentiation of CD141+Clec9A+, CD14-CD1c+CD206- and CD14-CD1c+CD206+ 
cells, both in absolute numbers and frequency of CD45+ cells (Figure 3-5a and Figure 
S3-5). Moreover, a major phenotypic difference was observed for CD141+Clec9A+ 
cells differentiated in MS5_FS12, which, unlike their recFSG counterparts, lacked the 
expression of CD1c, more closely resembling the phenotype of circulating blood DC1 
(Figure 3-5a). Furthermore, based on the total number of cells and their frequency 
within the CD45+ population, MS5_FS12 appeared to be more efficient in generating 
CD123+CD303/4+ cells and they were also capable of giving rise to a very rare 
population of Axl+Siglec6+ cells (Figure 3-5b). Overall, MS5_FS12 yielded 
significantly higher numbers of CD45+ hematopoietic cells as well as CD15+ 
granulocytes, even though CD15+ cells appeared to be significantly more frequent in 
recFSG samples (Figure 3-5c and Figure S3-5). Finally, CD3+ T cells and CD19+ B 
cells were not detected in both approaches, but MS5_FS12 were capable to maintain a 
significantly larger population of undifferentiated CD34+ cells as late as day 15 (Figure 
3-5c). Therefore, based on their ability of generating larger number of all the analysed 
subsets, as well as providing a more accurate phenotype for CD141+Clec9A+ cells, 






Figure 3-5. MS5_FS12 are superior to recombinant FSG to support human DCs differentiation 
from cord blood-derived hematopoietic progenitors. Flow cytometry analysis and quantification of 
human monocytes, conventional and plasmacytoid DCs (a-b) and other leukocytes (c) generated from 
CD34+ progenitors seeded on MS5 expressing human Flt3L, SCF and CXCL12 (FS12), as compared to 
mitomycin-treated MS5 supplemented with recombinant Flt3L, SCF and GM-CSF (FSG) (n=3 
independent cord blood donors. Mean ± SEM; * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 two-
















































































































































































































































































































































































2.6 MS5_FS12 promote human DCs differentiation in vivo in subcutaneous 
implants in NSG mice 
In order to test the ability of MS5_FS12 stromal cells to support human DCs 
differentiation in vivo, cord blood-derived CD34+ progenitors were injected along with 
MS5_FS12 or MS5_CTRL in subcutaneous Matrigel-based implants. The use of 
synthetic basement membrane matrix (Matrigel) allowed the generation of “organoids” 
localised under the skin of immunodeficient mice retaining both the supportive stromal 
cells and the CD34+ progenitors in close contact and favouring their interaction. After 
12 days of differentiation, the Matrigel-based “organoids” were recovered and their 
cellular content was analysed by flow cytometry. Human CD45+ hematopoietic cells 
were detected in both MS5_FS12 and MS5_CTRL, even if significantly higher numbers 
of cells were obtained from the stromal cells expressing human cytokines (Figure 3-6). 
In addition, unlike MS5_CTRL, MS5_FS12 were capable of supporting the 
differentiation of CD141+Clec9A+ and CD14-CD1c+ cells. On the other hand, 
CD123+CD303/4+ cells were generated in both conditions (MS5_CTRL and 
MS5_FS12) at the same frequency within CD45+ cells, even though MS5_FS12 yielded 
a significantly higher amount of cells (Figure 3-6). Furthermore, when compare to in 
vitro cultures, MS5_FS12 failed to give rise to CD14-CD1c+CD206+ and 
CD14+CD16+ cells, even though a not significant increase in the number of 
CD14+CD1c-CD206- and CD14+CD1c+CD206+ cells was detected (Figure 3-6). 
All together these results demonstrated that the MS5_FS12 stromal niche was capable 
of supporting the differentiation of CD141+Clec9A+, CD14-CD1c+ and 






Figure 3-6. Engineered MS5_FS12 promote human DCs differentiation in vivo in subcutaneous 
implants in NSG mice. Flow cytometry plots and quantification of human DCs generated in vivo by 
injecting basement membrane matrix (Matrigel®) preparations containing CD34+ progenitors along with 
engineered MS5 (MS5_FS12) into NSG mice. Matrigel implants (plugs) were recovered 12 days after 
injection and the presence of human DCs was assessed by flow cytometry (n=5/6 plugs from 4 
mice/group in two independent experiment. Mean ± SEM; * p<0.05, ** p<0.01, *** p<0.001, **** 



































































































































































































































































































In this chapter, the establishment of a novel approach to promote human DCs 
differentiation from CD34+ HSPCs is reported. 
Based on the knowledge that dendritic cell are constantly replenished by specific 
progenitors (CDP) that reside in the bone marrow hematopoietic niche, the generation 
of a “humanised” niche capable of supporting DCs development was hypothesised. To 
this end, the human homologues of growth factors essential for the maintenance of a 
functional hematopoietic niche in mouse were identified, consisting in human SCF, 
CXCL12 and TPO (Table 1-3). Moreover, human Flt3L was also considered due to its 
fundamental role in DCs development8,17 as well as the wide expression of its receptor 
(Flt3) in human hematopoietic progenitors183,184.  
In order to recapitulate the bone marrow niche microenvironment, mouse stromal cell 
lines (MS5 and OP9, i.e.) were transduced with multiple combinations of retroviral 
vectors expressing the selected human factors and their ability to support human DCs 
development was tested in vitro using CD34+ cord blood-derived hematopoietic 
progenitors. Flow cytometry analysis of the generated cells from 3 independent cord 
blood donors allowed to conclude that the expression of human Flt3L, SCF and 
CXCL12 in MS5 stromal cells (MS5_FS12) represent the most efficient combination of 
factors supporting human DCs differentiation in vitro (Figure 3-2).  
The most commonly used protocol to generated human DCs in vitro reported in 
literature203 is based on the differentiation of CD34+ hematopoietic progenitors on 
mitomycin C-treated MS5 supplemented with recombinant human Flt3L, SCF and GM-
CSF (recFSG). Therefore a comparison of this approach with the newly generated 
MS5_FS12 stromal niche was performed. Flow cytometry analysis of the terminally 





differentiation, and this observation was based on the higher yield of DCs obtained 
(Figure 3-5) as well as on the ability of MS5_FS12 to maintain a pool of CD34+ 
undifferentiated progenitors until the late stages of differentiation (Figure 3-5c). 
Moreover, this novel approach clearly demonstrated that GM-CSF, a cytokine 
extensively used in in vitro studies of human DCs33,198, is dispensable for human DC 
generation.  
Unexpectedly, a consistent and reproducible negative regulation of DCs development 
by human TPO was observed. Indeed, the addition of TPO in all the cytokines 
combinations leading to DCs differentiation was able to abrogate the generation of 
CD141+Clec9A+ and CD123+CD303/4+ cells (Figure 3-2) as well as shifting the 
balance of CD1c+ cells towards the differentiation of CD14-CD1c+CD206+ cells at the 
expenses of the CD14-CD1c+CD206- subset (Figure 3-3). These observations were 
partially in contrast with previously reported protocols based on the use of TPO for 
human DC subsets differentiation in vitro69,202. Proietto et al. reported the successful 
differentiation of human DC subsets from G-CSF-mobilised CD34+ hematopoietic 
progenitors cultured for 21 days in presence of human recombinant Flt3L (100ng/ml) 
and TPO (50ng/ml). Flow cytometry analysis provided evidences of the differentiation 
of CD14-CD11c+CD1b/c+, CD14-CD11c+Clec9A+ and CD14-CD11c-CD123+ cells, 
described as cDC2, cDC1 and pDC, respectively. Moreover, even though only a limited 
number of markers was provided for the phenotypic characterisation of these cells, 
additional experiments assessing the expression of DC-specific transcription factors as 
well as the production of cytokines in response to activation stimuli and their ability to 
induce proliferation of CD4+ allogeneic T cells were performed to further support their 





More recently, Balan et al. reported that an initial 7 days expansion of cord blood-
derived CD34+ progenitors in medium supplemented with recombinant human Flt3L 
(100ng/ml), SCF (100ng/ml), IL-3 (20ng/ml) and TPO (50ng/ml) could improve the 
differentiation of XCR1+ DC1s but failed to give rise to DC2 (pDC not assessed)202.  
However, these protocols significantly differed from the method described here, both in 
terms of concentration and duration of the TPO stimulation. Therefore, even if it is not 
possible to rule out a potential positive effect of TPO in the expansion of early DC 
progenitors, these experiments demonstrated the detrimental effect of TPO in the 
terminal differentiation of human DC subsets (Figure 3-2). 
 
3.1 Characterisation of human DC subsets generated in vitro in stromal cells 
co-cultures 
The phenotypic characterisation of the DC subsets generated using the MS5_FS12 
stromal niche supports the conclusion that in vitro generated cells closely resemble their 
in vivo blood counterparts. For instance, unlike the ones generated in MS5+recombinant 
FSG34,45, CD141+ Clec9A+ cells differentiated in MS5_FS12 do not express CD1c, in 
agreement with human blood DC1 phenotype (Figure 3-5a). Moreover, the phenotype 
of CD14- CD1c+ CD206- has been extensively characterised and appeared to be 
consistent with circulating human DC2 subset (Figure 3-3c and Figure S3-3b). 
However, the identification of cell types based on flow cytometry analysis of their 
phenotype represents a biased approach limited by the restricted number of markers that 
can be simultaneously assessed. For this reason, future work will aim at perform RNA 
sequencing (RNAseq) analysis of FACS-sorted subsets generated in vitro and compare 
them to physiologically circulating blood DC subsets. This will allow a more robust 





described additional DC subsets62. For instance, the presence of a small population of 
Axl+Siglec6+ cells may be confirmed and further characterised. 
On the other hand, functional validation of the cellular output of this in vitro system still 
needs to be completed. Indeed, the responsiveness of CD1c+ cells to TLR4 stimulation 
has been assessed, but preliminary results suggesting the specific activation of CD14- 
CD1c+ CD206- and CD14- CD1c+ CD206+ cells by the TLR8 agonist VTX-2337 need 
to be repeated. If confirmed, this result will further suggest the close relationship of 
these subsets with circulating blood DC2. Furthermore, the presence of functional and 
subset-specific TLRs will need to be assessed in the other described subsets, including 
TLR3 stimulation in CD141+ Clec9A+ DC1 and TLR7 and TLR9 in CD123+ 
CD303/4+ pDC. More importantly, the detection of specific cytokines secretion, such as 
IFN-λ for DC1 or IFN-α/β for pDCs, in response to TLR stimulation will further 
validate the identity of these cells. 
 
3.2 Heterogeneity of in vitro generated CD1c+ cells and their GM-CSF 
dependency 
A more refined phenotypic analysis of CD1c+ cells generated in vitro using MS5_FS12 
stromal cells revealed the presence of at least three different subsets that can be 
identified based on the expression of CD14 and CD206: CD14- CD1c+ CD206-, CD14- 
CD1c+ CD206+ and CD14+ CD1c+ CD206+ cells. 
Flow cytometry analysis of blood samples from healthy volunteers demonstrated that 
only the CD14- CD1c+ CD206- cells, a phenotype consistent with bona fide DC2, 
could be detected in vivo, whereas both CD14- CD1c+ CD206+ and CD14+ CD1c+ 
CD206+ cells were absent in healthy donors PBMCs (Figure 3-3b).  
In order to characterise the growth factors requirements for their development, the 





progenitors in either MS5_FS12 or MS5 expressing human GM-CSF (MS5_GM) 
(Figure 3-4a). Flow cytometry analysis of the differentiated cells demonstrated that, 
unlike CD14- CD1c+ CD206- cells, both CD14- CD1c+ CD206+ and CD14+ CD1c+ 
CD206+ subsets were successfully generated in the presence of human GM-CSF. More 
importantly, MS5_GM appeared to be more efficient then MS5_FS12 in inducing the 
differentiation of CD206+ cells, even if statistical analysis did not reach significance 
(Figure 3-4b). These results were consistent with preliminary in vivo experiments (n=1) 
in NSG mice, where human PBMCs were injected intravenously in mice bearing B16 
melanoma tumors engineered to express the human isoforms of either Flt3L or GM-
CSF (Figure S3-4). The analysis of human cells recovered at the tumor site (lung) 
highlighted the GM-CSF dependency of CD14- CD1c+ CD206+ and CD14+ CD1c+ 
CD206+ cells. Consistently with in vitro data, the differentiation of these two subsets 
correlated with a reduction in the total number of CD14+ monocytes (Figure 3-4b and 
Figure S3-4). Moreover, the CD14- CD1c+ CD206- subsets expanded in vivo only in 
response to human Flt3L, as observed in vitro in the MS5_FS12 samples (Figure 3-4b 
and Figure S3-4). 
The heterogeneity of DC2s have been recently described in human62,96, consistently 
with previously reported mouse data21,22. Yin et al. described the identification of two 
subsets within the CD1c+ cells displaying different phenotype and function and that can 
be separated based on the expression of CD5. Gene expression analysis suggested that 
while CD5hi cells expressed higher levels of DC2-specific genes, CD5low cells 
preferentially expressed monocyte-related genes96. With a different experimental 
approach Villani et al. also highlighted the existence of two subsets within the CD1c+ 
cells, defined as DC2 (CD1c+_A) and DC3 (CD1c+_B). DC2 were characterised by the 





DC3 expressed a CD14+ monocyte-like gene set and was defined as “inflammatory”62. 
Even though this characterisation was mainly based on single-cell RNAseq data in 
human PBMC, the expression of CD163 was proposed as one of the markers allowing 
the separation of these two subsets62. Therefore, the expression of both CD5 and CD163 
was assessed in the CD14- CD1c+ CD206- and CD14- CD1c+ CD206+ cells generated 
in vitro in the MS5_FS12 stromal niche. However, our cells did not align clearly with 
published subsets (Figure 3-3a Figure S3-3b). Conversely, the phenotype of in vitro 
differentiated CD14+ CD1c+ CD206+ was consistent with the one described for human 
inflammatory DCs (infDC) by Segura et al. Human infDC were identified in 
inflammatory fluids such as arthritic synovial fluid or tumor ascites, and based on their 
transcriptome analysis were proposed to be derived from monocytes81.  
In summary, while CD14- CD1c+ CD206- cells are exclusively dependent on Flt3L in 
vitro and can be expanded from PBMCs in vivo in the presence of human Flt3L, the 
CD14- CD1c+ CD206+ and CD14+ CD1c+ CD206+ cells resulted to be both Flt3L- 
and GM-CSF-dependent and can be induced in vitro and in vivo by human GM-CSF. In 
addition, the differentiation of both subsets correlates with a reduction of the absolute 
numbers of CD14+ monocytes in vitro and in vivo (Figure 3-4 and Figure S3-4). All 
together these results may suggests a potential monocytic origin of the CD14+ CD1c+ 
CD206+ and CD14- CD1c+ CD206+ subsets, even though experimental evidences 
supporting this conclusion are not provided. 
In order to decipher the identity of CD14+ CD1c+ CD206+ and CD14- CD1c+ CD206+ 
cells two main approaches may be considered for future experiments. On one side, RNA 
sequencing analysis can be performed to characterise the gene expression profiles of 
these in vitro generated subsets and compared them to ex vivo isolated inflammatory 





resulting set of data can be also compared to available gene expression profiles for 
infDC or inflammatory macrophages60. Furthermore, a functional characterisation of 
CD14+ CD1c+ CD206+ and CD14- CD1c+ CD206+ cells can be achieved by assessing 
their ability to efficiently induce T cells responses. Indeed, it has already been 
demonstrated that infDC promote T helper 17 (Th17) cells differentiation from naïve 
CD4+ T cells by secreting Th17 cell-polarising cytokines60.  
 
Figure 3-7. Heterogeneity of CD1c+ cells in vitro and in vivo 
 
3.3 Differentiation of human DCs in vivo in NSG mice 
Successful generation of human DCs in vivo have been achieved by the administration 
of human recombinant Flt3L in fully reconstituted humanised mice (Table 1-6). 
However, the mice “humanisation” is a time-consuming process (~ 12 weeks) that 
requires an initial sub-lethal irradiation of the animals. Therefore the ability of the 
MS5_FS12 stromal niche to support human DCs differentiation in vivo was tested. Flow 

































containing human CD34+ progenitor along with MS5_FS12 cells demonstrated the 
generation of CD141+Clec9A+, CD14-CD1c+ and CD123+CD303/4+ cells as early as 
day 12 in NSG mice (Figure 3-6). 
However, in order to functionally validate the in vivo differentiated cells, future 
experiments will aim at testing their ability to efficiently activate human T cell. Such 
approach will also provide a platform to study human DCs interaction with T cells in 
vivo. Therefore, preliminary experiments were performed to test whether intravenously 
injected human T cells were capable of migrate towards the subcutaneous Matrigel-
based implant and interact with the in vivo differentiated human DCs. As shown in 
Figure S3-6, cell trace violet (CTV)-labelled T cells were injected intravenously in NSG 
mice bearing a subcutaneous implant (plug) containing human DCs (day 12). Flow 
cytometry analysis 4 days after T cells injection revealed the presence of human CD45+ 
cells in both spleen and Matrigel plug. However, non-dividing CTV+CD3+ T cells were 
only detected in the spleen of the animals, demonstrating their inability to reach the plug 
and interact with human DCs (Figure S3-6). 
An alternative approach to assess the function of in vivo differentiated human DCs will 
be used in future experiments, based on the assessment of antigen-specific T cells 
proliferation in vivo. To this end, human T cells will be transduced with a retroviral 
vector (pMSGV1-F5AfT2aB) coding for the a and b chain of the F5 anti-MART1/A2 
TCR670. Subsequently, CD34+ HSPCs from an HLA-A02*01+ cord blood donor will be 
differentiated in vivo using MS5_FS12 stromal cells in subcutaneous Matrigel plugs. 
After 12 days of differentiation, UV-killed cell lines expressing the melanoma antigen 
MART1 will be injected into the plug as a source of antigen for the in vivo 





cells and the antigen-specific proliferation will be measured by CTV dilution of the T 
cells recovered from the plug. 
This system will provide a functional validation of the generated human DCs by testing 
their ability to cross-present exogenous antigens. Moreover, it may represent a very 
useful platform enabling the study of human T cells interaction with DCs in vivo, for 






4 Supplementary figures 
 
Figure S3-1. Generation of engineered stromal cell lines (MS5) expressing human cytokines. (a) 
Strategy to clone human bone marrow niche factors into retroviral vectors (pMX). (b) Validation of 
FACS-sorted lines expressing single cytokines by flow cytometry, based on the expression of fluorescent 
reporters and antibody staining of trans-membrane proteins (huFlt3L and huSCF, i.e.). (c) Validation of 
human CXCL12 expression by qPCR in MS5_12 after puromycin selection. (d) Engineered MS5 lines 
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Figure S3-2. Human DC differentiation strictly depends on Flt3L and it is improved by the 
presence of the niche factors SCF and CXCL12. Representative flow cytometry plots of CD34+ 
progenitors differentiated in vitro on engineered MS5 lines for 15 days in absence of huFlt3L. 
Quantification of in vitro generated cells expressed as absolute number and percentages of human CD45+ 
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Figure S3-3. In vitro differentiated CD1c+ cells are heterogeneous. (a) Quantification of in vitro 
generated CD1c+ cells from CD34+ HSPCs co-cultured with huFlt3L-producing MS5 lines expressed as 
percentages of human CD45+ cells (n=3 independent cord blood donors. Mean ± SEM; * p<0.05, one-
way ANOVA test). (b) Histograms of a representative experiment showing cell surface markers 
expressed in human monocytes and CD1c+ cells generated in vitro with MS5_FS12 as compare to cells 


















































































Figure S3-4. MS5_FS12 support the differentiation of CD1c+ CD206- cells that cannot be generated 
with GM-CSF alone in vitro and in vivo. (a) Generation of mouse melanoma B16 cells expressing 
human Flt3L and human GM-CSF by retroviral transduction (pMX-IRES-GFP vector) and validation by 
assessing cytokines secretion in vitro (supernatant) and in vivo (serum) by ELISA. (b) Intravenous (i.v.) 
injection of mouse melanoma cells (B16) expressing human Flt3L and GM-CSF into NSG mice followed 
by i.v. injection of human PBMCs at days 7 and 8. Metastatic tumors in the lungs were collected at day 9 



































































































































































































































































Figure S3-5. MS5_FS12 are superior to recombinant FSG to support human DCs differentiation 
from cord blood-derived hematopoietic progenitors. Quantification of in vitro generated cells from 
CD34+ HSPCs co-cultured with MS5 expressing human Flt3L, SCF and CXCL12 (FS12), as compared to 
mitomycin-treated MS5 supplemented with recombinant Flt3L, SCF and GM-CSF (FSG) (n=3 
independent cord blood donors. Mean ± SEM; * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 two-




























































































































































































































































Figure S3-6. Engineered MS5_FS12 promote human DCs differentiation in vivo in subcutaneous 
implants in NSG mice. Human T lymphocytes were injected intravenously in NSG mice carrying 
subcutaneous Matrigel implants containing human DCs differentiated in vivo from cord-blood-derived 
CD34+ progenitors using MS5_FS12 stromal cells. Four day after T cells injection, the presence and 










































Chapter 4 Modelling human definitive hematopoiesis using iPSC 
1 Introduction and objectives 
The establishment of a reliable system to differentiate human DC subsets from iPSCs 
represents an invaluable platform to study human DC biology. Indeed, the possibility to 
generate human DCs from an inexhaustible source of genetically matched or patient-
specific cell lines in combination with highly efficient genome editing techniques such 
as CRISPR/Cas9, would enable a better understanding of human DCs biology and their 
potential application in clinical therapies. In the last decade, numerous studies reported 
the generation of DCs from human PSCs (either ESC or iPSC)656,659,660,664–666. However, 
a full characterisation of their phenotype, function and hematopoietic origin was not 
provided.  
DCs originate from HSCs and they are constantly replenished by bone marrow 
precursors (CDP) during adult life. Therefore, the induction of a definitive 
hematopoietic program during differentiation of pluripotent stem cells is essential to 
drive the development of human DCs. Numerous publications described the 
differentiation of hematopoietic progenitors from pluripotent stem cells mainly based on 
two approaches: (i) the formation of embryoid bodies (EB) in the presence of factors 
driving hematopoietic differentiation; (ii) the co-culture of PSC with mouse bone 
marrow stromal cells supporting hematopoietic differentiation (OP9 or MS5, e.g.). Both 
systems have been quite extensively characterised, and the generation of a variety of 
terminally differentiated cells have been reported. However, no reliable marker has been 
identified to successfully discriminate between primitive and definitive progenitors at 
early stages of differentiation, and the assessment of the potential of those cells still 





The goal of this chapter is to develop an in vitro system mimicking the embryonic 
events leading to the generation of definitive hematopoietic progenitors, from the initial 
mesoderm commitment through the differentiation of hemangioblast-like progenitors 
and resulting in the formation of hemogenic endothelial cells, which undergo 
endothelial-to-hematopoietic transition (EHT) and give rise to hematopoietic 
progenitors. Promoting the definitive hematopoietic program while recapitulating these 
early embryonic events in vitro may represent a successful strategy to induce human 
DCs differentiation. 
 
1.1 Objectives  
In order to establish an in vitro protocol to generate human iPSC-derived DC subsets 
the objectives of this chapter were: 
- To develop an in vitro culture system to promote the differentiation of definitive 
hematopoietic stem and progenitors cells from human iPSC; 
- To assess the potential of in vitro differentiated hematopoietic progenitors to 
generate human DC subsets in vitro and in vivo; 
 
2 Results 
2.1 OP9 stromal cells expressing human Flt3L induce SOX17 up-regulation 
in iPSC-derived cells in vitro 
Mouse stromal cells have been extensively used to support hematopoietic differentiation 
of human PSCs. In order to test if human growth factors involved in hematopoietic 
maintenance and DCs development in vitro may play a role in the early stages of 
embryonic haematopoiesis, mouse stromal cells constitutively expressing the human 





mouse bone marrow-derived stromal cell lines, MS5 and OP9, has been performed to 
evaluate their ability to induce the differentiation of CD34+ cells from iPSC. Flow 
cytometry analysis at day 10, 12 and 14 of differentiation using two iPSC lines (iKCL4 
and iKCL11) demonstrated that OP9 cells are superior to MS5 in generating CD34+ 
cells, as shown by the statistically significant increased of the total number of cells 
generated (Figure 4-1a). Moreover, due to the higher yield of CD34+ cells, day 12 was 
chosen as the best time-point for all future experiments. Based on these results, OP9 
cells were transduced with retroviral vectors expressing human Flt3L (pMX-IRES-
mCherry), SCF (pMX) and CXCL12 (pBABE-Puro). After transduction, cells were 
FACS-sorted and validated based on the expression of fluorescent reporters as well as 
antibody staining of trans-membrane proteins (SCF, i.e.) (Figure 4-1b).  The potential of 
these lines to support the differentiation of CD34+ cells was first assessed using two 
iPSC lines (iKCL4 and iKCL11) and no significant difference was observed in the total 
number and frequency of live cells as compared to regular OP9 (OP9_CTRL) (Figure 
4-1c). However, to evaluate if any variation in the transcriptional profile of these cells 
was induced by the presence of human growth factors, the expression of genes involved 
in different stages of hematopoietic commitment during embryonic development was 
assessed by qPCR. Messenger RNA extracted from bulk populations of cells obtained 
from iPSC co-cultures with engineered OP9 (OP9_F, OP9_S and OP9_12) was used. A 
first validation of the ability to detect human cDNA as well as the specificity of the 
qPCR primers was performed in iPSC samples differentiated on OP9 and cord blood-
derived CD34+ progenitors, respectively (Figure S4-1a-b-c). Subsequently, the 
expression of genes known to be up-regulated in hemogenic endothelium (SOX17), 
definitive hematopoietic cells (RUNX1, MYB) and early and late hematopoietic 





and Figure S4-1d). Gene expression results highlighted the significant up-regulation of 
SOX17 expression in samples differentiated in the presence of human Flt3L (Figure 
4-1d). Moreover, even if hematopoietic genes were induced in all the engineered OP9 
samples when compared to undifferentiated iPSCs, no significant difference was 
observed among the tested cytokines (Figure 4-1d and Figure S4-1d). 
In conclusion, even though no difference was observed in the yield of CD34+ cells 
generated from engineered OP9 (OP9_F, OP9_S and OP9_12) when compared to 
OP9_CTRL, a statistically significant up-regulation of the hemogenic endothelium 
transcription factor SOX17 was detected in OP9_F. The same condition also induced a 







Figure 4-1. OP9 stromal cells expressing human Flt3L induce SOX17 expression in cells 
differentiated from human iPSC. (a) Hematopoietic differentiation of human iPSCs using mouse 
stromal cell lines OP9 and MS5 in a time-course experiment. The generation of CD34+ cells from two 
human iPSC lines (iKCL4 and iKCL11) was assessed by flow cytometry (n=8-10 technical replicates 
from 7 independent experiments for each time-point. Mean ± SEM; * p<0.05, paired student’s t-test). (b) 
Validation of FACS-sorted engineered OP9 stromal cells expressing human Flt3L (F), SCF (S) and 
CXCL12 (12) by flow cytometry. (c) Differentiation of human iPSC into CD34+ cells using OP9 stromal 
cells (CTRL) and engineered OP9 expressing human Flt3L (F), SCF (S) and CXCL12 (12) at day 12. 
Quantification of n=9 technical replicates from 6 independent experiments using two iPSC lines (iKCL4 
and iKCL11) expressed as absolute number of cells and frequency of live cells (Mean ± SEM; * p<0.05, 
**p<0.01, Kruskal-Wallis test). (d) Gene expression analysis by qPCR of cDNA samples obtained by 
reverse transcription of mRNA extracted from bulk cell populations resulting from 12 days of iPSC co-
culture with engineered OP9 stromal cells (n=7 technical replicates from 6 independent experiments 
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2.2 Human Flt3L exclusively induces the differentiation of 
CD43+CD41+CD90+ hematopoietic cells from iPSC 
In order to further understand the consequences of Flt3L expression in the 
differentiation of hematopoietic progenitors from iPSC, a more extensive phenotypic 
analysis of the generated progenitors was performed by flow cytometry. To this end, the 
expression of surface proteins marking either endothelial or hematopoietic commitment 
was evaluated in iPSC-derived CD34+ cells generated in OP9_CTRL, OP9_F, OP9_S 
and OP9_12 stromal lines. The expression of CD73 was first evaluated to discriminate 
between endothelial (CD73+) and non-endothelial progenitors (CD73-). Within the 
CD73- subset, the combination of CD43 and CD90 expression was used to identify cells 
committed to the hematopoietic fate (CD43+) and cells displaying a hemogenic 
endothelium phenotype (CD34+CD73-CD43-CD90+). Finally, the expression of CD41 
and CD90 was evaluated within the CD43+ compartment, in order to detect the 
presence of early hematopoietic progenitors (gating strategy in Figure 4-2a). No 
significant difference was observed in the absolute number and frequency of the CD43+ 
cells as well as the CD73-CD43-CD90+ HE cells among the different engineered 
stromal lines tested (Figure 4-2b and Figure S4-2a).  Conversely, a significant increase 
in the frequency of CD43+CD41+ cells was exclusively observed in cells differentiated 
in OP9_F stromal cells, and this was consistent with a significant reduction of the 
CD43+CD41- subset (Figure 4-2b and Figure S4-2a). A more in-depth analysis of the 
CD43+CD41+ population highlighted the existence of a CD43+CD41+CD90+ subset, 
whose absolute numbers and frequency within CD34+ and CD73- cells was 
significantly increased in OP9_F (Figure 4-2b). 
All together these results demonstrated the existence of a CD43+CD41+CD90+ subset 







Figure 4-2. OP9 stromal cells expressing human Flt3L exclusively induce the differentiation of 
CD43+ CD41+ CD90+ hematopoietic cells from human iPSCs. (a) Gating strategy to identify iPSC-
derived endothelial and hematopoietic cells and representative example of CD34+ expression levels in 
each subpopulation. (b) Flow cytometry analysis of endothelial and hematopoietic subpopulations 
generated by culturing human iPSC for 12 days in the presence of OP9 (CTRL) and OP9 expressing 
human Flt3L (F), SCF (S) and CXCL12 (12). Quantification of absolute number of cells, frequency of 
CD34+ cells and frequency of CD73- non-endothelial cells for n=7-9 technical replicates from 4 
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2.3  Human Flt3L and SCF promote the differentiation of arterial vascular 
endothelium from human iPSCs 
The development of both endothelial and hematopoietic progenitors during 
embryogenesis are strictly correlated. Therefore, phenotypic analysis of the CD73+ 
endothelial-committed progenitors generated in vitro using OP9, OP9_F, OP9_S and 
OP9_12 was performed by flow cytometry. To this end, the expression of CD184 
(CXCR4) was evaluated (gating strategy in Figure 4-3a), as endothelial progenitors’ 
potential to differentiate in arterial (CD184+) or venous (CD184-) vascular endothelium 
correlates with the expression of CD184. No significant variation was observed in the 
absolute number and frequency of CD73+ cells among the different engineered OP9 
lines tested. However, qualitative analysis of these cells highlighted a significant 
increase of the CD184+ fraction in both OP9_F and OP9_S, corresponding to a 
reduction of CD184- subset frequency within CD34+ and CD73+ cells (Figure 4-3b-c). 
These results correlated with a consistent but not significant increase of the expression 
of CXCR4 mRNA as measured by qPCR (Figure 4-3d).  
Hence, the stromal cells-derived human Flt3L and SCF were capable to influence the 
development of iPSC-derived endothelial progenitors, by promoting the differentiation 






Figure 4-3. OP9 stromal cells expressing human Flt3L and SCF promote arterial vasculature 
differentiation from iPSCs. (a) Gating strategy to assess heterogeneity of iPSC-derived endothelial cells 
and representative example of CD34+ expression levels in each subpopulation. (b) Flow cytometry 
analysis of CD34+ CD31+ CD73+ endothelial cells generated in iPSC co-cultures with OP9 (CTRL) and 
OP9 expressing human Flt3L (F), SCF (S) and CXCL12 (12) at day 12 of differentiation. (c) 
Quantification of absolute number of cells, frequency of CD34+ cells and frequency of CD73+ 
endothelial cells for n=7-9 technical replicates from 4 independent experiments using iKCL4 and iKCL11 
lines (Mean ± SEM; * p<0.05, ** p<0.01, one-way ANOVA test). (d) Quantitative PCR analysis of 
CXCR4 (CD184) expression in iPSC-derived cells at day 12 of differentiation (n=7 technical replicates 



















































































































































































































2.4 Human Flt3L promotes the differentiation of iPSC-derived CD34+ 
progenitors capable of generating CD14-CD1c+ cells in vitro 
In order to test whether the presence of human Flt3L produced by OP9 stromal cells 
would affect the potential of iPSC-derived progenitors to differentiate into human DC 
subsets, CD34+ cells differentiated using OP9_CTRL and OP9_F were sorted by 
magnetic beads separation and re-plated on either MS5 (MS5_CTRL) or MS5 
expressing human Flt3L, SCF, TPO and CXCL12 (MS5_FST12). Terminally 
differentiated cells were analysed by flow cytometry at day 15, assessing the presence 
of human CD45+ hematopoietic cells as well as the expression of markers 
characterising human DC subsets. Human CD45+ hematopoietic cells were detected in 
all conditions, even though higher numbers were generated in MS5_FST12 samples. 
Likewise, all samples supported the differentiation of CD14+ cells, which were 
increased when human cytokines were present (MS5_FST12). On the contrary, only 
iPSC-derived CD34+ progenitors generated in OP9_F stromal cells were capable to 
give rise to CD14-CD1c+ cells, and this was improved when the terminal differentiation 
was performed using MS5_FST12 (Figure 4-4a-b). 
In conclusion, based on one preliminary in vitro experiment, the presence of human 
Flt3L in the early differentiation of iPSC into CD34+ progenitors correlated with the 
ability of these cells to generate CD14-CD1c+ cells when cultured on MS5 and 






Figure 4-4. OP9 stromal cells expressing human Flt3L promote the differentiation of iPSC-derived 
CD34+ hematopoietic progenitors capable to generate CD14- CD1c+ cells in vitro. (a) Experimental 
strategy and flow cytometry panels of in vitro generated iPSC-derived CD14+ and CD14+ CD1c+ cells. 
Human iPSC were first differentiated into CD34+ progenitors using OP9 (OP9_CTRL) and OP9 
expressing human Flt3L (OP9_F). At day 12 of differentiation, CD34+ cells were isolated by magnetic 
beads separation and further differentiated in vitro using either MS5 (MS5_CTRL) or MS5 expressing 
human Flt3L, SCF, TPO and CXCL12 (MS5_FST12) for 15 days. (b) Quantification of cellular output 
expressed as absolute number of cells and frequency of CD45+ cells (n=1). 
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2.5 Human Flt3L promotes the differentiation of iPSC-derived CD34+ 
progenitors displaying in vivo hematopoietic potential in NSG mice 
To test the in vivo potential of iPSC-derived hematopoietic progenitors differentiated 
using OP9, OP9_F, OP9_S and OP9_12, CD34+ cells generated in each OP9 stromal 
line were isolated by magnetic separation and injected subcutaneously in NSG mice 
along with Matrigel and MS5_FS12 stromal cells. Matrigel implants were recovered 12 
days after injection and flow cytometry analysis was performed to detect the presence of 
differentiated human CD45+ hematopoietic cells. 
Among all the tested samples, only CD34+ progenitors generated using OP9_F stromal 
cells were capable of differentiate in CD45+ hematopoietic cells (Figure 4-5). Further 
analysis of human CD45+ cells showed that 52% of these were expressing the 
monocyte-macrophage markers CD14 and CD16, whereas within the CD14-CD16- 
population approximately half of the cells were CD1c+ (62.8%) while only a fraction  
(30.1%) appeared to be positive for CD141 expression (Figure 4-5).  
Overall this preliminary experiment (n=1) suggested that hematopoietic progenitors 
generated from iPSC in the presence of human Flt3L (OP9_F) exclusively included a 
population of cells capable of giving rise to terminally differentiated CD45+ 






Figure 4-5. OP9 stromal cells expressing human Flt3L generate iPSC-derived CD34+ progenitors 
displaying in vivo hematopoietic potential in NSG mice. (a) In vivo differentiation of iPSC-derived 
CD34+ cells from OP9 and engineered OP9 co-cultures. Human iPSC were differentiated into CD34+ 
cells on OP9 (CTRL) and OP9 expressing human Flt3L (F), SCF (S) and CXCL12 (12). At day 12 of 
differentiation, CD34+ cells were isolated by magnetic beads separation and injected subcutaneously into 
NSG mice along with MS5 (MS5_CTRL) or MS5 expressing human Flt3L, SCF and CXCL12 
(MS5_FS12) in basement membrane matrix (Matrigel®) preparations. Cells were recovered from Matrigel 













































































The generation of iPSC-derived dendritic cells requires the induction of a definitive 
hematopoietic program. Therefore, the ability of an engineered feeder-based approach 
to promote the development of definitive progenitors capable of DCs differentiation was 
tested. Mouse bone marrow stromal cells (OP9) expressing human hematopoietic 
growth factors Flt3L, SCF and CXCL12 were generated by retroviral transduction, and 
their potential to support hematopoietic differentiation was assessed in co-culture 
experiments with human iPSC. 
Flow cytometry analysis of the resulting iPSC-derived CD34+ cells highlighted an 
essential role of human Flt3L in the development of a subset of CD34+ CD73- CD43+ 
CD41+ CD90+ cells, a phenotype consistent with multipotent progenitors characterised 
by high HSC activity both in human cord blood and iPSC-derived hematopoietic 
cells623,671,672. This effect appeared to be specific for human Flt3L, and was not observed 
when human SCF or CXCL12 were used (Figure 4-2). Moreover, human Flt3L also 
promoted the differentiation of arterial vascular endothelium, as demonstrated by the 
significant higher frequency of CD73+ CD184+ cells corresponding to a reduction of 
the CD73+ CD184- (venous) fraction of iPSC-derived endothelial progenitors (Figure 
4-3). A similar effect was also described when human SCF was provided (Figure 4-3). 
Finally, preliminary experiments in vitro and in vivo suggested that the phenotypic 
differences observed in the OP9_F sample correlate with an improved hematopoietic 
potential of the generated progenitors. Indeed, CD34+ cells isolated from either OP9 
(OP9_CTRL) or OP9 expressing human Flt3L (OP9_F) co-cultures had the unique 
ability to give rise to human CD45+ hematopoietic cells in vivo in MS5_FS12 stromal 
niches (Figure 4-5). Likewise, only the cells generated in OP9_F were capable of 





4-4). Of note, in this in vitro experiment MS5_FST12 were used, even though they were 
later identified as sub-optimal for DC generation. However, the observed results were 
consistent with the differentiation potential described for this line in cord blood-derived 
HSPCs experiments (Figure 3-2). Nevertheless, further characterisation is needed to 
clearly establish the identity of these CD73- CD43+ CD41+ CD90+ cells as well as 
their differentiation potential. 
 
3.1 Characterisation of in vitro generated CD73- CD43+ CD41+ CD90+ 
hematopoietic progenitors  
The main effect observed in the iPSC-derived hematopoietic progenitors generated in 
OP9_F stromal cells is the differentiation of a unique subset of cells characterised by 
the expression of the hematopoietic markers CD43, CD41 and CD90 within the CD73- 
non-endothelial progenitors population. As previously mentioned, this phenotype is 
consistent with multipotent progenitors detected both in human cord blood samples as 
well as in iPSC-derived “HSC-like” cells, displaying a superior hematopoietic 
potential623,671,672. However, the absence of reliable extracellular markers to discriminate 
between primitive and definitive hematopoietic progenitors and the lack of a broad 
consensus on the phenotype of PSC-derived definitive cells represent a potential 
limitation of such approach. Therefore, a more extensive characterisation of the gene 
expression profile of these cells may allow a better understating of their identity and 
potential. In this regard, gene expression analysis by qPCR was performed in bulk 
populations of cells differentiated in engineered OP9 stromal cell (Figure 4-1 and 
Figure S4-1). This preliminary analysis highlighted that cells generated in OP9_F 
expressed significantly higher levels of SOX17, a transcription factor involved in the 
specification of hemogenic endothelium and proposed mark the appearance of definitive 





hematopoietic-related transcription factors, such as PU1, MYB and RUNX1, appeared 
to be modulated in these experiments, even though the observed differences were not 
significant (Figure 4-1).  However, their up-regulation might be underestimated due to 
the massive dilution of this rare subset among other iPSC-derived hematopoietic and 
non-hematopoietic cells.  
For this reason, future experiments will aim at assessing the expression of specific 
genes marking the onset of definitive hematopoiesis597,623,645,648  by qPCR at single-cell 
level. The gene expression analysis of index sorted single cells will allow to correlate 
the gene signature characterising definitive hematopoietic cells with the phenotype of in 
vitro generated progenitors, enabling a more accurate assessment of their differentiation 
potential. Indeed, the most reliable confirmation of HSC emergence is the ability to give 
rise to all hematopoietic lineages including Type2 B cells, the only cell type exclusively 
originating from HSCs. This can be tested both in vivo, by injecting iPSC-derived 
progenitors in sub-lethally irradiated NSG mice and assessing their repopulation 
capability, and in vitro, by using stromal cell lines supporting hematopoietic 
differentiation (OP9 or OP9-DLL1, e.g). 
Finally, an additional validation of the definitive origin of CD43+ CD41+ CD90+ cells 
can be achieved in genetically modified human iPSC, by CRISPR/Cas9-mediated 
abrogation of key transcription factors required for definitive hematopoietic cells 
development, such as MYB and RUNX1. It is anticipated that the lack of MYB or 
RUNX1 will impaired the generation of definitive progenitors in iPSCs co-cultures with 
OP9 and OP9_F, and the disappearance of the CD43+ CD41+ CD90+ cells would 






3.2 Human Flt3L and SCF modulate iPSC-derived vascular endothelium 
specification  
The expression of CD73 in iPSC-derived CD34+ cells clearly separates the endothelial-
committed progenitors from cells displaying hematopoietic potential, including the 
hemogenic endothelium. Furthermore, the expression of CD184 (CXCR4) can be use to 
distinguish from arterial (CD184+) and venous (CD184-) vascular endothelium within 
the CD73+ endothelial cells539.  
Therefore, the effect of human cytokines expressed by engineered OP9 stromal cells on 
the specification of the iPSC-derived vascular endothelium was assessed in vitro. Flow 
cytometry analysis demonstrated that the presence of both human Flt3L and SCF affects 
the specification of CD73+ endothelial progenitors by promoting the differentiation of 
CD73+ CD184+ arterial vascular endothelium, which correlates with the reduction of 
the CD73+ CD184- venous counterpart (Figure 4-3b-c). Gene expression analysis of 
CXCR4 further supports this observation (Figure 4-3d).  
In this regards, a further confirmation of the arterial and venous nature of CD73+ 
CD184+ and CD73+ CD184- cells can be achieved by assessing the expression of 
specific genes associated to arterial (EFNB2 and DLL4) and venous (NR2F2) 
vasculature by qPCR.  Moreover, in vivo potential of these cells can be tested by 
subcutaneous injection of either CD73+ CD184- or CD73+ CD184+ cells in Matrigel 
plugs in NSG mice. The presence of large EPHB4- arterial vasculature or small 
EPHB4+ venous endothelium can be detected by immunostaining of histological 
sections of the explanted Matrigel grafts. 
3.3 How does Flt3L affect hemato-endothelial development in human iPSC 
cultures? 
A dual effect of human Flt3L in the development of both hematopoietic and endothelial 





OP9 stromal cells expressing Flt3L promoted the differentiation of CD43+ CD41+ 
CD90+ hematopoietic cells as well as the arterial specification in vascular endothelial 
cells. Therefore, the next question that needs to be answered is what are the mechanisms 
underlying Flt3L effect on hemato-endothelial development. One of the most interesting 
candidates that could participate in this process is the Notch signalling pathway. In fact, 
it has been recently demonstrated that Notch signalling is essential for endothelial-to-
hematopoietic transition in human PSC-derived hematopoietic progenitors 
development539. On the other hand, the Notch pathway has been implicated in the 
regulation of vasculogenesis in different model organisms, and more importantly it has 
been shown to promote arterial specification of the vascular endothelium539,673. Hence, 
based on these observations, it is possible to hypothesise that Flt3L may promote 
indirectly the activation of Notch signalling pathway, which would explain the 
improved hematopoietic differentiation as well as the arterial vasculature induction. In 
this regard, a simple experiment to verify this hypothesis will consist in the use of 
Notch specific inhibitors, such as GSI (gamma-secretase inhibitors), in iPSC co-cultures 
with OP9 expressing human Flt3L (OP9_F). The abrogation of Flt3L-mediated 
modulation of both endothelial and hematopoietic development would confirm the 
involvement of Notch signalling in this process. 
On the other hand, a second relevant aspect that requires clarification is the 
identification of the receptor mediating the Flt3L-depended effect observed. Indeed, 
preliminary experiments failed to detect both intra- and extra-cellular expression of Flt3 
in iPSC-derived CD34+ cells (Figure S4-3a-b), and this was further confirmed by Flt3 
expression analysis by qPCR (Figure S4-3c). However, Flt3 and Flt3L expression has 
been reported in the early phases of embryonic development in the IAHCs and 





observations will require further confirmation, alternative scenarios can be proposed.  In 
this regard, the involvement of the VEGF signalling pathway may represent an 
interesting option. Indeed, VEGF has been identified as an essential regulator of Notch-
dependent arterial specification in mice674, and VEGFR2 (KDR) binding triggers the 
expression of both Notch and its ligand DLL4575,675,676. Moreover, VEGFR2 (KDR) is 
highly expressed in the early mesoderm as well as in hemogenic and non-hemogenic 
endothelial cells in human iPSC differentiation in vitro. Therefore, a first hypothesis 
may be based on the presence of Flt3L-responsive cells capable of secreting human 
VEGF, which signals through VEGFR2 receptor inducing Notch activation. A simple 
evaluation of the presence of human VEGF in the supernatant of iPSC co-cultures with 
OP9_F by ELISA may provide a first answer to this question.  
Alternatively, a second explanation might rely on the cross-reactivity of Flt3L with 
other members of the receptor tyrosine kinases (RTK) family. In this regard, VEGFR2 
(KDR) represents an interesting potential candidate.  
The generation of human iPSC lines knockout for Flt3 may provide a very useful 
genetic model to assess the involvement of this receptor in the modulation of both 
hematopoietic and endothelial differentiation from iPSC in vitro, and the same approach 


































4 Supplementary figures 
 
Figure S4-1. OP9 stromal cells expressing human Flt3L induce SOX17 expression in cells 
differentiated from human iPSC. (a) Positive control of qPCR primers using mRNA extracted from 
cord blood-derived CD34+ progenitors. (b) Detection of human GAPDH expression from serial dilution 
of mRNA extracted from bulk population of cells from day 12 co-cultures of human iPSC with stromal 
OP9 cells (n=3 technical replicates). (c) Expression profile of hematopoietic and endothelial genes in 
cells obtained from OP9 co-cultures as compared to undifferentiated iPSCs (left). Assessment of qPCR 
primers specificity by gel electrophoresis (right). (d) Gene expression analysis by qPCR of cDNA 
samples obtained by reverse transcription of mRNA extracted from bulk cell populations resulting from 
12 days of iPSC co-culture with engineered OP9 stromal cells (n=7 technical replicates from 6 


























































































































































































































Figure S4-2. OP9 stromal cells expressing human Flt3L exclusively induce the differentiation of 
CD43+ CD41+ CD90+ hematopoietic cells from human iPSCs. (a) Quantification of additional 
subpopulations from figure 2d, expressed as absolute number of cells, frequency of CD34+ cells and 
frequency of CD73- CD31+ cells (n=7-9 technical replicates from 4 independent experiments using two 




Figure S4-3. Flt3 expression in iPSC-derived CD34+ cells. Analysis of Flt3 (CD135) expression in 
iPSC-derived hematopietic and endothelial cells by extracellular (a) and intracellular (b) flow 
cytometry (n=1). (a) Overlay of Flt3 expression in subsets generated from OP9_F, OP9_S and OP9_12 
co-cultures (blue) as compared to OP9_CTRL (grey). (b) Intracellular expression of human Flt3 in 
subsets generated from OP9_CTRL, OP9_F, OP9_S and OP9_12 (blue) as compare to isotype control 
(dotted line). (c) Gene expression of Flt3 in cDNA samples obtained by reverse transcription of mRNA 
extracted from bulk cell populations resulting from 12 days of iPSC co-culture with engineered OP9 





















































































































































































































Chapter 5 Genome-editing of human iPSCs 
1 Introduction and objectives 
The establishment of a reliable protocol supporting the differentiation of human 
dendritic cells from iPSCs would represent a major improvement in the understanding 
of human DCs biology. Indeed, iPSCs can be genetically manipulated by genome-
editing techniques, such as CRISPR/Cas9, enabling the study of human DCs in a 
genetically tractable environment.  
The understating of the transcriptional network driving DCs development is mainly 
based on observations from genetically modified mouse models93,219,220, and subset-
specific transcription factors driving DCs differentiation have been identified in the 
mouse. However, the current understanding of the transcriptional regulation of human 
DC is based on observations from patients harbouring genetic mutations in key 
transcription factors involved in the development of the mononuclear phagocyte 
system71,236. Therefore, testing the potential of genetically modified iPSCs to 
differentiate into human DC subsets would represent an invaluable approach to further 
identify essential factors involved in DCs development. Furthermore, the same strategy 
may be used to modulate dendritic cells immunogenicity as well as tolerance, by 
targeting specific pathways involved in either process. For instance, an extremely 
interesting source of potential targets is represented by the variety of factors known to 
modulate DCs immunogenicity as well as their ability to efficiently induce a tumor-
specific cytotoxic T cell response309. If successful, this approach may not only shed new 
light on the mechanisms involved in the immune response against malignancies, but it 






1.1 Objectives  
The aim of this chapter is the generation and validation of human iPSC lines knockout 
for known and unknown transcription factors involved in dendritic cells development as 
well as immune regulatory checkpoints using CRISPR/Cas9 system. 
Therefore, the objectives of this section were: 
- to modulate iPSC-derived DCs immunogenicity by targeting PD-L1 at the iPSC 
level; 
- to generate clonal populations of human iPSC knockout for known and 
unknown transcription factors regulating human DC development including ID2, 
E2-2, IRF8, IRF4 and GATA2; 
 
2 Results 
2.1 CRISPR/Cas9-mediated PD-L1 knockout in human iPSC 
In order to generate an iPSC line knockout for human PD-L1, the efficiency of different 
version of CRISPR/Cas9 vectors was first tested in the human melanoma cell line SK-
MEL-28. SK-MEL-28 cells were chosen for their ability to express human PD-L1 in 
response to IFN-γ exposure, allowing the quantification of the impaired protein 
expression by flow cytometry. These preliminary experiments aimed at identify the 
more efficient CRISPR/Cas9 vector as well as validate the single-guide RNA designed 
to target human PD-L1.  
Single guide RNA (sgRNA) targeting exon 1 of the genomic sequence of human PD-L1 
was identified using the CRISPR design tool from the Zhang Lab (http://crispr.mit.edu). 
Complementary oligos carrying the 20nt sequence specific for human PD-L1 were 
annealed and cloned into three different versions of the lentiviral-based CRISPR/Cas9 





Puro/LentiCas9-Blast (Figure 5-1a and Figure S5-1a). Lentiviral particles were 
generated and used to transduce the human melanoma SK-MEL-28 cell line. Seven days 
post-transduction the expression of PD-L1 in response to IFN-γ stimulation was 
measured by flow cytometry, highlighting an initial down-regulation of the protein in 
the cells co-transduced with LentiGuide-Puro (PDL1) and LentiCas9-Blast vectors 
(Figure 5-1b top and Figure S5-1b top). Transduced cells were then incubated in 
selection medium containing either Puromycin (LentiCRISPR v1 and LentiCRISPR v2) 
or a combination of Puromycin and Blasticidin (LentiGuide-Puro/LentiCas9-Blast) for 
seven days and the expression of PD-L1 was assessed by flow cytometry 16 days post-
transduction. After selection, PD-L1 expression was abrogated in more than 60% of the 
cells transduced with LentiCRISPR v2 and LentiGuide-Puro/LentiCas9-Blast vectors. 
Conversely, only 7% of the cells targeted with LentiCRISPR v1 lack PD-L1 expression, 
which was completely unaffected in control cells transduced with the vector not 
expressing the 20nt sgRNA (Figure 5-1b bottom and Figure S5-1b bottom). Moreover, 
genomic DNA extracted from bulk population of cells targeted with the different 
vectors was analysed by Sanger sequencing in order to detect the presence of insertions 
or deletions (INDELS) in the targeted genomic region. The analysis of sequencing 
results showed that while 100% of the analysed samples (6/6) for LentiCRISPR v2 and 
LentiGuide-Puro/LentiCas9 targeted cells presented a 120bp and 167bp deletion, 
respectively, INDELS were detected in only 66% (4/6) of the samples targeted with 
LentiCRISPR v1 (Figure 5-1c and Figure S5-1c). Based on these results, the two-vector 
system LentiGuide-Puro/LentiCas9-Blast was selected for human iPSC targeting, and a 
line constitutively expressing Cas9 was generated and validated by Western Blot 





(PDL1) vector and single-cell clones of Puromycin-resistant cells were isolated (Figure 
5-1e). 
Hence, an iPSC line constitutively expressing Cas9 was generated (iPSC-Cas9) and 
single-cell clones of iPSC targeted by a PD-L1-specific sgRNA were isolated. Future 
work will aim at validate the successful targeting in monoclonal populations by 
assessing the presence of genomic mutations by Sanger sequencing. 
 
Figure 5-1. CRISPR/Cas9-mediated PD-L1 knockout in human iPSC. (a) Design of single guide 
RNA (sgRNA) targeting exon 1 of human PD-L1 gene and cloning into LentiGuide-Puro vector. (b) 
Evaluation of PD-L1 expression by flow cytometry in human melanoma cells (SK-MEL) transduced with 
LentiCas9-Blast vector along with LentiGuide-Puro in the presence (right) or absence (left) of the sgRNA 
targeting PD-L1 (right). Protein expression was evaluated before (top) and after (bottom) 7 days of 
puromycin selection. (c) Validation of PD-L1 targeting at genomic level in SK-MEL cells transduced 
with LentiGuide-Puro (PDL1) and the LentuGuide-Puro (BB) control. The presence of INDELS was 
assessed by Sanger sequencing. (d) Validation of an iPSC line constitutively expressing Cas9 by Western 






























































































2.2 Generation of human iPSC lines knockout for transcription factors 
potentially involved in human DCs development 
The abrogation of transcription factors potentially involved in human DC development 
can be achieved in iPSC by genomic editing using a CRISPR/Cas9-based approach. 
Therefore, based on the knowledge acquired from the mouse model as well as from 
human patients affected by DC deficiency candidate genes were identified, including 
the transcription factors IRF8, IRF4, GATA2, Id2 and E2-2. Single-guides RNA were 
designed for each factor using the CRISPR design tool from the Zhang Lab 
(http://crispr.mit.edu) and subsequently cloned into the LentiGuide-Puro vector as 
reported in Figure 5-2a, Figure 5-3a and Figure S5-2a. Two of these vectors, namely 
LentiGuide (IRF8) and LentiGuide (Id2), were used to generate lentiviral particles and 
transduced the previously established iPSC-Cas9 line (Figure 5-1d). After 7 days of 
Puromycin selection, the presence of INDELs was assessed using the online “tracking 
of indels by decomposition” (TIDE) tool form the van Steensel Lab 669 in bulk 
populations of both targeted lines. Decomposition analysis of the Sanger sequencing 
data demonstrated the presence of numerous mutations for both Id2 and IRF8-targeted 
cells, with a total efficiency of targeting estimated in 69% and 77.2% of the cells, 
respectively (Figure 5-2b and Figure 5-3b). The presence of inconsistent sequencing 
chromatograms in proximity of the expected double-strand break in the targeted 
samples as compare to the non-targeting controls LentiGuide (BB), further confirmed 
the efficient targeting of the expected genomic locus (Figure 5-2b and Figure 5-3b). 
Single-cell clones were subsequently isolated for each line, resulting in the 
establishment of 11 and 9 monoclonal populations of cells for Id2 and IRF8-targeted 
iPSC, respectively (Figure 5-2d and Figure 5-3d). Finally, TIDE analysis of Sanger 
sequencing data was performed in all the isolated clones for each cell line. Clone #3 of 





suggesting the presence of a homozygous mutation in the Id2 genomic locus (Figure 
5-2c). In silico translation of the mutated genomic sequence allowed to identify the 
presence of an early stop codon resulting in a 28 amino acids (aa) truncated protein 
(Figure 5-2c).  
 
Figure 5-2. Generation of human Id2 knockout iPSC lines by CRISPR/Cas9 targeting. (a) Design of 
single guide RNA (sgRNA) targeting exon 1 of human Id2 gene and validation of the cloning into 
LentiGuide-Puro vector by Sanger sequencing. (b) Evaluation of the presence of INDELS in bulk 
population of Cas9-expressing iPSC transduced with the LentiGuide-Puro (Id2) vector after 7 days of 
puromycin selection. Sequencing data of the genomic region flanking the targeted site were analysed 
using TIDE-calculator 669. (c) Evaluation of INDELS by TIDE-calculator analysis of Sanger sequencing 
results in a monoclonal population (clone #3) of iPSC targeted with LentiGuide-Puro (Id2) and in silico 
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1 -13 (37.3%) -8 (34.4%) - -
2 -12 (50.6%) +3 (34.3%) - 0 (0.3%)
3 -13 (94.3%) - - -
4 -13 (43.9%) -10 (47.8%) - -
5 -13 (92.6%) - - -
6 -10 (53.8%) - - 0 (33%)
7 -10 (38.7%) -1 (29.6%) - -
8 -13 (33.5%) -10 (33.3%) +17 (2.6%) -
9 -1 (43.7%) +1 (43.5%) - 0 (1.8%)
10 -8 (49.7%) +1 (37.8%) - 0 (0.8%)








of single-cell clones of CRISPR/Cas9-targeted iPSC and corresponding genomic mutations identified by 
TIDE. 
 
In order to characterise the genomic mutations predicted by TIDE analysis, a 
heterozygous mutated clone (IRF8 #3) expected to carry a -14bp deletion and a +1 
insertion was further analysed by Sanger sequencing. To identify the specific location of 
the described mutations for each allele, the targeted locus was amplify by PCR and 
amplicons were cloned into a donor vector (pUC19). Chemically competent bacteria 
(E.Coli DH10) were then transformed with the pUC19 vectors carrying either one of the 
two genomic sequences corresponding to two mutated alleles. The analysis of 10 
bacteria colonies enabled the precise identification of the two mutations characterising 
clone #3 of IRF8-targeted cells, and allowed the in silico prediction of early stop codon 
insertions resulting in a 13aa truncated protein for the -14bp allele and a 18aa protein 
for the +1 allele (Figure 5-3c).  
In conclusion, using a lentiviral-based two-vector CRISPR/Cas9 system, a Cas9-
expressing iPSC line was transduced with sgRNA targeting human Id2 and human 
IRF8. Monoclonal population of cells were isolated, and two cell lines knockout for Id2 






Figure 5-3. Generation of human IRF8 knockout iPSC lines by CRISPR/Cas9 targeting. (a) Design 
of single guide RNA (sgRNA) targeting exon 1 of human IRF8 gene and validation of the cloning into 
LentiGuide-Puro vector by Sanger sequencing. (b) Identification of INDELS in bulk population of iPSC-
Cas9 cells transduced with LentiGuide-Puro (IRF8) after 7 days of puromycin selection by TIDE analysis 
of Sanger sequencing data. (c) Evaluation of INDELS by TIDE-calculator analysis of sequencing results 
in a monoclonal population (clone #4) of iPSC targeted with LentiGuide-Puro (IRF8) and in silico 
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10 20 30 40 50
WT allele
Clone #
1 -18 (49.1%) +1 (31.3%) - - -
2 -4 (43.5%) +1 (51.2%) - - -
3 -14 (46.3%) -9 (44.9%) - - -
4 -14 (49.5%) +1 (43.5%) - - -
5 -4 (45.7%) +1 (48.9%) - - -
6 -12 (49.1%) +1 (46.3%) - - -
7 -18 (8.2%) -4 (6%) +1 (19%) - 0 (25%)
8 -14 (23.2%) -12 (27.7%) -9 (21.2%) +1 (21.3%) -















3 Supplementary figures 
 
Figure S5-1. CRISPR/Cas9-mediated PD-L1 knockout in human iPSC. (a) Strategy to clone human 
PD-L1 sgRNA into LentiCRISPR v1 and LentiCRISPR v2 lentiviral vectors. (b) Evaluation of PD-L1 
expression by flow cytometry in human melanoma cells (SK-MEL) transduced with LentiCRISPR v1 
(PDL1) (left) and LentiCRISPR v2 (PDL1) (right) vectors, before (top) and after (bottom) 7 days of 
puromycin selection. (c) Validation of PD-L1 targeting at genomic level by Sanger sequencing, in SK-
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Figure S5-2. Generation of LentiGuide-Puro vectors targeting human E2-2, IRF4 and GATA2 
genes. (a) Design of sgRNA specific for human E2-2, IRF4 and GATA2 and validation of the successful 































































Chapter 6 Overall discussion and conclusions 
The main goal of this project was to recapitulate the development of human dendritic 
cells in vitro from induced-pluripotent stem cell. To this end, the overall process was 
split in two independent steps: a first specification of definitive hematopoietic 
progenitors from iPSC and a second phase in which HSPCs were induced to 
differentiate into human DCs.  
 
In order to define the best conditions supporting DCs differentiation, cord blood-derived 
hematopoietic progenitors were use in in vitro experiments. 
Human dendritic cells arise from a common progenitor (CDP) residing in the 
hematopoietic niche in the bone marrow. In order to recapitulate the niche 
microenvironment in vitro, engineered mouse stromal cells (MS5) expressing the 
human growth factors Flt3L, SCF, CXCL12 and TPO were generated (Figure S3-1). 
Numerous combinations of factors were screened based on their ability to support DCs 
differentiation from cord blood-derived hematopoietic progenitors. As a result, MS5 
expressing human Flt3L, SCF and CXC12 (MS5_FS12) were identified as the best 
condition to promote DCs development in vitro (Figure 3-2). Two main observations 
arose from the comparison of the different stromal lines generated: i) GM-CSF is not 
required for human DCs development; ii) TPO is a negative regulator of human DC1 
and pDC differentiation. Moreover, MS5_FS12 were compared to the more commonly 
used protocol based on MS5 supplemented with recombinant Flt3L, SCF and GM-CSF 
(MS5+recFSG). As a result, MS5_FS12 yielded a significantly higher amount of cells 
for all the analysed subsets (DC1, DC2 and pDC). More interestingly, MS5_FS12 were 
also capable of maintain CD34+ progenitors to an undifferentiated state up to 15 days of 





More extensive analysis of the DC2 subset revealed that CD1c+ cells generated in vitro 
using MS5_FS12 are heterogeneous. Indeed, three subsets of CD1c+ cells could be 
identified based on the expression of CD14 and CD206: CD14- CD1c+ CD206- cells, 
CD14- CD1c+ CD206+ cells and CD14+ CD1c+ CD206+ cells. In order to understand 
the physiological relevance of these cells, further characterisation was performed. The 
phenotype of CD14- CD1c+ CD206- cells aligns with bona fide DC2 detected in human 
blood. Conversely, none of the CD206+ subsets were present in the blood of healthy 
volunteers (Figure 3-3). All CD1c+ subsets were activated by TLR4 stimulation (LPS) 
and preliminary data suggest that functional TLR8 was expressed only in CD14- CD1c+ 
CD206- and CD14- CD1c+ CD206+ cells (Figure 3-3).  Moreover, CD14- CD1c+ 
CD206- cells were not differentiated nor expanded when only GM-CSF was provided in 
vitro and in vivo, highlighting their exclusive dependence on Flt3L. On the contrary, 
CD206+ cells were induced more efficiently by GM-CSF both in vitro and in vivo 
(Figure 3-4 and Figure S3-4). All together these observations suggest that i) CD14- 
CD1c+ CD206- cells closely align with circulating human DC2 subset; ii) CD14- 
CD1c+ CD206+ and CD14+ CD1c+ CD206+ cells do not exist in vivo in blood at 
steady state and may have a monocytic origin. However, further characterisation of 
these subsets is needed and the assessment of their presence in peripheral tissues at 
steady state or during inflammation in vivo represents a very important question that 
needs to be addressed in future experiments. 
The ability of MS5_FS12 stromal cells to support human DCs differentiation in vivo in 
NSG mice was also tested. The injection of stromal cells along with human CD34+ 
progenitors in subcutaneous Matrigel plugs enabled the formation of three-dimensional 
“organoids” in which human DCs differentiate (Figure 3-6). The main advantage of this 





within 12 days of differentiation and with no irradiation. The next goal is to provide 
evidences of the functionality of the in vivo generated subsets and to test their ability to 
interact with other human cell types (T cells, tumors, e.g.). Once established, this 
approach will enable the study of human DCs responses in in vivo models of diseases, 
for instance in the context of infection or cancer.  
 
The successful differentiation of human DCs from iPSC requires the generation of 
definitive hematopoietic progenitors in vitro. Several publications reported the 
generation of human DC-like cells, expressing markers or fulfilling functions that are 
consistent with their DCs identity. However, very little is known about the 
hematopoietic programs involved in the differentiation of iPSC-derived DCs. In this 
manuscript, an in vitro culture system based on mouse stromal cells (OP9) expressing 
human hematopoietic growth factors (Flt3L, SCF, CXCL12, i.e.) was used to promote 
the generation of definitive progenitors capable of differentiating into human DCs. In 
this regard, the expression of human Flt3L in OP9 stromal cells (OP9_F) was the only 
condition tested that appeared to affect the development of iPSC-derived HSPC. Gene 
expression analysis showed a significant up-regulation of the transcription factor 
SOX17 in bulk population of cells differentiated in OP9_F (Figure 4-1). Moreover, the 
presence of Flt3L induced the differentiation of CD73- CD43+ CD41+ CD90+ cells, a 
phenotype consistent with multipotent progenitors displaying HSC-like potential 
(Figure 4-2)623,671,672. In addition, Flt3L expression promoted the differentiation of 
CD73+ CD184+ arterial vascular cells (Figure 4-3). Finally, iPSC-derived CD34+ cells 
from OP9_F co-cultures displayed an improved ability to give rise to human CD45+ 
cells in vivo in Matrigel plugs as well as to differentiate into CD14- CD1c+ cells in 





differentiation and the arterial vasculature induction are consistent with a potential 
activation of the Notch signalling pathway, a key regulator of definitive hematopoiesis. 
All together these observations may support the hypothesis that human Flt3L expression 
is capable of promoting the activation of the hematopoietic definitive program. 
Therefore, a more extensive characterisation of the gene expression profile and 
differentiation potential of cells generated in OP9_F is needed, to validate or refute this 
hypothesis.  
 
In conclusion, two aspects characterising the differentiation of human DCs from iPSC 
have been investigated in this project. On one hand, a reliable system to support the 
differentiation of DC subsets from hematopoietic stem and progenitors cells has been 
established both in vitro and in vivo.  
Moreover, a novel effect of human Flt3L in the early events of human embryonic 
hematopoiesis has been described. Preliminary evidences may suggest that Flt3L 
positively regulates the induction of a definitive hematopoietic program, even though 
further validation is required.  
Finally, human iPSC lines knockout for DC-related transcription factors as well as the 
immune regulatory molecule PD-L1 have been generated using CRISPR/Cas9.  
Future work will aim at merging together all the different aspects investigated in this 
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